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	ABSTRACT 
 
Toxoplasma gondii is an obligate intracellular parasite, that is able to infect 
any nucleated cell. An important global pathogen, T. gondii can cycle between 
primary and secondary hosts, thus enabling widespread penetrance. Within its 
intracellular niche – a membrane-bound parasitophorous vacuole – T. gondii is 
nevertheless able to subvert a variety of host cell processes to allow its 
continued survival and replication. This includes modulation of host signalling 
processes as well as the scavenging of nutrient macromolecules.  
In recent years, microRNAs have emerged as important regulators of 
cellular processes including inflammation, tumorigenesis and metabolism, as 
well as development. It has become increasingly clear that this species of non-
coding RNA is of great importance in ‘fine tuning’ many cellular responses. I 
hypothesise in this work that host cell miRNAs may be yet another means by 
which T. gondii manipulates its host upon infection.  
Using high-throughput-sequencing, I examine host cell transcriptional 
responses to infection both at the mRNA and microRNA level, using two 
strains of T. gondii at a variety of Multiplicities of Infection over a time 
course of 43 hours. Through these transcriptional analyses I identify a number 
of dysregulated pathways common in tumorigenesis, and contemplate the 
hypothesis that T. gondii may be behaving as an ‘intracellular tumour’, 
subverting host cell metabolic processes to mimic a long-known feature of 
cancer metabolism – that of aerobic glycolysis (the Warburg effect) – in order 
to satisfy its own energetic and metabolic needs.  
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	NOMENCLATURE  
 
 
Throughout this work, I have attempted where possible to adhere to the 
conventions of nomenclature set out by the Mouse Genome Informatics Mouse 
Genomics Database  (MGI, MGD) (Release 6.05).  
Upon first mention, gene names are written out in full. Subsequently, 
they are shortened to their official MGI symbol. If the product being referred 
to is a gene or transcript, this symbol is rendered in italics. If it is a protein, 
the symbol is rendered in upper case letters.  
 
Gene name: hexokinase 2 
Gene symbol: Hk2 
Protein: HK2 
 
The exception is where long lists of genes are presented, and repetitive use of 
italics styling is unwieldy.  
In certain cases, conventionally-used names for genes vary to a greater 
or lesser degree from the official symbol and can thus appear unfamiliar (e.g. 
p53 as Trp53 or Hif1β as Arnt ). In these cases, I give the official full name 
and indicate the ‘commonly-used’ name upon first mention, after which I use 
the official nomenclature only.  
A few special cases are gene families, such as NFkB, where the different 
members have very different official gene names and so I use the 
conventionally-used term as an umbrella, specifying individual names by 
official name or symbol where appropriate. 
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I. Introduction 
 
1.1 Toxoplasma gondii  
Toxoplasma gondii is an obligate protozoan parasite, capable of infecting a 
wide rage of hosts – virtually all warm-blooded animals, in fact. It is a 
coccidian apicomplexan, a member of a group which includes other 
intracellular parasites such as Plasmodium (the causative agent of malaria). 
As with most apicomplexans, T. gondii has a complex life cycle which includes 
both sexual and non-sexual phases. However, where many other coccidians 
have only the faecal-oral route for transmission, T. gondii  has managed to 
widen its breadth of host infection by adapting to employ carnivorism and 
trans-placental infection, the latter of which has severe implications for human 
transmission. It is thought that T. gondii infects up to half of the world’s 
population, exhibiting wide variation in different countries (16-40% in the 
United Kingdom compared to 50-80% infection in continental Europe, France 
having a notably high rate) (1). Despite this broad infection, the majority of 
human infections are asymptomatic, or at most characterised by mild, flu-like 
symptoms. However, in certain cases, the infection can result in toxoplasmosis 
and can have extremely severe, even fatal consequences. In 
immunocompromised patients, those infected with HIV or transplant 
recipients on immunosuppressive therapy for instance, toxoplasmic 
encephalitis (TE) can result (in fact, it is estimated that T. gondii infection 
kills 15-20% of all AIDS patients (2)). In women who experience the infection 
for the first time during pregnancy, the parasite is able to cross the placental 
border, and the foetus is left prone to hydrocephalus, intracranial calcification 
and chorioretinitis (3). Infection generally arises as a result of three things: 
ingestion of oocysts, ingestion of tissue cysts or congenital infection, acquired 
trans-placentally. This is better understood in the context of the parasite’s life 
cycle. 
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1.1.2 Life Cycle 
The sexual phase of the life cycle occurs only in the primary/definitive host, 
which are members of the cat family, but the asexual phase can take place in 
virtually any warm-blooded animal. T. gondii  exists in several different forms 
including tachyzoite, bradyzoite, sporozoite, merozoite, micro- and macro-
gametocyte. Each of these represents a stage in the parasite’s development, 
and the first three are potential routes for infection. The tachyzoite (whose 
characteristic crescent-shape gives its name to the parasite: toxo meaning “arc” 
and plasma meaning “form”) is the rapidly dividing asexual form of the 
parasite, able to actively penetrate cells of the infected animal. Bradyzoites on 
the other hand, divide slowly and reside in tissue cysts. Both of these forms 
occur in intermediate hosts. Infected cats, however, provide the appropriate 
environment for the sexual phase of the cycle, in their small intestine 
epithelial cells (4). This phase includes the production of gametes, and 
fertilisation. Maturation of the fertilised gamete also occurs here, and mature 
oocysts are then discharged (though they are at this stage unsporulated). 
Sporulation, which renders the oocysts infective, happens outside: this is the 
only form of the parasite that can survive outside its host. 
Once sporulated, the oocysts – in water or feed contaminated with cat 
faeces – make their way into intermediate hosts (usually livestock or humans). 
Here, the parasite switches to the rapidly dividing form: this is the acute 
phase of infection, resulting in a concerted immune inflammatory response 
(hence the flu-like symptoms) and tissue necrosis. Once the parasite has 
actively penetrated its host’s cells, it reverts to the bradyzoite form, and 
quiescent tissue cysts develop. Though these cysts can form in most visceral 
organs, they preferential develop in neural and muscular tissues, mostly being 
found in the brain, eyes, cardiac and skeletal muscle (5). Normally, these 
tissue cysts persist for lengthy periods of time (perhaps up to the lifetime of 
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the host, though this has not been conclusively shown), and, in 
immunocompetent hosts, should generally not permanently re-activate, though 
it may be that tissue cysts undergo multiple rounds of re-activation and re-
encystment (6, 7). When these cysts are eaten by a naïve host, the parasite 
once again undergoes a phase-change and the bradyzoites revert to the 
rapidly-dividing tachyzoite phase, and the similar pathway of acute infection 
followed by encystation occurs in the predator (1). (Figure 1.1) 
 
Figure 1.1 Transmission and Life Cycle of Toxoplasma gondii.  
Toxoplasma gondii’s definiteive host are members of the Felidae, where the sexual cycle 
occurs (a). Following this, oocysts are shed (b) into the environment where, upon sporulation 
(c), they may be eaten by intermediate hosts (d). From here, there are two potential routes of 
further transmission: transplacental transmission of tachyzoites (e) and transformation into 
bradyzoites and subsequent ingestation of these tissue cysts (f) by other intermediate hosts or 
the definitive host. Adapted from (1) 
 
1.1.3 Host Cell Effects 
Since the parasite can only undergo genetic exchange when two strains infect 
a single cat, any recombinants from these events then go through selection in 
their secondary hosts, and this has had important consequences for the 
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population structure and likely evolution of the parasite. It appears that 
Toxoplasma gondii exists as four distinct clonal lineages in Europe and North 
America, within which strains are nearly identical (8, 9). These lineages 
exhibit marked differences in virulence and show distinct geographical 
distributions as well (9, 10). Most chronic infections in humans – and in 
animals eaten by humans – are caused by Type II strains. And, while infection 
with Type II strains rarely cause mortality in mice, in humans these are often 
associated with severe disease, such as congenital toxoplasmosis (10). Type I 
strains, though highly virulent in mice (with an LD100 of 1 parasite as 
compared to LD100 of >103 in Types II and III), are relatively rare in human 
disease. These differences in genotype and virulence have led to many 
‘classical’ genetics experiments such as Quantitative Trait Locus mapping, to 
elucidate the basis for the phenotypic differences between strains (11). In 
addition to these lineages, a genetically diverse set of so-called ‘atypical’ South 
American isolates has also been identified. These often result in serious disease 
even when the hosts do not have a deficiency in immuncompetence and for 
this reason, their population structure is currently under investigation (12).  
Following invasion of the host cell, T. gondii establishes its replicative 
niche through the formation of a parasitophorous vacuole (PV), from which 
host cell membrane components can be selectively excluded (13). Thus 
sheltered, the parasite can begin its replicative cycle through endodyogeny. As 
well as benefiting from the physical (albeit selectively permeable) barrier of 
the PV membrane (PVM), T. gondii additionally embarks upon a broad 
programme of host cell reprogramming, effectively ‘hijacking’ a number of 
endogenous host cell pathways and subverting cellular functions both to 
protect itself from host immune pathways but also (presumably) to render its 
environment more hospitable in terms of nutrient availability. The means by 
which T. gondii is able to do this are not completely known but has been 
shown in a few cases to be thanks to the discharge of parasite factors by the 
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parasite’s secretory organelles: the rhoptries and dense granules.  
Given the tractability of classical genetics in T. gondii, many such 
parasite effectors have been identified as a result of genetic crosses. For 
instance, ROP16 was identified as the parasite factor responsible for 
differential maintenance of STAT3/6 activation upon infection by strains of 
Types I and III (sustained activation) and Type II (transient). These 
differences were found to segregate into the F1 progeny of a IIxIII cross and 
subsequent QTL analysis pointed to the Rop16 locus (11, 14). Given that 
many such parasite factors have been identified using (at least in part) these 
crosses, it is unsurprising that many of the now-known effectors are virulence-
related (ROP18, ROP5, for instance(15, 16)) or strain specific in some other 
manner (GRA15 (17) or MAF1 (18), which mediates strain-specific 
mitochondrial association of PVs). Far fewer secreted factors have been 
identified that are not polymorphic among strains. Two such are GRA16, 
which was identified by computational prediction of putative secreted proteins 
followed by epitope tagging (19) and, more recently, a putative secreted 
protein MYR1 that underpins the induction of host cell myelocytomatosis 
oncogene (MYC), which was identified through a mutagenesis screen (20, 21). 
While the exact mechanisms by which T. gondii is able to subvert host 
cell processes are not always known, there is a great deal more information on 
how these processes are modulated once that subversion has been initiated. 
The main areas of focus here have been the immune response and apoptosis 
(including but not limited to via NFkB). 
At the centre of the host’s innate immune response to infection are 
macrophages, whose protective actions are manifold. They are capable of 
responding directly to microbial products, resulting in the production of 
powerful reactive intermediates and can themselves engage in phagocytosis. 
Furthermore, they also represent an important link between innate and 
adaptive immunity: they can present antigenic peptides, and therefore 
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activate CD4+ and CD8+ T cells, which can then start clearing infection by 
eliminating cells in which parasites have taken refuge (22). The earliest events 
leading to recognition of Toxoplasma by the host are not as yet wholly clear, 
but it appears that a parasite-derived cyclophilin may bind to the chemokine 
(C-C motif) receptor 5 (CCR5). The downstream effect of this appears to be 
the setting in motion of the innate inflammatory response, triggered by the 
production of the cytokine interleukin 12 (IL12) from dendritic cells (DCs) 
(23). Another pathway responsible for these earliest events in the innate 
response to the parasite may be that triggered by Toll Like Receptors (TLRs), 
as disruption of downstream components of this pathway – myeloid 
differentiation primary response gene 88, MYD88 in particular – almost 
always lead to fatality in mice (24). This pathway again leads to the 
production of IL12, either through the NFkB branch, or via the MAPK one. 
In any case, following the recognition of the parasite by cells of the innate 
immune system, a programme of resistance is then begun.  
The vigorous inflammatory response which is the result of the initial 
infection by the parasite is associated with high levels of pro-inflammatory 
cytokines. The major cytokine responsible for the control of the acute infection 
is IFNG, particularly given its role in inflammation and in activating 
macrophages to a microbicidal state.  In fact, it was shown early on that after 
having been injected with anti-IFNG antibodies and infected with the parasite 
(with strain ME49, and infection being induced either intra-peritoneally or 
orally), most of the infected mice died during the acute phase of the infection 
(25). Moreover, hosts lacking IL12 – the cytokine responsible for stimulating 
the production of IFNG by NK cells and T cells – also succumb to unchecked 
tachyzoite proliferation (26). The production of IFNG by T- and NK- cells is 
mediated by transcription factors, STAT proteins and, importantly, members 
of the NFkB family (24).  
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The NFkB pathway is a critical host cell pathway that is modulated by 
a multitude of input signals and itself regulates a vast array of pathways. 
Most of the studied pathways that NFkB is involved in have been imunne-
related or to do with apoptosis – both processes are highly relevant for T. 
gondii infection. A few of the stimuli of this pathway include mediators of 
infection such as lipopolysaccharide (LPS) as well as pro-inflammatory 
cytokines, as noted above, including TNF and IL1. The role of NFkB in T. 
gondii infection has been rather contentious, with reports both indicating 
activation and suppression at various different points of the pathway (27–29). 
This is rendered even more complex by the fact that several NFkB-dependent 
genes are themselves negative regulators of the pathway, and that among its 
myriad targeted genes are both ‘pro-parasite’ and ‘pro-host’ examples. For 
example, pro-inflammatory cytokines such as Il12 and Tnfa are targets of 
NFkB’s, but so are several anti-apoptotic factors, such as the Inhibitors of 
Apoptosis (IAPs).  It is likely that host cell context and strain have a large 
role to play. Indeed, Type II GRA15 has been shown to activate the pathway 
in a strain-specific manner (17), but other mechanisms exploited by other 
Type strains cannot be ruled out. While the precise of role of NFkB in T. 
gondii infection has yet to be completely elucidated, one of its major effects – 
suppression of apoptosis – is definitely observed after parasite infection.  
 It is not surprising that apoptosis might be one of the mechanisms by 
which hosts defend themselves against pathogens, and this is observed in both 
bacterial and viral infection (30–32). Unlike necrosis, apoptosis is a highly-
ordered process that follows many well-defined steps. It usually proceeds via 
one of two pathways of activation cascades, extrinsic and intrinsic 
(mitochondrial), depending on the stimulus. The mitochondrial mechanism 
has been related to pathogen invasion and the cascade initiated by a number 
of stimuli including infection, DNA damage or nutrient starvation. Following 
the mitochondrial pathway ultimately results in the formation of the 
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apoptosome, in a manner that is dependent on the release of cytochrome c, 
somatic (CYCS, commonly termed cytochrome c) from the mitochondria into 
the cytosol. Formation of the apoptosome ultimately results in the activation 
of the ‘executioner’ enzyme, caspase 3 (CASP3). The extrinsic pathway 
depends on the binding of a ligand such as tumor necrosis factor (TNF, 
usually called TNFα) or Fas ligand (TNF superfamily, member 6) (FASL) to 
a cognate receptor of the TNF “death family” to trigger activation of caspase 8 
(CASP 8). Caspase 8 can then either directly or indirectly (through triggering 
CYCS release) activate CASP3 (33). Toxoplasma gondii has been shown to 
suppress host cell apoptosis when it was stimulated along either the extrinsic 
or intrinsic pathway (34). 
Given that inappropriate implementation of an apoptotic programme 
could be disastrous for an organism, the control of apoptosis is very tightly 
managed. This is largely achieved through the balance of pro- and anti-
apoptotic genes, specifically of the BCL-2 family (35), and it does appear that 
T. gondii can evade apoptosis by modulating that balance (29). However, this 
is not the complete story, as T. gondii has also been shown to prevent CYCS 
release and also interfere with the activity, recruitment or processing of the 
caspase enzymes themselves (36). The fact that apoptosis is at the 
convergence of a number of important host cell pathways effectively renders 
any of these a potential target for modulation by the parasite.  
Merely evading host cell immune or apoptotic pathways is unlikely to 
be the entire story when it comes to T. gondii modulation of host cells, 
however. Being an obligate intracellular parasite, T. gondii depends upon its 
host to derive a number of nutrients (37) and there is evidence that host-to-
PV trafficking can occur via host endocytotic pathways to serve this purpose 
(38). The parasite is a an auxotroph for a number of key metabolites, 
including purine (39), cholesterol (40), choline (41) and a number of essential 
amino acids (37, 39). Moreover, even when T. gondii is able to synthesis 
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metabolic building blocks itself, it may not always do so. While the mechanics 
of how this is achieved have not yet been fully elucidated, parasite modulation 
of the host cell environment in order to enable more fruitful scavenging must 
be considered.  
 
1.2 MicroRNAs 
 
The earliest hint of microRNAs (miRNAs) was found in Caenorhabditis 
elegans, through a number of experiments looking at larval development and 
the action of heterochronic genes. Genetic screens for new heterochronic genes 
identified lin-4, whose action was shown to be as a negative regulator of, 
among others, lin-14. This did not seem to be the action of a classical 
transcriptional-regulator, though, with many strands of evidence weaving 
together to present the case for RNA-RNA interactions. While levels of the 
target gene’s transcripts remained constant, LIN-14 protein levels decreased in 
a temporal manner, a decrease for which the gene’s 3’ Un-Translated Region 
(UTR) was required. Investigation into the regulator itself, lin-4, revealed that 
it was unlikely to encode a protein: neither start nor stop codons were 
identified and nonsense mutations did not alter the rescuing power of the lin-4 
product. Instead, it seemed that the two products of the gene – a barely-
detectable 61nt transcript and a more abundant 22nt transcript – were the 
active species as RNAs, a notion that was strengthened by the fact that both 
transcripts had the potential to base pair directly with the target mRNA. 
Secondary structure for the larger transcript was also proposed as being a 
stem-loop, a structure now known to be characteristic of miRNA precursors. 
Because of this gene’s involvement in developmental timing, their products 
were termed small temporal RNAs (stRNAs) (42).  
A second heterochronic gene that appeared to encode a functional 
regulatory RNA with potential binding to its target’s 3’ UTR was discovered 
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seven years later, in the laboratory of Gary Ruvkun (43). The discovery of a 
second stRNA, let-7, was intriguing enough but this study also raised the idea 
that the scope of regulation by stRNAs might be wider than previously 
thought. Let-7 appeared to have several targets, which included lin-14. Thus, 
it became likely that these stRNAs were part of a much more complex 
regulatory network: they were each able to downregulate the expression of 
multiple genes, and target genes themselves were likely to have multiple 
stRNAs as regulators. That same year, a larger scale study of let-7 
conservation revealed the presence of perfect homologues in the genomes of 
Drosophila melanogaster and humans. Moreover, let-7 expression was 
demonstrated to occur in 14 other species, in many of which it appeared to be 
temporally expressed (44).  
The true extent of this new kind of gene regulation only really became 
apparent thanks to the emergence and elucidation of RNA interference 
(RNAi) and its mechanisms (45, 46). It was while examining silencing RNA 
intermediates (siRNA) in lysates of D. melanogaster embryos injected with 
long dsRNA RNAi precursors that Elbashir et al (47) noticed the potential 
presence of endogenous small RNAs the same size as the siRNA products they 
had wanted to characterise. These endogenous small RNAs, along with 37 
candidates from HeLa cells, were characterised later that year (48) and found 
to be expressed as 21-22nt RNA transcripts, to apparently come from 
precursors that folded into hairpins and, largely, to be conserved across 
organisms. Consecutive papers in that same issue of Science (49, 50) 
characterised further small RNAs in nematodes: It was now clear that these 
regulatory RNAs did indeed represent an “abundant class” (49). Beyond what 
had already been elucidated with lin-4 and let-7, however, the roles of these 
new regulators was unclear and could not necessarily be presumed to involve 
development: it was thus agreed that the term microRNA would be used to 
refer to these genes. 
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1.2.1 Structure, Biogenesis, Mode of Action 
As with the discovery of miRNAs themselves, elucidation of their biogenesis 
owes much to work done on pathways involved in RNAi. In early 2001, the 
Hannon laboratory identified the RNAse III family nuclease, Dicer, as the 
enzyme responsible for cleaving dsRNA silencing precursors into the active 21-
22nt molecules involved in silencing (51). Later that year, Hutvágner et al 
showed that this same enzyme was also the one responsible for processing of 
the stem-loop precursor (pre-miRNA) transcripts into the mature (21-22nt) 
form (52). Here, following transfection of Dicer-targeted siRNA, HeLa cells 
were examined for let-7 expression. In contrast to un-transfected or control 
siRNA-transfected cells, HeLa cells in which Dicer had been silenced exhibited 
an absence of mature let-7 along with an accumulation of the larger (~72nt) 
precursor.  
Unlike tRNAs and snRNAs, miRNA genes are transcribed by RNA 
Polymerase II (53, 54), as ‘conventional’ long transcripts, including the 
stabilising 5’ cap and a polyadenylated tail. Once transcribed, the pri-miRNAs 
undergo a first round of processing within the nucleus by an enzyme complex 
termed the ‘microprocessor’ (55, 56). This complex recognises the pri-miRNA 
through binding of the protein DiGeorge syndrome critical region gene 8 
(DGCR8, also known as PASHA) (57) which then allows the RNAse III 
family member DROSHA (58) to process the transcript into a 60-70nt hairpin 
structure, the pre-miRNA. Exportin 5 then mediates transport of this 
precursor, in a Ran-GTP-dependent manner (59, 60) to the cytoplasm, where 
the pre-miRNA is processed by a second protein complex, again containing an 
RNAse III family-member (DICER) and a dsRNA binding protein (Trans-
activation Response RNA Binding Protein, TRBP). Cleavage by DICER 
removes the loop, resulting in the production of a short (~22nt) RNA duplex 
molecule (consisting of the miRNA and miRNA* arms of the stem) with 2-3nt 
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overhangs. The mature (miRNA) strand of the duplex is then preferentially 
incorporated into the miRNA-induced silencing complex (miRISC) (61) which 
mediates the repression of target mRNAs. 
 
 
Figure 1.2 Canonical microRNA biogenesis, with the characteristic stem-loop structure 
providing the basis for computational analyses of miRNA-seq data. 
After transcription, the nascent pri-miRNA is cleaved by the microprocessor complex (which 
includes Drosha and DGCR8) into the pre-miRNA (circled in red). The pre-miRNA is the 
stage at which most miRNA-seq experiments assay for discovery and profiling of miRNAs, 
given its distrinctive stem-look structure. My own analyses in subsequent chapters search for 
this characteristic pattern. From here, it is exported to the cytoplasm where its loop is 
cleaved off by the Dicer/TRBP complex. One half (previously termed star strand) is 
degraded, leaving behind the mature miRNA. The RISC complex, which includes Ago2, then 
mediates the main mechanism of gene regulation. Adapted from (62).  
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The concept of regulator non-coding RNAs is not new. As early as 1969, 
Britten and Davidson set forward a model of gene regulation in the journal 
Science, that rested on non-repetitive, non-coding sequences as master-
controllers (63). This theory did not gain wide acceptance at the time 
however, as the term ‘junk DNA’ began to grow in use to refer to non-coding 
DNA (64). Despite this somewhat pejorative term, other types of functional 
yet non-coding RNA have been well-characterised since Britten and 
Robinson’s publication, and several of these non-coding RNAs have been 
revelead to be vast classes with complex functions. 
Some features of each of these is described below: 
 
piRNAs (PIWI-interacting RNAs): Like miRNAs, piRNAs are small in size, 
approximately 24-31nt and also mediate post-transcriptional regulation. 
Unlike miRNAs, however, this class of small non-coding RNAs performs its 
functions by associating in a complex with the PIWI subfamily of Argonaute 
proteins (rather than the Ago subfamily) and appear to function primarily 
through epigenetic silencing of, for example transposable elements, rather than 
transcript silencing (65). PIWI proteins were first identified in Dropsophila, in 
terms of germline development and as such, the bulk of piRNA research has 
focused on regulation in this context.  That being said, recent studies have 
shown piRNA expression in somatic tissues as well, with dysregulation being a 
feature in, for example, several types of tumour (66).  
 
snRNAs (small nuclear RNAs): Small nuclear RNAs were first discovered in 
the late 1960s, and have been shown since then to play an important role in 
the maturation and processing of mRNAs. They are often divided into two 
classes, Sm- and Lsm, based on both specific sequence features as well as 
which protein partners are required for their function. Sm-class snRNAs are 
transcribed by RNA polymerase II and exported to the cytoplasm where they 
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are processed into stem-loop structures and where the ribonucleoprotein Sm 
core particle is formed (this process requires a number of protein cofactors 
such as the Survivor Motor Neuron complex). Upon re-importation into the 
nucleus, most of the snRNA snRNAs form part of the spliceosome and thus 
are key to the correct progression of intron-removal. Unlike other Sm-class 
snRNAs, U7 snRNA appears to mediate histone processing (67).  
The second class of snRNAs, Lsm, comprise U6 and U6atac genes, which are 
transcribed by RNA polymerase III and, unlike the Sm-class, do not leave the 
nucleus. They too aid in the splicing process, and are essential for correct 
removal of introns (68). 
 
snoRNAs (small nucleolar RNAs): Small nucleolar RNAs represent another 
size range of non-coding RNAs, from 60-300nt. An abudant and diverse class, 
snoRNAs can be subgrouped based on conserved sequence motifs: C/D or 
H/ACA. They were initially characterised in terms of rRNA processing, by 
through 2’-O-methylation or pseudouridination. However, they are 
increasingly being found to function in telomere synthesis, modifications of 
tRNAs or even mRNAs (67). As with snRNAs, snoRNAs operate within 
ribonucleoprotein complexes, the assembly of which is a highly directed 
process.  
 
lncRNAs (long noncoding RNAs): As with the other main classes of ncRNA, 
lncRNAs have been identified in several animal species, including mouse, 
zebrafish and humans, as well as in plants such as Arabidopsis and maize. In 
the realm of parasites, lncRNAs have been identified in Plasmodium 
Toxoplasma and Neospora. Despite a few well-studied examples (such as the 
Xist gene which has a large role in X chromosome inactivation via dosage 
compensation), classifications of lncRNAs (in terms of mechanism or 
secondary structure, for instance) appears difficult to generalise, other than 
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they are over 200nt in length, transcribed by RNA polymerase II, and can be 
capped and polyadenylated, and even spliced. As such, one popular method of 
classification and naming has relied on position in reference to the genomic 
context. Here, lncRNAs are classed based on whether they are: intronic 
without overlapping exons; intergenic; bidirectional (in relation to the 
promoter of the nearest protein-coding gene); antisense (overlapping exons of 
a protein-coding gene but in the antisense direction); or sense-overlapping, 
sometimes called transcribed pseudogenes which, while overlapping a protein-
coding gene’s exon, do not produce a protein (69). These RNAs have been 
shown to be involved in a multitide of cellular regulatory processes including 
transcription, RNA degradation, translation, chromatin remodelling and 
splicing (69, 70). Moreover, lncRNAs have been found to function in processes 
involved in immune modulation, development, chromatin modulation and 
have also ben shown to be dysregulated in disease states. This has prompted 
Ulitsky and Bartel to comment, of the intergenic subset though this 
observation could probably be extended to other classes of lncRNAs, that they 
are defined “more by what they are not than by what they are” (71). High-
throughput inhibition screens via CRISPRi are now underway, to be able to 
probe lncRNA function at scale and early results indicate involvement in 
regulation of cell growth in a cell-type specific manner (72).  
 
1.2.2 Methods of Discovery 
1.2.2.1 The ‘Early Days’ 
Though the first miRNAs (lin-4 and let-7, as above but also bantam, a 
Drosophila miRNA that emerged from a transposon-based gain-of-function 
screen (73)), were discovered by classic forward genetics, such screens have 
not been very successful in identifying new miRNA genes. This is partially a 
logistical problem: the small size of the molecules means that mutations in 
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these loci are relatively rare, and, given the often (at least partially) 
redundant roles of miRNAs, successful mutants are difficult to score (74).  
 That the mechanisms of siRNA production involved the same 
machinery as the processing of miRNAs proved to be very useful when it came 
to the identification of new candidates. While characterising siRNAs from 
exogenously-introduced dsRNA, Elbashir et al (2001) found that these 
fragments contained 3’ hydroxyls and a 5’ terminal phosphates, features that 
they exploited by specifically adding sequencing adaptors to either end of a 
size-fractionated library with T4 RNA Ligase (which catalyzes the formation 
of phosphodiester bonds between nucleic acid termini with these 
modifications). The ability of this method to also enrich for endogenous 
miRNAs meant that it could be used to concatamerise, clone, and sequence 
these genes specifically (47).  
This process proved fruitful in the early years of miRNA discovery, 
with several groups employing it to characterise novel miRNAs. In the same 
2001 issue of Science mentioned previously, three groups expanded the 
number of known miRNA genes from two (let-7 and lin-4) to 93 (48–50), in 
humans, nematodes and Drosophila.1 Cloning of material from specific organ 
and tissue fractions, cell lines or developmentally-staged oraganisms further 
increased this number, with, for example, 34 novel miRNAs being 
characterised (some with highly tissue-specific expression) from mouse heart, 
livers and a variety of brain fractions (75), and 40 novel miRNAs from rat 
neuronal tissue (76). A large-scale ‘atlas’ of mammalian miRNAs was 
compiled in 2007 (77), with miRNAs cloned and sequenced from 250 distinct 
mouse, human and rat tissues.  
 Despite the wide success of this method, it quickly became clear that 
cloning was approaching its limits in terms of miRNA discovery. miRNAs that 																																																								1 This number refers only to the number of novel miRNAs discovered through cloning. In the 
cited works, the authors also employed phylogenetic comparisons to demonstrate expression of 
several more new miRNA genes in the named species as well as others.  
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are expressed at low overall levels or are expressed in a tissue- or 
developmentally-specific fashion might be overlooked. In fact, as early as 2003, 
it was asserted that the upper limit for novel miRNA discovery through 
cloning had been reached (78). The aforementioned large-scale atlas of 
mammalian miRNAs, though providing a comprehensive (at the time) and 
well-characterised compendium of miRNAs, only yielded a relatively meagre 
33 novel miRNAs discovered through cloning. Moreover, these methods of 
cloning were very labour-intensive and the (conventional) sequencing that 
followed often proved expensive.  
These considerations all indicated that alternative strategies for miRNA 
discovery needed to be developed.  
 
1.2.2.2 Computational 
Computational methods for identifying novel miRNA genes have largely been 
based on the premises of conservation among related organisms and structure 
(and, often, conserved structure). Though the sequence of steps might vary, 
most early methods either looked for conserved non-coding sequences and then 
folded them in silico or vice versa, identifying regions that were likely to fold 
according to certain rules and then comparing these to known miRNAs. The 
two first such miRNA-finding computational methods embody these 
strategies. 
 miRscan (79), developed in the Bartel laboratory, identified candidate 
stem-loops in the C. elegans genome and then searched for conservation in C. 
briggsae. Thus filtered, candidate stem-loops were then themselves scanned 
and scored for attributes gleaned from analysis of the 50 then-known C. 
elegans miRNAs, such as the extent of base-pairing within the stem, or the 
symmetry of bulges. When this approach was ‘trained’, using the C. elegans 
and C. briggsae genomes, half the known C. elegans miRNAs were found. 
Applying miRscan to the human genome using mouse and, subsequently, 
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(Taki)fugu rubripes (pufferfish) genomes for phylogenetic comparisons, 
identified 74 of the known 109 human miRNAs. Interestingly, the authors at 
the time argued that their method could be used to assign an upper bound to 
likely miRNA genes in the human genome. While their calculated figure was 
of 255, the current number of human miRNA genes in the current version 
miRBase (80) (version 21) stands at 2,5882, perhaps speaking to the inherent 
limitations of using a limited set of known miRNAs and conservation between 
distantly-related organisms as definitive criteria. 
  Another, possibly more effective computational method for identifying 
new miRNAs was miRseeker. Instead of beginning with a search for hairpins, 
this program instead looks for all conserved, non-coding sequence alignments 
between two or more genomic samples. Identified orthologous fragments are 
then folded in silico, and the resultant hairpin loop is scored on the basis of 
the quality of its folding. Structures that have passed this filter then are 
scored and ranked on the basis of whether or not they follow canonical 
miRNA evolution patterns in the divergence of their nucleotides (as described 
in (74)). Of the 24 then-known D. melanogaster miRNAs, 18 were in the top 
124 candidates identified by the program. Moreover, miRseeker predicted 48 
novel miRNAs, 24 of which were experimentally verified through Northern 
blotting.  
 
1.2.3 Methods of Verification / Profiling 
Such computational methods generate lists of putative miRNAs whose 
expression requires validation through experimental means, if the putative 
miRNA is to be included in miRBase. This can be achieved through a variety 
of means, from single-miRNA profiling via Northern blots to more recent 
highly-scalable deep-sequencing platforms. These techniques can also be used 
																																																								2 Though miRBAse has recently done away with the notion of *miRNAs so this number may 
be inflated.  
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to examine the potential differential expression of miRNAs across 
experimental conditions of interest. 
 
Northern Blotting 
As might be expected, given the well-established nature of the technique, 
Northern blots have been widely used to validate predicted miRNA expression 
profiles. However, their disadvantages are also obvious: a (comparatively) 
large amount of starting material is necessary to obtain useful signals, largely 
due to relatively low-hybridisation capacities of conventional oligonucleotide 
probes. These probes themselves need to be radioactively labelled – a practice 
that, increasingly, is falling out of favour due to safety concerns. Additionally, 
traditional methods of cross-linking RNA to membranes prior to probing (such 
as through exposure to UV light) are often suboptimal when considering 
molecules as short as miRNAs (81). A number of variations to the ‘classic’ 
Northern blot protocol have been developed to address these specific concerns. 
Improvements include the use of digoxygenin-labelled probes instead of 32P-
labelled ones (82), Locked- Nucleic Acid (LNA)-modified oligonucleotide 
probes (which resulted in a tenfold improvement in sensitivity (83)), or a 
modified cross-linking buffering system, using a water-soluble carbodiimide, 1-
ethyl-3- (3-dimethylaminopropyl), to immobilise the RNA to the membrane 
(81). 
More recently, a method has been devised that combines the benefits of 
all three modifications to the standard Northern blot protocol (84). Kim et 
al’s ‘LED’ protocol (LNA, EDC, DIG) was shown to be capable of detecting 
as low as 0.01–0.025 fmoles of synthetic miRNA with an exposure period of 
one minute (a great improvement from overnight or longer exposures typically 
required by isotopic methods). Nevertheless, despite these improvements, 
Northern blots for miRNAs are still time-consuming and laborious, given that 
only a few transcripts can be analysed at once. Moreover, the high cost of 
	 20	
LNA probes makes the method more suited to validation or profiling of just a 
few candidate miRNAs rather than to large-scale expression studies.  
 
Primer Extension, q-RTPCR 
Quantitative Real-Time PCR has been widely used as a verification 
measure for microarrays, and several groups have attempted to employ this 
method for the quantitation of miRNA expression as well. As with many of 
the other methods of miRNA analysis however, the short length of miRNAs 
raises significant problems. For a start, the length of primers used in qPCR is 
typically as long as the miRNAs themselves, and the criteria normally 
observed in primer selection for conventional qPCR to ensure specificity are 
difficult to adhere to. To address this, several modifications to primer design 
have been developed. Chen et al (2005) use stem-loop primers to increase the 
specificity of annealing, by hindering the adherence of non-specific (or pre-
miRNA) sequences and increasing the stability through base-stacking. This is 
followed by the addition of a TaqMan® miRNA-specific fluorescent/quencher 
probe and Taq polymerase. As the reaction proceeds along the template 
strand, the polymerase’s 5’ – 3’ exonuclease activity separates the fluorescent 
moiety of the probe from its quencher, yielding a measurable signal. Using this 
modified assay, the authors were able to distinguish between a miRNA 
precursor and the mature form, at a sensitivity of over 2000-fold (85). 
The TaqMan® assay has been extended for use as parallelised 
reactions, sold commercially as Array Cards, which consist of a 384-well plate 
with TaqMan® probes to individual miRNA targets per well). Similarly, 
Raymond et al (2005) have used LNA primers to increase the binding affinity 
of primers to target miRNAs. In 22 of the 30 miRNA assays that they 
conducted, they found that the inclusion of LNA bases in the primers either 
“significantly enhanced” or was “absolutely required” for primer extension and 
miRNA profiling (86). 
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 Improved sensitivity afforded by stem-loop or LNA-containing primers 
aside, the use of miRNA-specific probes can often prove expensive. Varkonyi-
Gasic et al further modified this assay to enable the use of universal reverse 
primers, instead of the costly LNA or fluorescent TaqMan® probes. The 
authors found that, at 35 PCR cycles, 20pg of starting material were sufficient 
to produce an appreciable signal (though a greater number of cycles resulted 
in a modest amount of non-specific amplification) (87).  
 
Microarrays 
The advantages of using microarrays for global transcriptional analyses have 
been well-documented, especially in the field of parasite-host research (88). 
Their relatively low cost, the ease of procuring starting material, as well as the 
existence of numerous thoroughly-tested programs for data post-processing 
(such as normalisation, clustering of genes and differential expression 
profiling) make arrays an attractive choice for large scale RNA profiling. 
Indeed, many of these advantages remain when arrays are applied to the 
analysis of small RNAs, but this class of molecule also presents its own 
challenges. Traditionally, the design of probes for microarrays has been based 
on selecting regions of genes with as much unique sequence as possible. In this 
manner, the likelihood of mRNA derived from a different gene hybridising to 
the probe can be minimised, even when other regions of genes may be highly 
similar. The small size of miRNAs greatly limits the scope of probe selection, 
however and thus the risk of mis-hybridisation is severe. This problem is 
exacerbated due to existence of miRNA families, whose members often differ 
by only a few nucleotides. Biases inherent in array hybridisation only add to 
these concerns: if the region of a miRNA that distinguishes it from a family 
member contains a run of nucloeotides that preferentially hybridise to the 
array, then not only is transcriptional information about the ‘correct’ miRNA 
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lost, but the expression profile of the closely-related, ‘incorrect’ miRNA is 
amplified, and may then be falsely labelled as being significant.  
The comparison between a TaqMan® qPCR array and a single 
conventional oligonucleotide array revealed that the false-discovery rate of 
differentially-expressed miRNAs was significantly higher using the microarrays 
than the q-RT-PCR (when measured as significantly-different expression 
levels between replicates on each platform). Moreover, overall correlation 
between the two platforms was also low (89). 
The challenges of using such short sequences as microarray probes has 
been addressed by a number of techniques aiming to increase the specificity of 
hybridisation. Wang et al’s array platform for Agilent (90), for example, uses 
hairpin sequences as probes, effectively blocking the hybridisation of longer 
matching target RNAs (pre-miRNAs, or degradation products from mRNAs, 
for example). Exiqon too have sought to improve hybridisation specificity by 
altering their probe-design. Here, LNA-containing oligonucleotides are used as 
probes, which results in a specific increase in melting temperature for 
perfectly-matched probe-target heteroduplexes. In fact, Castoldi et al found 
that even a single mismatch was enough to reduce the Tm of hybrids and 
result in enough destabilisation to appreciably lower the signal produced by 
such cross-hybridisation (91). Ambion’s (now defunct) MirVana arrays 
introduced spacers into the probe sequence, thus increasing the effective 
hybridisation length. 
Another kind of array modification to enable the accurate profiling of 
miRNAs has been to employ on-chip enzymatic reactions. In Nelson et al’s 
RAKE (RNA-primed Array-based Klenow Enzyme) method, arrays are 
spotted with oligonucleotides consisting of a miRNA-specific antisense probe, 
followed by a short stretch of thymidines and a 5’ spacer (which is consistent 
across all spots). After hybridisation with target RNA, the slide is treated 
with exonuclease, to degrade single-stranded spots (unbound by miRNA). The 
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klenow fragment of DNA polymerase then uses the bound miRNA as a primer 
and the spotted oligonucleotide as a template to then introduce biotin-
conjugated dATPs only to the miRNA-bound spots. Fluorescent labelling of 
these biotins then results in a measurable signal for the direct assessment of 
the miRNA targets. Advantages of this method include the fact that it 
includes neither reverse transcription nor amplification steps (both of which 
might introduce bias) and probe hybridisation is based on the 3’ end of the 
miRNA: for closely-related miRNAs, this is the area where nucleotide 
divergence is most often seen. In fact, the authors show that for six tested 
miRNA paralog pairs, RAKE distinguished between the pairs better even than 
Northern blotting (92).  
 
Next-Generation Sequencing 
In the past decade or so, the advent of Next-Generation or High-Throughput 
sequencing has profoundly altered the way that we think about genome-scale 
experiments, and the area of miRNA study is no different. This method boasts 
a number of advantages over those described in this chapter, and as such it is 
what I have employed for this work. I discuss its various instantiations as well 
as their strengths and limitations in Chapter 3.  
 
1.3 Thesis Overview 
MicroRNAs provide a potent means of altering a number of cellular processes 
and their potential is only now beginning to be understood. Thus, I wanted to 
explore what their impact was on host-parasite infection. To do this, I 
employed a variety of next-generation sequencing approaches to explore both 
the modulation of host miRNAs but also the possible existence of parasite-
encoded ones. RNASeq lends itself well to large-scale probing of host-cell 
interactions so I extended this study to look at mRNA alterations as well. The 
transcriptional observations (supported by the literature) that infection with 
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T. gondii results in a remodelling of host metabolic systems from numerous 
signalling angles then led me to probe the issue of aerobic glycolysis more 
directly, looking at protein levels of key enzymes in different host genetic 
backgrounds as well as using this metabolic remodelling as a (very putative) 
drug target. 
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II. Materials and Methods 
 
2.1 Cell Culture - General 
2.1.1 Cell Culture Medium 
All cell and parasite culture manipulations were performed in a Containment 
Level 2 Facility. Only fixed or lysed cellular material was removed from the 
room, except for a) receipt from or transfer to another laboratory, b) transfer 
to the -80 °C refrigerator for cryopreservation. In both these cases, live 
material was double-contained. 
Routine cell culture was performed in high glucose Dulbecco’s Modified 
Eagle’s Medium (Sigma-Aldrich) containing 4500 mg/L glucose, L-glutamine, 
sodium pyruvate, and sodium bicarbonate. To this medium was added Foetal 
Bovine Serum (Sigma-Aldrich, 10%), Penicillin/Streptomycin (Sigma-Aldrich 
100U/ml-100µg/ml), and 2mM L-glutamine (PAA), and the preparation was 
disposed of no later than two weeks of preparation. Thereafter, this 
supplemented medium is referred to as HG-DMEM. 
 
2.1.2 Mycoplasma Testing 
Cell and parasite cultures were tested upon first receipt into the laboratory for 
contamination by Mycoplasma spp. This was done either using the Lonza’s 
MycoAlert™ Mycoplasma Detection Kit (manufacturer’s instructions) or by 
sending a sample of cell culture supernatant to the Wellcome Trust – Medical 
Research Council’s Cambridge Stem Cell Institute for analysis. All live cells 
and parasites were subsequently tested when an infection (or any aberrant 
cellular behaviour) was alerted by any other user of the Containment Level 2 
Facility. 
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2.2 Host Cell Culture 
2.2.1 Host Cell Strains 
Host cells for routine parasite maintenance, for the RNASeq experiments and 
for the lactate assays were NIH/3T3 Mouse Embryonic Fibroblasts bought 
from DSMZ (Catalogue Number ACC-59). Host cells used for the Western 
Blots in Chapter 6 were HIF1A-KO and HIF1A-WT Mouse Embryonic 
Fibroblasts, a kind gift from Dr Ira Blader, SUNY Buffalo, New York.  
 
2.2.2 Host Cell Freezing 
Cells were seeded into 75 cm3 flasks two to three days before freezing. When 
cell monolayers achieved ~60% confluence, they were deemed suitable for 
cryopreservation. Cells were rinsed twice with PBS and detached using 1x 
Trypsin-EDTA (placed in the incubator to aid detachment). Following 
detachment, HG-DMEM was added to the cell suspension. Cells were pelleted 
by centrifugation (300 x g) and then resuspended in HG-DMEM for counting 
with an Improved Neubauer haemocytometer. Following counting, the cells 
were centrifuged, rinsed with PBS, and then re-centrifuged. The final cell 
pellet was then resuspended in enough cold freezing medium 
(FBS/10%DMSO) to ensure a final concentration of 1 million cells per mL. 
Following resuspension, cells in freezing medium were aliquoted into pre-
cooled cryovials, at a volume of 1 mL (1 million cells) per vial. These vials 
were placed in a Nalgene freezing container overnight at -80°C before 
subsequent storage in liquid nitrogen. Passage number was increased upon cell 
freezing. 
 
2.2.3 Host Cell Thawing 
Cryovials (stored as described in 2.1.2) were rapidly thawed in a 37° C water 
bath. Contents of the cryovials were then added dropwise to pre-warmed HG-
DMEM. Following centrifugation at 300 x g, cell pellets were resuspended in 
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HG-DMEM and the resulting suspension transferred to cell culture flasks. Cell 
culture medium in these flasks was replaced the following day. 
 
2.2.4 Host Cell Routine Maintenance (Subculture/Passage) 
For routine maintenance, cells were grown in 75 cm3 flasks and were not 
allowed to exceed 80% confluence at any time. Monolayers of appropriate 60-
70% confluence were washed twice with 1X PBS to remove traces of serum, 
and trypsin-EDTA was then added. Cell culture vessels were then returned to 
the incubator (37 °C, 5% CO2) to promote detachment, for 1-2 minutes. 
Detachment of cells from the vessel surface was then confirmed 
microscopically, and HG-DMEM added in order to halt the action of the 
trypsin-EDTA.  
Following collection of cells by centrifugation (300 x g), cell pellets 
were resuspended in HG-DMEM. Aliquots of the cell suspension were then 
applied to a each chamber of an Improved Neubauer haemocytometer and the 
number of cells/mL determined. The appropriate volume of cell suspension 
was then added to a fresh flask along with enough HG-DMEM to make up the 
correct volume for the size of the flask being used. Passage number was 
increased by one every time a culture was passaged. Cell lines were not 
allowed to exceed a passage number of 25. 
 
2.3 Parasite Culture 
2.3.1 Parasite Strains 
Type II Strain: ME49 B7 Clone or PTG-GFP 
Type I Strain: RH 88 or RH-GFP 
All parasite strains were a kind gift from Dr David Sibley, Washington 
University School of Medicine.  
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2.3.2 Routine Maintenance 
Parasite maintenance and propagation followed a pattern of lysis and re-
inoculation, whereby as soon as an infected host cell monolayer was fully 
lysed, an appropriate volume of the lysate was added to an uninfected flask of 
~70% confluent host cells.  
 
2.3.3 Parasite Harvest 
In order to maximize parasite yields, ~70% confluent host cell monolayers 
were inoculated 42 hours prior to parasite harvest such that the majority of 
host cells were observed (microscopically) had been infected, by at least 4 
parasites and yet remained un-lysed.  
Infected monolayers were then rinsed twice with 1X PBS to remove 
extracellular (and thus potentially dead) parasites. HG-DMEM was then 
added, and the monolayers were scraped using a rubber policeman. The 
infected host cells were then mechanically lysed by passing first through a 25G 
needle and then through a 27G needle, 5 times each. The lysate was filtered 
through a 3 µM polycarbonate filter membrane to remove host debris and the 
parasites from the filtrate were then collected by centrifugation at 1000 x g. 
Parasite pellets were resuspended in HG-DMEM. Aliquots of the parasite 
suspension were then applied to each chamber of an Improved Neubauer 
haemocytometer and the number of cells/mL determined. The appropriate 
volume of parasite suspension was then added to fresh HG-DMEM/10%FBS, 
which was then used to replace the medium in 70% confluent flasks or wells of 
host cells. Where a particular Multiplicity of Infection (MOI) was specified for 
an experiment, an additional three host cells were seeded and counted, in 
order to better determine an accurate MOI.  
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2.3.4 Parasite Freezing 
NIH/3T3 cells seeded in 25 cm3 flasks were infected with parasites when they 
were ~70% confluent. When heavily infected (though not lysed), the freezing 
protocol was begun. Cells were washed twice with PBS and detached with 
Trypsin-EDTA and the detachment was stopped with pre-chilled 
50%FBS/HG-DMEM and chilled on ice for two minutes. Pre-chilled 
20%/DMSO was then added to bring the volume up to 2 mL total per 
starting 25 cm3 flask. This suspension was transferred to pre-chilled cryovials 
(1 mL per vial) and transferred to a Nalgene freezing container. The freezing 
container was placed at -80 °C overnight and the vials then transferred to 
liquid nitrogen.  
 
2.4 Small RNA Library Preparation 
Given that much of the preparatory work in Chapter 3 was concerned with 
refining and optimizing Illumina’s in-house protocol (Solexa microRNA 
Sample Prep Protocol, v1.4B), the details of library preparation are covered in 
3.2. 
 
2.5 Bioinformatic Methods  
Given that the bioinformatics methods used for these studies often required 
modification and/or evaluation, the are discussed in the relevant chapters.   
 
2.6 RNA Extraction (for Chapters 5 and 6) 
RNA extractions were done according to the DirectZol instructions. All steps 
were conducted using RNAse-free labware and on surfaces treated with 
RNAseZap (Sigma Aldrich). Briefly, for each well in which cells had been 
grown/infected: Each well was washed twice with PBS, treated with 950 µL 
Tri Reagent (Sigma) and mixed well by pipetting. After five minutes, the 
mixture was transferred to a tube and centrifuged at 12,000 x g for one 
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minute. The supernatant was then transferred to a fresh tube and 950 µL 
Ethanol was added. A Zymo-Spin™ IIC Column was placed in a collection 
tube and loaded with 700 µL of the mixture. After centrifugation for one 
minute, the collection was emptied and the procedure repeated until all the 
mixture had been spun. The column was then placed into a new column and 
rinsed twice via centrifugation for one minute with 700 µL Direct-zol™ RNA 
PreWash solution. A wash step followed, using 700 µL of RNA Wash Buffer 
and a one minute centrifugation. After a final centrifugation step to ensure 
complete removal of the wash buffer, the column was eluted in 25 µL 
DNAse/RNAse-free water. Sample drying is discussed in Chapter 5. 
 
2.7 Lactate Assays 
Lactate assays were performed using Abcam’s Colorimetric/Fluorometric L-
Lactate Assay Kit (ab65330), according to the manufacturer’s instructions. 
Briefly, host cells were grown in 25 cm2 flasks until they were ~70% confluent. 
At this point they were infected or simply had their medium changed and 
returned to the incubator. Extracellular medium was removed, centrifuged ( 
1000 x g) to remove any potential parasite or cellular debris, diluted by a 
factor of two and placed on ice. Lactate standards were reconstituted and the 
assay was applied to standards and samples at the same time in black 96-well 
flat-bottomed plates (Greiner). After incubation, the plates were visualized 
using a Labtech FLUOstar Omega plate reader. 
 
2.8 Western Blot 
After infection (or growth) for the suitable time, ice-cold RIPA Buffer (Sigma 
Aldrich) with cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail 
(Roche) was added to 25 cm2 flasks. These were placed on ice for five minutes 
after which the lysate was scraped using a rubber policeman. Lysates were 
transferred to pre-chilled tubes and stored until further use.   
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 On the day of the western blot, the protein samples were clarified by 
centrifugation at 8000 x g for ten minutes. Protein concentrations were 
determined for each sample using a BCA Protein Assay (Thermo Scientific 
Pierce) according to the manufacturer’s instructions.  
 20 µg of each sample was added to an equal volume of 2X Laemmli 
sample buffer (Bio-Rad) with 30X Dithiothreitol (DTT) and the mixture 
boiled at 95 °C for five minutes. Following this, the lysate mixture was loaded 
into the wells of a 4-20% SDS-PAGE gel (Bio-Rad) and the gel was run at 
150 V for one hour in 1X TGS.  
After the gel was run, it was soaked in Transfer Buffer (25 mL Tris/190 
mM/20% Methanol) for fifteen minutes and then assembled into a transfer 
sandwich with a methanol-wetted membrane. Proteins were then transferred 
for 2.5h at 35 V. Transfer quality was checked with a Ponceau S stain 
following which the membrane was incubated with the primary antibody in 
5% Milk/TBST, overnight at 4 °C. The blot was then rinsed in TBST three 
times for ten minutes and then incubated with HRP-conjugated secondary 
antibody for one hour at room temperature. Following another three rinses as 
before, the blot was then incubated with ECL Plus Western Blotting 
Detection Reagents A and B at a 1:1 ratio (GE Healthcare) for one minute. 
After removal of the chemiluminescent substrate, the membrane was 
developed and visualized onto X-ray film (Fuji). [All steps of Western Blot 
apart from lysate preparation were done with Bo Shiun Lai] 
 
2.9 Fluorescence Microscopy 
Cells were seeded (and, if necessary, then infected) onto sterilized, gelatine-
coated coverslips. Though NIH/3T3 and HeLa is an adherent cell lines and 
would thus not usually need an additional substrate on the coverslips, the 
number of washes involved in the fixation process and the fact that 
monolayers are rendered somewhat fragile when infected meant that it was 
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necessary to coat sterilized coverslips with gelatine to ensure secure adherence. 
This was done by first sterilizing 22 mm2 glass coverslips in 70% ethanol (six 
times per coverslip), allowed to dry briefly on lint-free tissue paper and then 
rinsed twice in separate containers of 1X PBS.  After blotting the edges on 
lint-free tissue paper, the coverslips were then placed in the wells of 6-well 
plates. A 2% gelatin solution (Sigma Aldrich) was added to each well and the 
plates returned to the incubator for 30 minutes. After this, the gelatin was 
aspirated and the plates allowed to dry.  
 After growth, infection and/or treatment with methyl jasmonate 
(Sigma Aldrich), conditioned medium was removed from the wells and 
replaced with ice cold 4% paraformaldehyde (Pierce). After 15 minutes, this 
was aspirated and disposed of according to local safety guidelines. The wells 
were rinsed three times with pre-chilled PBS and either covered with PBS for 
storage at 4 °C or mounted immediately. Coverslips were mounted onto glass 
slides (Superfrost) using Vectashield Antifade Mounting Medium with DAPI 
(Vector Labs) and the edges sealed using a clear nail varnish said not to 
autofluoresce (Kai-Fai Leung, personal communication; Boots Natural 
Collection). 
 Images were captured using the AF6000 system with a Leica DM6000B 
upright fluorescence microscope and prepared for publication here using Fiji is 
just ImageJ, Fiji (93). 
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III. Identification of Putative Novel microRNAs 
 
3.1 Introduction 
3.1.1. High-Throughput-Sequencing / Next-Generation Sequencing 
The advent of high-throughput sequencing in the past ten years has changed 
many facets of genomic biology. The particular technical features (read 
lengths almost exactly the correct size, for example) and the emergence of the 
technology at a time when microRNAs too were just being discovered has 
meant that the application of NGS has been very useful in the field of miRNA 
research.  
Several methods of high-throughput sequencing have been developed 
and, though the methodologies may vary, the common features of all these 
platforms include those of parallelisation, speed of data generation and 
(relatively) low cost. Along with the ability to quickly produce vast amounts 
of sequence data, the fact that they determine sequence by ‘counting’ a signal 
produced by base-incorporation, rather than by interpreting an often-noisy 
hybridisation signal means that they can also be used for Digital Gene 
Expression (DGE). Put simply: counting the number of sequenced transcripts 
can thus be used as a direct measure of the expression of that transcript and 
so, these methods provide a robust platform both to discover new miRNAs 
and to determine their individual expression levels.  
The three ‘market leaders’ in high throughput sequencing are Roche’s 
454 system, ABI, with their SOLiD platform and Illumina’s Genome Analyzer, 
each with application-specific advantages and disadvantages (94). 
The 454 method, first commercialised in 2005 (95) essentially involves a 
bead-based parallelisation of pyrosequencing. Here, sheared sequence 
fragments are attached to beads such that a single fragment is bound per 
bead. Following amplification and denaturation of the bound fragments 
(resulting in a bead covered with identical template sequences) the beads are 
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then deposited into single wells, along with a light-generating enzyme mix. 
Sequential ‘waves’ of nucleotides are then applied to the wells: if a nucleotide 
is incorporated into the following position of the single-stranded, bead-
immobilised template, a stoichiometric number of photons is emitted. For 
each wave of applied nucleotides, the amount of light generated in each well is 
recorded and translated into sequence. The proportionality of light generated 
to the number of identical nucleotides incorporated into the template means 
that a single cycle is not necessarily limited to having extended the template 
has been extended by only one nucleotide, and thus, reads from 454 
sequencing technologies can be much longer than those produced by other 
high-throughput technologies (with read lengths of ~400bp, although far fewer 
reads will be generated. However, this advantage is also a drawback: the 
quantitation of emitted light intensities has been shown to falter when 
presented with for longer stretches of incorporated nucleotides. As a result, 
insertions or deletions (indels) of one or more nucleotides are the most 
common sequencing errors of this type of technology (96, 97). The long length 
of produced reads, along with 454’s propensity to produce indels rather than 
substitution errors (which are, arguably, easier to account for when the length 
of the read to be aligned is limiting (96, 98) mean that the application of 454 
to miRNA discovery and profiling – where accuracy, and depth of coverage 
are valued over read-length – would not be using the technology to its best 
advantage.  
ABI’s SOLiD platform for DGE is also bead-based but proceeds 
somewhat differently, employing a sequencing-by-ligation technique with di-
base interrogation. Here, adaptors are ligated to the ends of sequence 
fragments and made to bind to beads, where they are amplified via emulsion 
PCR. Sequencing primers complementary to the bound adaptor are added, 
along with ligase and four fluorescently-labelled ‘di-bases’. These di-base 
constructs consist of two nucleotides in a specific order followed by three 
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degenerate bases, ending with one of four fluorescent modifications, such that 
each of the four fluorescent colours itself corresponds to one of four possible 
dinucleotide combinations. Each position along the extending template 
sequence is thus tested for the nth and the n+1th base, and the correct di-
base (with the appropriate sequence of two nucleotides) is ligated and the 
fluorescence read. Following cleavage of the fluorescent moiety, the steps are 
repeated for the sequence immediately following the three degenerate 
(uncleaved) bases, yielding base-calls for sequence positions n, n+1 (from the 
first cycle), n+5 and n+6 (from the second cycle). After five such cycles, the 
primers are stripped and sequences re-probed with progressively shorter 
primers, so that eventually, each nucleotide position along the template 
sequence has been interrogated twice, with a different di-base combination. 
After the desired number of rounds, the resultant ‘gapped’ sequences are 
intercalated in so-called ‘colour-space’ and matched to a matrix of each of the 
possible di-nucleotide combinations to determine the full sequence.  
While this technology has advantages when it comes to distinguishing 
sequencing errors from natural variation (and is thus very useful when it 
comes to applications such as SNP calling, where these will have specific 
colour variations in the sequencing process), the fact that it involves not only 
per-cycle fluorescence cleavage steps but also several rounds of sequencing 
with different primers greatly increases the time taken for a run (99). 
Additionally, its use of colour-space, rather than the more familiar nucleotide- 
or base-space as a sequencing ‘alphabet’ means that end-users are usually 
unable to interpret ‘raw data’ themselves and must rely on SOLiD-specific 
tools for alignment.  
The sequencing technology implemented by Illumina, has, arguably, 
proven to be the most-widely adopted one, especially in the United Kingdom 
(according to a crowd-sourced map of sequencing facilities (100).  
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Figure 3.1. A schematic representation of the Illumina sequencing process. 
The main steps involved in the Illumina sequencing-by-synthesis process are shown here, with 
RNA fragments depicted in red; 3’ and 5’ adaptors in blue and violet. Individual nucleotides 
are represented as coloured stars. 
 
The first steps of the chemistry are very similar to other high-
throughput sequencing platforms, where genomic or transcriptomic sequence 
fragments of interest are ligated to adaptors. In the case of miRNA analyses, 
the adaptors are conceived such that they will only ligate to molecules 
possessing the characteristic 3’ OH and 5’ phosphate termini. Instead of being 
immobilised and amplified on beads, however, these templates are covalently 
attached to a slide where solid bridge amplification takes place. Much like 
Sanger sequencing, this technology relies on the use of dye-labelled terminator 
nucleotides but, importantly, these terminators are reversible (Reversible 
Terminator bases, RT-bases (87)). Instead of having to electrophorese and 
sort each fluorescently-terminated fragment by size (as in Sanger sequencing) 
after each cycle of Illumina’s RT-base addition, the fluorescence is read, and 
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the terminator is cleaved (leaving behind a now-unmodified nucleotide), 
allowing the reaction to proceed anew for the following base (Figure 3.1).  
 The process of having to incorporate, read and cleave, for every 
extended base, renders the sequencing reaction quite slow (Illumina’s own 
estimates for the Genome Analyzer were of ~48 hours for a 36-cycle run (102), 
though this figure has vastly improved with newer sequencers. Another result 
of the sequencing-by-synthesis chemistry of this method is that the length of 
resultant reads is quite short: At the technology’s inception, read lengths were 
only 27nt in length (103) though both improvements in the technology and 
the use of paired-end or mate-pairing methods now yield far longer reads, 
which make the technology especially useful for RNASeq (Chapter 6). 
Regardless, such short read lengths are not an issue when it comes to miRNA 
discovery and characterisation.  
 
3.1.2 Bioinformatic Challenges 
As with other platforms of DGE, Illumina’s Genome Analyzer technology is 
challenging on many levels. Though the sequencing itself has been greatly 
facilitated since the days of directional cloning, methods of library preparation 
are still complex multi-stage processes and, at least in the early days of 
implementation, little documentation was available. Once the sequencing has 
been performed, these experimental challenges are replaced by bioinformatic 
ones. The sheer volume of returned sequence means that traditional 
algorithms for interpretation are no longer feasible, and instead, novel tools 
need to be employed. While several such packages have emerged, in the early 
years they tended to be application- or platform-specific, having often been 
developed ‘in-house’ to tackle a single lab’s specific concerns (Krys Kelly, 
personal communication, Rory Stark and Kevin Howe, personal 
communication). When in-house methods are published as generalised tools, 
they may often simplify the process without fully describing what assumptions 
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are being made and whether these are applicable to the problem at hand (104, 
105). Indeed, many publications that employ DGE often describe their 
bioinformatic methods in a very cursory manner, without presenting 
arguments for each of the steps taken. Moreover, despite the relatively recent 
history of DGE, technologies and platforms are being changed and improved 
extremely quickly, meaning that software tools, unless actively maintained 
and updated for each hardware release on each platform, may not be able to 
keep pace.  
 
3.1.3 Novel miRNAs in Toxoplasma gondii 
To-date, only a handful of studies have sought to identify and characterise 
parasite miRNAs directly. Braun et al were the first to do so, by deep-
sequencing purified parasites of Type I RH, Type II Prugniaud and Type III 
CTG strains. They identified 14 putative miRNA families and performed 
northern blots on these. Seven families gave a positive signal, though this was 
often with ‘double banding’. The authors controlled for the possibility that 
these may be host miRNAs by running northern blots on uninfected host 
RNA as well, and found no visible signal (106). However, none of these 
miRNAs have to-date been included in miRBase, though a comment on the 
website provides a reason: A comment by the miRBase creator, Sam Griffiths-
Jones in February 2013 states, “We do have a few non-animal, non-plant 
miRNAs that have been published and submitted to us. The sets we don’t 
have were not submitted or it was agreed with authors not to deposit them. 
There is some controversy in the community about these” (107). He further 
goes on to cite a review that challenges the veracity of published putative 
miRNAs from a number of species, those identified by Braun et al in 
Toxoplasma gondii included (108). The main challenge from the review’s 
author is that the miRNAs identified by Braun et all either cannot be 
localised to the genome, lack star sequences, or can be shown to be fragments 
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of other RNAs, such as  a perfect match to T. gondii 18S rRNA. This is a risk 
of their analysis procedure, where they excluded rRNAs from their read set 
before performing alignments, rather than looking for rRNA fragments post 
hoc. Additionally, the fact that they employed a fairly low Phred cut-off score 
of 10, perhaps indicates that the libraries may have been of overall low-
quality. Given the group’s success in validating at least some of the candidates 
by northern blot does not of course preclude at least some of their putative 
miRNAs from being non-canonical, or ‘miRNA-like’ RNA species.  
The next study of Toxoplasma gondii miRNAs was performed in 2012 
by Wang et al (109), where miRNAs from RH and ME49 were compared. 
Interestingly, their parasites were purified from mice (rather than propagated 
in cell culture). Curiously, their cited method for parasite purification is for 
separating bradyzoites cysts from the brains of infected mice – it is not a 
usual method for tachyzoite isolation from mice, which would usually be done 
through intraperitoneal lavage of infected mice (Uas Müller, Stuart Woods, 
personal communication). Nevertheless, the authors maintain that “tachyzoites 
were purified” by this method (109). Nevertheless, their analysis revealed 356 
novel putative miRNAs, of which 17 were found to be related to 2 metazoan 
miRNA families (which are unnamed in the manuscript). That being said, a 
quick look at the sequences that are presented as novel putative miRNAs 
show some as being entirely composed of GT dinucleotides. Of course, some 
annotated miRNAs within the current instantiation of miRBase are similar, 
such as mmu-miR-466i, but that does not make them any more ‘real’. The 
authors find that seven of their putative miRNAs are supported by the Braun 
et al (110). 
Xu et al also used tachyzoites from live mice to perform their analyses, 
and they identified tachyzoites from intraperitoneal lavage of infected 
Kumning mice. The authors were able to identify 54 putative miRNAs from 
five strains of T. gondii. In an unusual choice, they did not also collect and 
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profile intraperitoneal lavage samples of uninfected mice, nor did they align 
their sequence reads to the mouse genome (111).   
The most recent analysis of putative T. gondii miRNAs is a wholly 
computational effort which holds as its central hypothesis the possibility that 
T. gondii export hairpins to the host where they would be processed and 
would act on host cell targets. Saçar et al first extracted all possible hairpins 
from the genome of T. gondii (ME49) and then used a machine learning 
approach to compare these to mouse, rat and Chinese hamster mature 
miRNAs, as a scoring filter. The resultant high-scoring hairpins were then 
checked against publicly-available T. gondii transcriptomic data. Apart from 
the fact that there is no evidence of pre-/pri-miRNA export form the parasite, 
this is nonetheless a compelling idea, one that has been proposed before (112). 
One of the limitations of Saçar et al’s study, however, is that their step of 
aligning their putative T. gondii-derived miRNAs to parasite transcriptomic 
data (to confirm expression) did not take into account any of the 
characteristic patterns of miRNA read alignment. Moreover, though they were 
looking specifically at miRNAs ostensibly of parasite origin, the transcriptomic 
datasets they were using would almost certainly contain host material as well. 
The fact that they cross map parasite-derived rodent-like miRNAs to the 
parasite transcriptome grown in human cells (and vice versa) might have been 
an attempt to ‘correct’ for this, but no mention is made in the text, and the 
reciprocal alignment (which would have been performed had this been a 
concern) was not performed.  
 Several of these studies highlight the need to look carefully at the 
genomic context in which miRNA precursors are encoded, and how that 
impinges on expected patterns of alignment and folding. At its most basic, a 
particular profile is expected, with a large stack of reads aligning preferentially 
to one of the stems of the pre-miRNA hairpins but with a few reads aligning 
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to the star strand and an even lesser proportion crossing the hairpin region. 
This is illustrated in Figure 3.2.  
 
 
Figure 3.2. A schematic representation of the steps involved in NGS analysis.  
After sequencing reads (blue) have had their adaptors (orange and purple) clipped off, they 
must be aligned to the genome (red). If they truly do originate from a miRNA-encoding locus, 
a characteristic profile is expected (green).  
 
Indeed, this is one of the criteria that miRDeep2 (113), a programme 
developed by Friedländer et al to identify novel miRNAs from sequencing 
data, uses. First, potential precursors are excised from the genome, based on 
the presence of alignment ‘stacks’ corresponding to potential mature, star and 
loop sequences. These potential precursors are then folded, using RNAfold and 
the secondary structures of these are evaluated and scored, based on the 
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likelihood of forming an unbifurcated hairpin loop (as compared to the 
appropriate randfold calculations). The potential precursors are also scored 
based on whether they contain a seed sequence similar to known miRNAs 
from a closely-related species and on whether they have been detected in more 
than one of the input samples. A list of known inputted miRBase miRNAs is 
also subjected to the same process as a control procedure, in order to then 
estimate the sensitivity of the programme (which is then fed back into the 
prediction scores for the putative novel miRNAs. As such, each potential 
miRNA receives a final combined miRDeep2 score from which the user can, if 
desired, select the criteria which are most likely to represent truly novel 
miRNAs given the particular experimental conditions. 
In this chapter I will discuss the application of Illumina’s GA 
technology – from sample library preparations to analysis of the resultant data 
to predict novel miRNAs – when applied to NIH/3T3 mouse embryonic 
fibroblasts mock-treated or infected for 24 hours with Toxoplasma gondii 
tachyzoites. I discuss several alternative methods of handling each step of the 
process, paying particular attention to some of the pitfalls that may be faced 
when dealing with these types of data.  
 
3.2 Methodology 
NIH/3T3 were infected with Type II, ME49 tachyzoites, at a Multiplicity of 
Infection (MOI) of 5:1 or left uninfected for 24h, after which total RNA was 
isolated using a TRI Reagent / column purification method. This material was 
collected by Dr Nadia El-Guendy in the lab of Dr Anthony Sinai at the 
University of Kentucky.  
 
3.2.1 MicroRNA Library Preparation  
Small RNA libraries were prepared from these RNA samples according to the 
Illumina-recommended protocol (version 1.4B). Given that this section deals 
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largely with probing several aspects of this protocol to better understand the 
mechanisms of library preparation, I include it here (rather than in 2.4). 
Briefly, the recommended protocol is as follows:  
1) Total RNA is electrophoresed on a 15% Tris-Borate-Urea (TBU) 
polyacrylamide gel alongside 10bp DNA ladders.  
2) The (invisible) gel slice corresponding to the miRNA fraction (20-30nt) is 
then excised, pulverised and the RNA eluted for 4h in NaCl, following which 
the 5’ RNA Adaptor is ligated (for 6h).  
3) The resultant preparation is electrophoresed again, on a 15% TBU 
polyacrylamide gel.  
4) The (invisible) gel slice corresponding to RNAs of size 40-60nt is then 
excised, eluted for 4h in NaCl and ligated to the 3’ RNA Adaptor.  
5) The full RNA construct (70-90nt) is electrophoresed on a 10% TBU gel, the 
corresponding (invisible) band excised, and the RNA eluted for 4h.  
6) Following RT-PCR using a tailed primer, the resultant amplified DNA 
product is then electrophoresed on a 6% Tris-Borate-EDTA polyacrylamide 
gel.  
7) The (now-visible) band is excised, eluted and sequenced.  
Given the lengthy and multi-step process involved in library 
preparation, I decided to examine several of the steps in detail and optimise 
them for efficiency if possible. 
 
Ladder Calibration 
Because the first few steps of the Illumina library preparation protocol 
involved the excision of bands that would be not be visible, it was important 
to ensure that the DNA ladders that were to be used as guides were well-
calibrated and migrated at rates similar to the RNA samples. To this end, I 
ran 10 and 25bp DNA ladders on a hand-cast 15% TBU polyacrylamide gel, 
alongside DNA and RNA standards of known sizes. I also included Drosophila 
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melanogaster total RNA, since that organism’s 2S ribosomal RNA is of similar 
size to miRNAs (30nt) (114) and could be used as additional RNA marker for 
ladder calibration. It appeared that there was some discrepancy between the 
migration rates of RNA and DNA (Figure 3.3, lanes 3-5) with the DNA 
samples (including the ladder) running marginally faster. This has been 
reported for formaldehyde-containing agarose gels (115) but may also, as we 
have found, have a small effect in polyacrylamide gels. This slight discrepancy 
was taken into account in all gel excision steps where a DNA ladder was used 
as a guide for an RNA sample. 
 
 
Figure 3.3 Analysis of migration rates between RNA and DNA reveals a slightly faster 
migration for DNA samples.  
A variety of RNA and DNA samples were run on a polyacrylamide gel to assess the migration 
of these two different species, and whether this might have any implication for downstream 
library preparation methods. The results from Lanes 3 (18bp DNA), 4 (18nt RNA, low 
concentration) and 5 (18nt RNA, high concentration) indicate that DNA appears to migrate 
slightly faster than RNA counterparts in polyacrylamide gels. The remaining lanes were run 
to ensure that any discrepancies arising from migration speeds were indeed a result of the 
DNA/RNA difference and not a ‘systemic’ difference between nucleic acid fragments and the 
corresponding bands on the reference ladder.  
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Ligation 
The unit definition for T4 RNA ligase is given as catalysing 1 nanomole of 5´-
[32P]rA16 into a phosphatase-resistant form in 30 minutes at 37°C and so, the 
ten units of enzyme specified by the protocol coupled with incubations of six 
hours seemed excessive. I verified this by performing the ligation reaction with 
an RNA standard for either the recommended six hours or for one hour, and 
found that the shorter incubation period was sufficient, as shown in Figure 
3.4. Indeed, more recent versions of the Illumina small RNA library 
preparation protocol perform ligations for one hour per adaptor (116).  
 
Figure 3.4. Analysis of different ligation times shows that a one-hour incubation is sufficient 
to yield sufficient ligation.  
Pairs of each ligateable or not a RNA standard (3’ and 5’ adaptor) were incubated with T4 
RNA ligase for either one or six hours (the latter being recommended in the Illumina 
protocol). Lanes 2 and 3 show that a one hour incubation is sufficient to ligate 3’ adaptors 
together. Controls were performed with the 5’ adaptor, lanes 9 and 10, which will not ligate 
due to the absence of a phosphate at the 5’ end and an OH group at the 3’ end. 
 
Samples 
The version of the microRNA library protocol that I followed recommended 
the inclusion of a co-precipitant carrier after the elution of the cDNA band, in 
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order to facilitate the identification of pellet. The manufacturers of Pellet 
Paint® note in their instructions that, while the carrier itself absorbs in the 
UV range used for nucleic acid quantitation, a batch-specific correction factor 
can be applied to offset its contribution to absorbance. This proved not to be 
the case with my samples, however, resulting in extremely erratic and 
inconsistent Nanodrop readings. As an alternative quantitation, I therefore 
performed gel electrophoresis of 1µL of each sample alongside various dilutions 
of DNA ladders. Though a number of cDNA libraries were prepared, only four 
were used for downstream analyses. The samples in Figure 3.5 labelled in red 
are the ones that were used for subsequent downstream analyses. FB1.1 and 
FB2.1 are replicates of uninfected cells while FB1.3 and FB2.3 are replicates 
of infected cells. 
Figure 3.5. Libraries and approximate concentrations. 
In order to best approximate the concentration of each of the cDNA libraries, aliquots were 
electrophoresed alongside known concentrations of GeneRuler ladder. The libraries’ 
concentrations were thus then estimated visually and placed into bins of 0-1ng, 1-5ng, 5-10ng. 
These assignments were blind-tested by two additional colleagues (Ajioka and Micklem, 
personal communication). Lanes and samples denoted in red are the ones that were taken 
forward for further experiments. FB1.1 and FB1.2 denote replicates uninfected cells; FB 1.3 
and FB2.3 denote replicates of infected cells.  
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These cDNA libraries were then sequenced, on the Illumina GA 
platform at the University of Tokyo, by the late Dr Junichi Watanabe. FB1.1 
and FB2.3 were sequenced on the same flow cell, while FB2.1 and FB1.3 were 
sequenced together on a separate one.  
 
3.3 Results 
3.3.1 Quality 
Illumina GA sequencing of the small RNA libraries yielded raw datasets of 
between eight to ten million reads each. Of these, a small proportion (<3 per 
cent) included bases whose quality was too low to be assigned (depicted as “.” 
or “N”, indicating an unknown nucleotide): these reads were discarded from 
further analysis. Since the datasets represented raw reads from the machine, 
the first pre-processing step was to determine the number of unique reads in 
each dataset. Interestingly, for each of the datasets, it appeared that the ~10 
million reads in each dataset collapsed to a relatively few ~2.5 million.  
 
 
Figure 3.6. Chart of library sizes 
 
Looking at the frequency distribution uncovered that in fact, the 
overwhelming majority of reads had been sequenced fewer than 1000 times. In 
02000000
40000006000000
800000010000000
12000000
FB1.1 FB2.1 FB1.3 FB2.3Uninfected	A Uninfected	B ME49,	MOI	5 ME49,	MOI	5
N
um
be
r	o
f	R
ea
ds
Raw	CompleteUnique
	 48	
all four libraries, it was found that over 99.9 per cent of the reads had been 
sequenced fewer than 1000 times each. Further examination of the datasets 
(Figures 3.7-3.10) revealed that much of the apparent homogeneity in the 
dataset could be accounted for by a very small number of unique sequences: 
The seven most-frequently sequenced reads in each library accounted for 
between ~1.5 and nearly 3 million reads in each dataset, corresponding to 
between 14 and 31 percent of each library. This observation led me to 
examine these most-frequently sequenced reads manually, to see if I could 
determine their origin. In the most extreme dataset (FB1.1), all seven of these 
reads could be traced to either adaptor-dimerisation or ligation of an adaptor 
to a polyadenylation signal (Figure 3.7). In the other uninfected control 
sample, the situation was less clear-cut, with adaptor-dimers, polyadenylation 
making an appearance but also the highly-expressed mouse microRNA let-7. 
Let-7 also appeared in the datasets from infected samples, but two other 
sequences (with no significant alignments to the mouse genome but significant 
alignments to the T. gondii genome) also featured prominently.  
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Figure 3.7. The most frequently sequenced reads in FB1.1 show significant adaptor 
contamination. 
The seven most-commonly-sequenced reads in the first replicate of the uninfected sample were 
examined manually, to ascertain what their composition might be. In all cases, the sequenced 
reads could be accounted for through some combination of adaptor concatamerisation or 
ligation of an adaptor to a polyadenlyation signal. 
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Figure 3.8. The most frequently sequenced reads in FB2.1 reveal adaptor contamination as 
well as let-7 miRNA. 
The seven most-commonly-sequenced reads in the second replicate of the uninfected sample 
were examined manually, to ascertain what their composition might be. Unlike the previous 
replicate, there were two cases in which a highly expressed miRNA was present. In all other 
cases, as in FB1.1 (Figure 3.7), the sequenced reads could be accounted for through some 
combination of adaptor concatamerisation or ligation of an adaptor to a polyadenlyation 
signal. 
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Figure 3.9. The most frequently sequenced reads in FB1.3 reveal adaptor contamination, let-7 
miRNA and unkonwn sequences. 
The seven most-commonly-sequenced reads in the first replicate of the infected sample were 
examined manually, to ascertain what their composition might be. Two cases were not found 
upon a search of BLASTN. Apart from that, the most frequently-sequenced reads were 
accounted for by adaptor concatamerisations, adaptor-polyA ligations or known miRNAs. 
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Figure 3.10. The most frequently sequenced reads in FB2.3 reveal adaptor contamination and 
unknown sequences. 
The seven most-commonly-sequenced reads in the first replicate of the infected sample were 
examined manually, to ascertain what their composition might be. Two cases were not found 
upon a search of BLASTN. Apart from that, the most frequently-sequenced reads were 
accounted for by adaptor concatamerisations, adaptor-polyA ligations or known miRNAs. 
 
Error 
The fact that adaptor-dimers, with some mismatches, made up a large portion 
of my datasets – and that the sequence of these adaptors is known a priori – 
led me to develop a method to assess the error rates of the sequencing process. 
This error rate would then inform the parameters chosen for alignment of the 
reads to the mouse genome.  
I created a set of short seed sequences by sliding a 9-mer window along 
the full adaptor-dimer sequence (blue and purple in Figures 3.7-3.10) and 
checked every resultant sequence tag against the full set of known mouse 
stem-loop pre-miRNAs (in either orientation on either strand) as well as 
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against each of my datasets. The most frequently-seen (in the datasets) 9-mer 
that did not match any part of any known mouse miRNAs was 
TCTACAGTC (a portion of the 5’ adaptor). I used this sequence as a 
signature tag to identify adaptor dimers, and performed an exact search for it 
in my datasets, the results of which are shown in Table 3.1. 
 
Table 3.1. High prevalence of the 5’ adaptor ‘tag’ in each library. 
Given the obvious contamination of my sequencing libraries by adaptor dimers containing the 
5’ adaptor, I performed a search for a 9-mer containing adaptor sequence within each. In 
terms of raw reads, close to half of each library contained this sequence, though this figure 
ranged from 7.6 to 12.5% when looked at as unique (collapsed) reads. 
Presence of 
TCTACAGTC tag 
Total reads Unique reads 
Percentage Percentage 
FB1.1 5,189,994 327653 
54.00% 12.50% 
FB2.1 4,132,876 303,535 
47.50% 11.60% 
FB1.3 3,347,642 275,351 
40.20% 9.70% 
FB2.3 3,396,108 304433 
32.10% 7.60% 
 
I then examined the ‘tails’ that followed these nine bases. Overwhelmingly, 
the consensus sequence among the tails consisted of, as expected, bases 
corresponding to the remainder of the 5’ adaptor and then the 3’ adaptor but 
there was nevertheless quite a lot of variability, and this variability is what I 
chose to exploit in determining an error rate.  
For each of the reads that contained the TCTACAGTC tag, I 
performed alignments to the reference (adaptor-dimer) sequence and recorded 
the number of mismatches for each read. The collated per-read or per-tail 
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mismatch rates for each dataset are shown in figure 3.11. The error rates 
appear more consistent between samples sequenced together than between 
biological replicates (FB1.1 and FB2.3 vs FB2.1 and FB1.3).  
 
 
Figure 3.11. Mismatch analysis between the actual and expected tails following the 5’ adaptor 
tag reveals sequencing batch effects and an error rate of >2nt. 
Following the identification of the 9-mer 5’-adaptor tag (Figure 3.10), the tails following this 
tag were examined in each of the seqenced libraries and mismatches tallied up. This revealed 
an average error of 1.78nt.  
 
In three of the four datasets, the average number of mismatches per 
read was less than two. The average across all samples was 1.78 and as such, I 
used a mismatch allowance of two in subsequnt alignments. [While in FB2.3, 
the average number of mismatches was 2.34, using a higher mismatch 
allowance of three for its subsequent genome alignments did not prove to be 
much of an advantage in terms of genome coverage, but only served to vastly 
increase the amount of time taken for both the alignment and subsequent 
analyses].  
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3.3.2 Removal of Adaptors: 
Since miRNAs are shorter than the full length of an Illumina sequence read 
(36nt)3, the issue of adaptor-removal from sequence reads is two-fold. First, a 
trace of the 3’ adaptor should be a requirement for a read to be deemed as 
having come from a miRNA (rather than, for example, a degraded mRNA or 
a pre- or pri-miRNA). Second, these traces of adaptor must be removed before 
reads can be aligned to the reference genome.  
The most common method of adaptor removal (those suggested in the 
MirDeep2 package (104) or the UEA sRNA ToolKit (105) for instance) consist 
of simple, exact searches for a specified minimum number of nucleotides 
matching the adaptor, and trimming reads accordingly. These methods, 
though simple to implement, have a number of disadvantages.  
The quality of reads produced through deep sequencing – especially 
from earlier generation machines – tends to drop towards the 3’ end of reads 
(117) and, since this is where the adaptor is expected to be located, searches 
for exact matches may miss a significant number of adaptor fragments. 
Moreover, given that the presence of a 3’ adaptor fragment should be a 
requirement for inclusion of a read in downstream analysis, by missing 
adaptor sequences, simple searches may disqualify reads that in fact do 
contain 3’ adaptor but have been mis-sequenced to a certain extent.  
For sequencing runs where the quality remains high even towards the 
3’ end of the read, or for very large datasets that can afford such losses, these 
types of approaches might be satisfactory. For datasets such as mine, 
however, from earlier generation machines with un-optimized runs, allowances 
for sequencing errors are needed. The risk of allowing mismatches in adaptor-
retrieval is that a ‘nonsense’ sequence or a degradation product might be 
incorrectly identified as adaptor and thus removed, with the remainder of the 
read being retained for downstream analysis. However, this can to some extent 																																																								3 The longest mouse miRNA in mirBase version 19 is 27nt  
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be accounted for: if indeed a ‘nonsense’ sequence fragment was falsely 
identified as adaptor and trimmed, it is likely that the earlier portion of the 
read (the supposed microRNA) would also be nonsense. If so, it would be 
unlikely to align to the reference genome. If it did, or if the fragment 
originated from a degraded mRNA, it would not align according to the 
specified pattern expected of miRNAs. In subsequent alignment and coverage-
determination steps, therefore, it would eventually be discarded anyway.  
The alternative – to discard reads from the outset because they do not contain 
an exact match to the 3’ adaptor – is to exclude them from ‘redemption’ 
through alignment at all.  
Another drawback of simple searches is that they fail to detect 
instances of adaptor concatenation, unless explicitly described and searched 
for. And, as shown in (Figures 3.7-3.10), due to adaptor truncation and the 
presence of some mismatches, many variations of adaptor contamination exist: 
identifying and specifying each of them in turn to then search and trim is 
laborious and sure to miss some instances.  
One program that addresses both the issue of mismatches and of 
adaptor dimerisation is ScreenLinker4. This program aligns adaptor sequences 
to sequence reads using an “end-gaps-free” alignment, which aligns the entirety 
of one sequence (the adaptor) against another (the read under consideration), 
but does not penalise mismatches at either end. This type of alignment, while 
foremost searching for the ‘expected’ situation of an overlap between the 
beginning of the 3’ adaptor sequence and the end of the read, also can be 
made to look for overlaps between the 5’ and 3’ adaptors, as well as 
concatamers thereof. Effectively, each read is screened twice, for each adaptor 
sequence provided. In the aligned region, a certain number of mismatches and 
indels are also allowable. However, screenLinker’s scoring, while it allows for 
mismatches, also allows for indels. These are known to be far less frequent in 																																																								4	The ScreenLinker program was a kind gift from Gordon Brown, CRUK.  
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Illumina datasets than those from other sequencing platforms and might 
render the programme too stringent, categorising sequences as being entirely 
made up of adaptor when they are not. 
Thus, there exists a delicate balance between an allowance for 
mismatches and stringency when it comes to excluding adaptor sequences. 
Indeed, whichever adaptor-trimming method is used, the ‘test’ is the 
alignment pattern that it produces.  
The strategy that I ultimately opted to employ to search for and 
remove adaptor fragments was a combination of the above methods. First, I 
aligned the raw reads against the adaptor sequence, using an exhaustive 
‘affine:overlap’ model5, which requires the inclusion of the start or end of the 
query (raw read) and the start or end of the target (adaptor sequence). This 
model of alignment gives rise to successful alignments following two possible 
configurations: Either the alignment would place the adaptor at the 3’ end of 
the read (the desired situation) or at the 5’ end of the read (spurious match or 
5’ adaptor concatemerisation). To distinguish between these two cases, I 
filtered the successful alignments on both the position of the adaptor match 
and the length of the sequence preceding the match (the length of the 
presumed miRNA). This enabled me to retain only those reads that followed 
the pattern: read—3’ adaptor, with a minimum read length of 16nt.  
Following this, I screened the resultant reads for 5’ adaptor 
contamination, by applying a 12nt window along the length of the 5’adaptor 
and searching for these sequences within the clipped set. Reads that produced 
alignments to any 5’ Adaptor 12-mer were discarded.  
One interesting though little-discussed problem with adaptor removal is 
the issue of whether to retain or discard the final nucleotide when a read ends 
in T (the first nucleotide of the 3’ adaptor). Arguably, this is more of a 
concern when it comes to first-generation sequencing runs where reads were 36 																																																								5 This alignment was performed using exonerate (282) 
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nucleotides in length but, with the longest miRNA in miRBase being reported 
as being 34 nucleotides long, it is nevertheless an issue worth considering, 
especially if datasets are to be used for novel miRNA discovery in species 
where the ‘rules’ have not yet been fully characterised. As with many aspects 
of next-generation sequence manipulation, this issue is perhaps best thought of 
in a cost-benefit manner: The risk of allowing an adaptor-derived trailing T to 
stand might mean the difference between the read aligning to the genome or 
being discarded. If, on the other hand, single trailing Ts are removed but 
derive from true miRNA sequence, the remaining read will still align to the 
correct locus, albeit with a slightly less-well-resolved 3’ end. These alignments 
will not affect differential expression of known miRNAs (no currently-
described mouse miRNAs are that long) nor will they affect novel miRNA 
prediction, where precursor sequences flanking the putative miRA are excised 
and subjected to folding and other tests anyway. For this reason, I retained 
reads ending in U (T), but clipped this final nucleotide.  
I sought to assess my method of adaptor removal empirically, by 
comparing it to the two other ones, by applying each of them to one of my 
datasets (FB1.1).  
For the Simple Search method, I used a naïve regular expression search (as 
suggested by Krys Kelly, personal communication), to extract reads that 
contained at least one nucleotide of sequence (A, T, C or G) followed by the 
first eight nucleotides of the 3’ adaptor sequence while also requiring the 
presence of this pattern. Of course, this method retains all lengths of 
remaining sequences (including, for example those instances where the eight 
bases of adaptor occur a single base in from the 5’ end of the read). Most 
aligners typically have some minimum number of bases that they can usefully 
align to a reference and furthermore, the shortest known mouse miRNA is 
16nt long. Thus, I excluded from the dataset any trimmed reads that were 
shorter than this.  
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I fed the same initial dataset to the screenLinker programme, using its 
default mismatch/indel score cut-off of 0.85, again with a minimum retained 
length of 16nt.  
 
The number of unique and total reads retained using each of these three 
methods is shown in Figure 3.12.  
 
 
Figure 3.12. A sequential adaptor removal method yields a higher raw:unique read ratio 
compared to a naive regular expression search or screenLinker programme. After performing 
adaptor removal using one of the three methods described in the text (naive regular 
expression search, screenLinker or my sequential removal), read numbers were assessed. The 
sequential method yielded a moderate raw library size but a greater diversity of reads.  
 
Prioritising only the number of retained reads is not a wholly 
satisfactory way to choose an adaptor removal strategy, however, as this 
criterion gives no indication of how the retained reads will ultimately align to 
the genome. Thus, I then used Bowtie (118) with a mismatch allowance of 
two to align each set to the mouse genome, the results of which appear in 
Table 3.2. 
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Table 3.2. Alignment statistics of pilot adaptor clipping – FB1.1 clipped according to one of 
the three methods 
Reads clipped using one of the three adaptor-trimming methods were aligned to the mouse 
genome using Bowtie with a mismatch allowance of 2. The sequential and naive regular 
expression methods yielded high raw alignments but again, my sequential method yielded a 
greater diversity of aligned reads (more unique reads). 
 Simple ScreenLinker My method 
Aligned Reads -
Unique 
68,160 130,181 335,960 
Aligned Reads – 
Total/Raw 
3,186,788 340,871 1,649,877 
 
As a control, I then filtered the successful alignments on their location, 
looking at matches to the locus encoding one of the most ubiquitous miRNAs: 
let-7a6. Using the alignment pattern to a well-characterised miRNA enables us 
to evaluate the pattern of alignment produced by each of these methods: 
whether they retain reads that align indiscriminately to the genome or 
whether they retain reads that have likely come from true miRNA loci (Figure 
3.13).  
 
																																																								6	This was done using the coverage programs described in Chapter 4	
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Figure 3.13. Coverage of the let-7a locus using different adaptor trimming methods reveals 
that a sequential method of adaptor removal performs best.  
The well-characterised let-7a locus was probed after 3’ and 5’ adaptors were removed with 
either a pre-written programme ScreenLinker (a), my own sequential method (b) or a simple 
search (c), all described in main text. The ScreenLinker and sequential method performed 
similarly, with my own revealing slightly higher read counts being retained. NB the very small 
(but nevertheless present) proportion of coverage shows the putative *strand locus. 
 
While my method and the screenLinker method appear to be fairly 
similar according to the metrics tested above, with screenLinker being slightly 
more stringent as expected, the simple search produces some puzzling results. 
It retained the most raw reads (Figure 3.12) and also produced the greatest 
total number of aligning raw reads, though these alignments came from the 
smallest number of unique sequences (Table 3.2). The alignment pattern along 
the let-7 locus provides more insight into how this might have occurred. 
Simple searches appear to retain a relatively small number of highly-sequenced 
reads. However, this type of adaptor-removal procedure completely disregards 
the issue of 5’ adaptor contamination and this contamination, when allowed to 
proceed through alignment, can lead to spurious matches to the genome 
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(especially when alignment allows for mismatches). Indeed, the most highly-
represented read retained by the simple search that also aligned to the mouse 
genome was the trimmed read “TTCTACAGTCCGACGATC”, which the 
simple search had retained as though it were a true miRNA. However, this 
18mer is in fact part of the sequence of the 5’ adaptor however, and a clear 
result of adaptor concatamerisation7. This is further borne out by looking at 
the coverage profile of let-7a, where the simple search produced the fewest 
matching alignments: though more reads in total may have been retained, 
their pattern of alignment is clearly sub-optimal when it comes to identifying 
patterns of miRNA read provenance.  
Having chosen an appropriately-balanced adaptor-removal strategy, I 
then applied this to the other datasets (Figure 3.14). 
 
 
Figure 3.14. Number of reads retained from each library after adaptor clipping. 
After using the sequential adaptor removal method described above, the number of raw and 
unique (collapsed) reads were tallied. All libraries showed a retention of over 1 milion unique 
reads. 
 
 																																																								7 In fact, this is another indication that the method of relying only on alignment to screen out 
adaptor sequences is insufficient to exclude them. 
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3.3.3 Alignment  
I used the per-read error calculations above to produce genome alignments for 
each dataset, using Bowtie (118). Alignment statistics for each dataset are 
shown in Figure 3.15. Rather few reads ended up aligning to the M. musculus 
genome – between eight and 19% of the unique trimmed reads. When looked 
at under the lens of raw reads (Figure 3.16), the situation is slightly better 
with most alignment percentages doubling. That being said, the number of 
unique mapping reads themselves is also quite small – under 300,000 in all 
libraries. 
 
 
Figure 3.15. Reads that aligned to the genome, as a percentage of the trimmed population. 
The adaptor-removed reads were aligned to the mouse genome, using Bowtie (119). Between 
eight and 19% of the unique (collapsed) reads were retained after alignment, while between 23 
and 45% of raw reads were retained. 
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Figure 3.16: Raw number of reads that aligned to the mouse genome. 
Adaptor-trimmed reads were aligned to the mouse genome using Bowtie (119). Aligned 
population sizes ranged from 170,762 to 268,739, whereas these same libraries accounted for as 
raw (uncollapsed) reads ranged from 838,860 to 1,827,933 reads per library. 
 
Reads that aligned to the mouse genome according to these parameters 
were then selected either for expression analyses of known mouse miRNAs 
(Chapter 4) or for the identification of novel miRNAs.  
 
3.4 Discussion 
3.4.1 Novel microRNAs in Mouse only 
In order to predict novel miRNAs expressed in my dataset, I used miRDeep2 
(113) to analyse my aligned reads. At a score  0, (an estimated signal-to-
noise ratio of 1.5 or above), 415 of the 1281 miRNAs in miRBase were picked 
up in my datasets by miRDeep2 (81%).  
At this same score, 180 novel miRNAs were predicted over all four 
samples. Two had significant hits to rRNA or tRNA and were thus excluded 
from consideration as potential mouse miRNAs. 34 of the remaining putative 
miRNAs were scored using read-evidence from the infected samples only, 
which could be explained in two ways: either these are T. gondii miRNAs 
which also map to the mouse genome or, these could be mouse miRNAs 
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expressed only under conditions of infection. Given that potential novel 
miRNAs are scored not just on sequenced reads but also with a strong 
emphasis on genomic context (and the folding of that context), it is unlikely 
that these miRNAs derive from the parasite. Nevertheless, in order to be as 
sure as possible of their origin, I aligned them to the T. gondii genome. 26 of 
them were found to align and could thus not, on the basis of alignment alone, 
unambiguously be deemed mouse miRNAs. The remaining (which did not 
produce alignments to the parasite genome) were added to the list of putative 
novel mouse miRNAs, now numbering 152. These miRNAs are listed in the 
Appendix. 
 
3.4.2 Novel microRNAs in Toxoplasma only 
During the preparation of the RNA samples for sequencing, it is impossible to 
exclude T. gondii RNA from that of the infected host and so, of course, a 
proportion of the sequenced reads will have come from parasite material. I 
thus sought to mine these reads for putative parasite miRNAs. Since reads 
mapping to both the mouse and T. gondii genomes are difficult to resolve 
based on origin, I used a subtractive method as a starting point. I aligned to 
the parasite genome (with the mis-match allowances of two) only those reads 
that did not map exactly to the mouse genome. 
Since none of the miRNAs predicted be any previous study (106, 109, 
120–122) have as yet been accepted for inclusion into miRBase, far less 
information about their characteristics is available. As such, the number of 
miRNAs returned by miRDeep2 is quite small (this is also a result of the 
small proportion of sequenced RNA having come from parasite material to 
begin with) and accordingly, their confidence level is lower. 
As a control, I performed this same analysis on the uninfected samples, 
and excluded any putative miRNAs identified by miRDeep2 that were present 
in both infected and uninfected sets.  
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Six microRNAs were thus identified as putative T. gondii microRNAs 
at a score > 0. These miRNAs are listed alongside the putative novel Mus 
musculus ones in the Appendix. 
 
3.5 Discussion 
3.5.1 Library Preparation 
It is clear that sequencing data produced by such methods as Illumina require 
careful handling and that there are many pitfalls. This is especially true of 
early-generation machines and processes, where many of the ‘quirks’ had still 
not been worked out. For instance, my datasets did not include any quality 
information (such as Phred scores), which would have aided greatly both in 
terms of adaptor trimming and in terms of alignment. The majority of 
alignment algorithms (at least in their more modern versions) allow for 
FASTQ scores to be taken into account.  
 Instead, I attempted to calculate an error rate based on the presence of 
adaptor-dimers in my libraries. In fact, there were a great many adaptor 
dimers – something that should occur far less with newer library preparation 
protocols. For instance, Illumina’s TruSeq v2 Small RNA Prep Guide now 
includes an adenylation step to prevent concatamerisation. Other library 
preparation kits now include the use of hairpin adaptors (123), or the 
destruction of unligated adaptors at every stage (124).   
 
3.5.2 Adaptor Removal 
Even if adaptor dimers are correctly removed (or are not formed in the first 
place), the construction of sequencing reads still means that for small RNA 
sequencing, adaptor trimming is necessary – and even desirable, given the 
structure of the product to be sequenced. Nowadays, read lengths are longer 
than 36nt and so the confusion between the potential end of a miRNA and 
the beginning of the 3’ adaptor is no longer such an issue. The issue of the 
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final trailing nucleotide being ambiguous between the miRNA and the 
beginning of the adaptor is also less of a risk. That being said, more 
sophisticated adaptor removal algorithms have also been developed: cutadapt 
(125) is one of these, that affords the ability to require the 3’ adaptor and/or 
screen for 5’ contamination as well as potential dimers.  
 
3.5.3 Alignment 
Since the emergence of NGS, several different alignment algorithms have been 
developed to aid in dealing with the large volumes of sequence read data. It 
could be argued however that the number of tools has grown at a faster pace 
than users’ ability to evaluate them. And, a number of issues are still under-
addressed. As Kang and Friedländer note, “Overall, the field of mapping 
sRNAs is understudied […]” (126), a concern they raised particularly in the 
context of multi-mapping. There is some debate as to the number of times a 
read should be “allowed” to map to a reference genome, complicated by the 
fact that some miRNAs do in fact come from highly repeated genomic regions. 
There are several possibilities, which impact both the coverage of the genome 
and the interpretation of expression data from such alignments. Perhaps the 
most common (and arguably most stringent) method to deal with this issue is 
simply to exclude all reads that map to the genome more than a certain 
threshold number of times. Apart from having the obvious disadvantage of 
throwing away vast amounts of what might be useful data, this method is 
unsatisfactory in other ways. Most published papers that do this, for example, 
do not justify the selection of a particular cut-off, beyond a vague mention of 
reads aligning to rRNA regions. Moreover, these cut-offs vary widely, with 
some groups using a cut-off of one (only allowing reads that map to a single 
location) (127, 128), or five miRDEEP2 (129), and others extending this 
number up to 500 (130).  
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Some alignment programs attempt to address these concerns by 
providing options for selecting or reporting multiply-mapping alignments. 
SOAP (Short Oligonucleotide Alignment Program) (131), reports the “best” of 
all possible alignments for a certain read (i.e. the alignment with the fewest 
mismatches, or highest quality score) and, if there are more than one such 
alignments, the user can choose whether to include all, none or one picked at 
random. Similarly, Bowtie also gives the user these three options but does so 
for all valid alignments, not just the “best”. So, if a read has two alignments 
with no mismatches and one with two mismatches (and a threshold has been 
specified such that two mismatches are ‘allowed’), the user can then opt to 
report all three alignments, just the two best or a single one chosen at random 
(from either the two best or all three). That being said, the default behaviour 
of these algorithms is often unclear (random assigning is the default for 
Bowtie, for instance, although even this is not thought to be truly random but 
rather “pseudorandom” (132)). Of course there is no guarantee that any such 
alignment will be the correct one, and, even choosing to report the “best” 
alignments may not be adequate, especially if one considers the possible issue 
of miRNA editing. Two groups have sought to clarify this issue using local-
weighting and probabilistic distribution of multi-mapping reads (133, 134), 
but despite their utility, it is likely that unless they are incorporated into 
existing miRNA analysis pipelines or easily-compatible standalone packages 
they will find a limited audience.    
For my purposes, all alignments produced for the prediction of novel 
miRNAs would later be scored according to other criteria, such as similarity 
to known miRNAs and stringent folding parameters, and thus, I opted to 
accept all possible alignments, which is considered by some to be a more 
prudent choice, in the absence of better easy-to-use statistical methods (135).  
 The libraries I used had a large amount of adapter-dimerisation that 
needed to be filtered out, and of the remaining reads, only a fraction aligned 
	 69	
correctly to the genome. As a result, the novel miRNAs identified here must 
be treated with caution. The huge data generation possibilities afforded by 
NGS mean that the number of putative novel miRNAs in the sample space 
has exploded and miRBase, the foremost database for miRNAs has, through 
its self-admittedly “inclusive” (80) approach, likewise seen its population 
increase very rapidly. A tempting parameter in ‘scoring’ putative novel 
miRNAs is to use ‘real’ ones as a baseline (i.e. ones from miRBase). But, this 
automatically biases the criteria for inclusion. For instance, to take the multi-
mapping scenario above: if one aligns all mouse miRBase miRNAs to the 
mouse genome with no mismatches, then it does appear that the vast majority 
of them align once and once only (data not shown). A naïve researcher may 
then use this as a criterion for scoring a putative novel one. However, if one 
considers how  those miRBase miRNAs were themselves found (did the 
researchers who found them have a unique-mapping criterion?) the arguments 
underpinning several parameters quickly becomes circular. It will therefore be 
essential (as is beginning to happen (80, 136)), as more and more RNAseq 
experiments identify ever-greater numbers of putative novel miRNAs, to 
ensure that the bioinformatics approaches remain firmly rooted in the 
mechanisms of miRNA biogenesis and proceed alongside a well-curated 
reference set. 
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IV. Modulation of Host microRNAs 
 
4.1 Introduction 
4.1.1 MicroRNAs and Toxoplasma gondii 
Despite the considerable interest that miRNAs have garnered in recent years, 
relatively few studies have looked directly at potential changes in the miRNA 
landscape of host cells following T. gondii. 
One of the earliest was Zeiner et al’s study (137), where the authors 
used miRNA microarrays to assess differences in miRNA expression at 6-, 12- 
and 24-hours after infection, as compared to changes at these time points in 
mock-infected cells. The experiment was performed in HFF cells, using RH at 
an MOI of 5. The limitations of microarrays in looking at miRNA expression 
are discussed in Chapter 1, but nevertheless, several miRNAs appeared to be 
dysregulated as a result of infection. The authors concentrated on a single 
polycistronic cluster of miRNAs (the miR-17~92 cluster) which was 
upregulated two-to-threefold in infected cells. This cluster encodes miRNAs 
whose dysregulation has been shown to have potent effects in oncogenesis; 
they are overexpressed in a vast array of cancer types. Its targets include such 
key regulators as Pten and Bcl2l11, and knock-out of this family’s miRNAs 
has resulted in a pro-apoptotic phenotype. However, the regulation of and by 
this family is likely to be quite complex. The earliest association was with 
MYC, where the transcription factor has been shown to directly upregulate 
this miRNA family. Thus, the overexpression of miR-17~92 family members 
may be a result of parasite-induced upregulation of MYC (21). This may not 
be the only regulatory mechanism relevant in T. gondii-mediated modulation, 
however. This miRNA family is strongly repressed under hypoxia in a direct 
Trp53-dependent manner, with a concomitant strong sensitization to hypoxia-
driven apoptosis. Toxoplasma gondii infection follows this pattern, given that 
it is known to induce and stabilise the expression of HIF1A even under 
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normoxic conditions (138), and also results in downregulation of TRP53 
protein levels (19). It may therefore be that hypoxia-related signalling 
pathways are stimulated by the parasite but the concurrent downregulation of 
Trp53 (see Chapter 6) places the upregulation of miR-17~92 solely under the 
control of MYC. In any case, it is clear that when unpicking the regulatory 
networks affected by T. gondii, miRNAs have a role to play.   
To my knowledge only two other studies have looked at the impact of 
parasite infection on host miRNAs. The first is another global study, where 
Cai et al infected human macrophages with an atypical T. gondii strain 
designated China 1 and performed miRNA microarrays to asses the difference 
(139). Computational analysis of the upregulated miRNAs’ pri-miRNAs 
showed that many of them (including the gene that encodes members of the 
miR-17~92 family) contained potential STAT3 binding sites. Moreover, 
siRNA against STAT3 blocked the expression of this pri-miRNA following 
infection. While it is unclear what the behaviour of STAT3 is in host cells 
infected by the China 1 strain (the authors’ Western Blot only STAT3 protein 
levels dropping with siRNA transfection in the absence of infection), it is 
likely that STAT3’s possible involvement adds yet another level of complexity 
to the regulation of this important miRNA family.  
The final study dealing with host miRNAs in the context of T. gondii 
looked in great detail at two particular miRNAs: miR-146a and miR-155. 
They found that miR-146a was upregulated in Type II infection (expression 
was unchanged following RH infection, even though it was applied at the 
same MOI of 3 which implies a much higher parasite burden per cell at each 
of the time points).  The researchers also looked at miR-155, and found that it 
was upregulated in both strains. Following these results, Canella et al then 
looked at miRNA expression in the brains of chronically-infected mice and 
found that both of these miRNAs were upregulated (as compared to 
uninfected mice). They were able to correlate high cyst burden in these mice 
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(differential cyst burden was induced by infection with different progeny of a 
IxII cross) with high levels of miR-146a. Moreover, mice in which miR-146a 
had been knocked out exhibited a greater resistance to infectious challenge 
with the PruA7 strain (Type II). This set of striking experiments make it 
clear that the modulation of host miRNAs by T. gondii can have far reaching 
effects in vivo – even beyond the life stage where differences were first 
assessed.  
 
4.2 Methodology 
I began my analysis with the aligned libraries from Chapter 3.  
 
4.2.1 Coverage 
Most alignment programs, however their mode of action, report successful 
alignments as start and end co-ordinates, both of the query sequence and of 
the match. For this positional information to be used either to identify 
putative novel miRNAs or to track expression of known loci, it needs to be 
translated into depth-of-coverage. That is, for a given window of interest 
along the reference sequence (usually the reference genome), we need to know 
the number of reads from the sequencing dataset that have mapped.  
A naïve approach to this would be to create an array for each 
chromosome, consisting of as many elements as the chromosome has bases, 
with each array-element initialised to zero. Then, for each aligned read, for 
every position from the start to end co-ordinates of the match, the 
chromosome array would be incremented by one (Figure 4.1).  
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Figure 4.1. Generating coverage from aligned reads using a naïve method of array sweeping is 
computationally costly. 
Using a ‘dummy’ set of aligned reads, generating coverage across a genome could be achieved 
by sweeping across a genome array and incrementing each position of each read – this is a 
computationally costly method, requiring 79 increment operations.  
 
Effectively, this means that every nucleotide of every read needs to be 
treated separately, to appropriately increment the chromosome array. For 
large datasets, this approach can be very computationally expensive.  
 
A faster method, with lower memory usage, implements the strategy of 
run-length encoding. Here, instead of recording and marking every base in 
each read, only the start and end co-ordinates of alignments are considered, as 
potential positions of change in coverage. This approach is likely to be 
effective for datasets – such as small RNA libraries – that are expected to 
align to a reference genome in a relatively sparse fashion, as oases of stacked 
reads in a desert of zero coverage. That being said, given the overlapping 
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nature of aligned sequencing reads, the framework for creating the run-length-
encoded coverage array needs to be established with care, to avoid, for 
example, ‘off-by-one’ errors (OBOEs) or overlooking the starts and ends of the 
coverage arrays themselves. The steps that I took while constructing the 
program to create and populate run-length-encoded coverage arrays are shown 
in Figure 4.2.  
 
For each aligned read, the start and ‘end+1’ co-ordinates were collected 
and sorted uniquely (such that, for instance, for several aligned reads with the 
same genomic start co-ordinate, that position would appear in the list only 
once: as a single position of change). To this list were appended the first 
position of the chromosome as well as a ‘dummy’ co-ordinate one position 
beyond the end of the chromosome (these two extra co-ordinates need to be 
defined explicitly since our reads are not guaranteed to overlap the 
chromosome ends). This list of co-ordinates was then used to create an empty 
array, with as many elements as there were changes in coverage. Each 
sequenced read is then taken in turn and the corresponding coverage elements 
incremented appropriately.  
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Figure 4.2 (a). Run-length encoding implementation to coverage generation 
 
Figure 4.2 (b). Run-length encoding implementation to coverage generation 
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Figure 4.2(a-c). Implementing run-length encoding to generate coverage across a genome is 
more efficient than genome sweeping. 
This schematic shows that by considering positions of change in read alignments instead of 
the entire length of each read, computational coverage generation can be made more efficient. 
 
Using this method, for each chromosomal array, far fewer increment 
operations need be performed than with the per-base method. In the example 
in Figure 4.2, for instance, the per-base approach requires 79 increment 
operations (the entire length of each of the reads summed), scanning every 
position along the chromosome. Using run-length encoding on the other hand, 
this number is reduced to nine, only scanning and checking ten array elements 
per read.  
 
4.2.2 Locating Features within Coverage Maps 
Once coverage from alignments has been recorded, the next step is often to 
collect this coverage (the number of reads aligned) for specific regions of 
interest: known miRNAs, for example. Intuitively, once would begin at the 
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first position of the incremented coverage array and read across until the start 
co-ordinate of the region of interest had been reached and then record 
coverage information from there up to the end co-ordinate. Again this 
approach is time consuming and computationally expensive, as it requires 
scanning of the entirety of the array (chromosome) within which the target 
region lies. 
 
A faster reporting method can be achieved by implementing binary 
searches. This approach splits the search field into halves and evaluates 
whether the target has been found (as being the central element), or whether 
this central position is too high (the target is to the ‘left’ of the central 
element) or too low (the target is to the ‘right’). The half that is shown to 
contain the target is then itself split, and its central position, left and right 
halves are again evaluated. The entire process of splitting and evaluating is 
applied recursively until the midpoint of the sub-array and the target are 
found to be one and the same (Figure 4.3) This is applied to find both the 
start and end co-ordinates of the region of interest, which, once located, are 
used to look up the coverage information from the coverage array.  
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Figure 4.3. A binary search method is a rapid and efficient way to locate a featyre of interest 
within an array. 
Once coverage maps have been generated, a binary tree method can be used to locate known 
end co-ordinates of microRNAs. In this method, each region of interest is split in two and 
each half is examined to see if the feature is present. The correct half is then itself split in 
half, recursively, until the feature of interest has been found. 
 
This reporting method is thus used to generate tables of count data, to be 
then evaluated for the presence of differentially-expressed microRNAs.  
 
4.3 Results 
After aligning the sequenced reads to the genome (as in Chapter 3 except 
allowing only a single mismatch per read), I then generated coverage for all 
known Mus musculus miRNAs according to their co-ordinates from miRBase, 
and produced tables of count data for known miRNAs. The highest scoring 
span across the entirety of the miRNA was taken as the count, for each 
miRNA.  
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4.3.1 Differential Expression Analysis 
There exist a number of tools to assess the differential expression through 
deep sequencing experiments. While it was not designed for such small 
datasets such as mine, I nevertheless applied EdgeR (140). EdgeR uses a 
method of estimating dispersions in order to apply its statistical tests. These 
are difficult to estimate correctly when samples/replicates are highly divergent 
(as mine were). But, EdgeR allows for some batch effects, which I identified as 
being related to the flow cell each sample was sequenced on. So, I separated 
the replicates based on this factor to help correct for batch effects arising from 
this. Though 30 microRNAs were initially identified as being differentially 
expressed with a p-value <0.05, after multiple-testing correction at an FDR < 
0.05, this number fell to five (Tables 4.1 and 4.2).  
 
Table 4.1. microRNAs upregulated following infection 
miRNA logFC 
mmu-miR-3096b-3p* 4.9 
mmu-miR-1935* 3.1 
mmu-miR-200b-3p 5.9 
* These two microRNAs have since been removed from the miRBase database as they were 
shown not to be genuine microRNAs. 
 
Table 4.2. microRNAs downregulated following infection 
miRNA logFC 
mmu-miR-3080-5p -5.5 
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4.4 Discussion 
There were several issues with this set of experiments, as was detailed in 
Chapter 3. Largely, the low quality and poor depth of coverage by the 
libraries had severe knock-on effects, leading to few confident assessments of 
differential expression. As a result, only an extremely limited picture of host 
miRNA regulation in response to T. gondii infection can be gleaned.  
Of the four miRNAs found to be dysregulated following infection, two 
have subsequently been removed from miRBase (80). Mmu-miR-3096 family-
members showed reads that were inconsistent with processing by the usual 
miRNA machinery, in a variety of recent validation experiments that used 
AGO-CLIP and Dicer knock-out to identify miRNAs whose expression is 
likely to have emerged from canonical processes of miRNA biogenesis (136). 
The other now-excluded miRNA, mmu-miR-1935 was found in the same study 
to be a repeated Alu/B1 SINE element, also transcribed in a method 
inconsistent with canonical miRNA biogenesis. 
 Thus, two miRNAs remained as being dysregulated by T. gondii 
infection, one downregulated and one upregulated.   
 
mmu-miR-3080-5p 
Unfortunately, mmu-miR-3080 is an extremely poorly characterised miRNA, 
not just in Mus musculus but in any species. It has been showed to be 
moderately upregulated in CCR6+ regulatory T-cells isolated from mice (141) 
but it was one among several miRNAs and so not focussed on. Besides, Dunay 
et al have shown that, in vivo at least, CCR6 does not mediate any kind of 
response (positive or negative) to survival after infection with T. gondii (142), 
which makes this a rather undistinguished connection to parasite infection.    
Another large-scale miRNA study identified mmu-miR-3080-5p as being 
downregulated during hypoxia in mouse kidneys (143). This may be more 
relevant to T. gondi-host interactions, given that Hypoxia inducible factor 1, 
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alpha subunit (HIF1A) is known to be modulated following infection (138, 
144, 145). In the hypoxia/miRNA experiment, Ho et al found that, strikingly, 
DICER overexpression in Human Umbilical Vein Endothelial Cells resulted in 
a reduction in HIF1A following 24h of growth in hypoxic conditions. Similarly, 
HIF1A-target genes (such as Hexokinase 2) were also downregulated in a 
Dicer-dependent manner, under hypoxia. However, the situation appears to be 
more complex: Dicer mRNA too was underexpressed under conditions of 
hypoxia. What this implies for mmu-miR-3080 is extremely unclear, given 
that it was one of 148 miRNAs to have been downregulated as a consequence: 
it may simply be a casualty of mass Dicer downregulation during a hypoxia-
like state induced by parasite-infection, but there is far too little evidence to 
support this idea at the moment (HIF1A and T. gondii infection are discussed 
in much greater detail in Chapter 6).  
 
mmu-miR-200b-3p 
The majority of known miR-200b functions are related to the epithelial-
mesenchymal transition, a key process for differentiation and metastasis. In 
the context of cancer, miR-200b has been found to be an antagonist of this 
transition – this finding extends to several types of cancer and it is considered 
a tumor suppressor (146). Interestingly, miR-200 family members have also 
been shown to be transcriptionally upregulated by MYC (147) which is likely 
to be related to the upregulation of MYC in T. gondii-infected cells (21) (this 
too is discussed in further detail in Chapter 6). Another related function of 
miR-200b’s is its involvement in the cell cycle. Yu et al were exploring 
monocyte/macrophage differentiation and the downregulation of p38 mitogen-
activated protein kinase (MAPK) interacting protein (p38IP) that occurred 
during it. They searched for potential miRNAs that might target that gene 
and miR-200b-3p was a candidate. A luciferase assay and target mutagenesis 
showed that it was a direct target. Crucially, p38IP has been shown to be a 
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mediator of the G2/M cell cycle transition and downregulation of p38IP 
blocks this transition. Thus, it could be that an upregulation of mmu-miR-
200b works towards blocking the cell cycle at this stage – which is a well-
known effect on host cells by T. gondii (148, 149).  
Despite these two intriguing miRNAs being dysregulated following 
infection by the Type II strain ME49, the fact that the depth and quality of 
the sequencing libraries were too low to obtain more information is rather 
disappointing. That being said, the complexities of NGS analysis are often 
best done ‘in practice’ rather than in theory. Subsequent efforts are likely to 
be of far higher quality – not just because of technological advances in the 
library preparations and sequencing themselves but also the available 
algorithms and quite simply my ability to think critically about these different 
parameters. For that reason, the following chapter demonstrates a more 
technically-sound analysis of host cell miRNA dysregulation in the face of T. 
gondii infection.  
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V. A Deeper Examination of microRNAs and 
Toxoplasma gondii  
 
5.1 Introduction 
Despite the ultimately unsatisfactory sequencing depth (which thus tainted all 
further analyses), a few interesting preliminary results did emerge. As a result, 
I decided that to repeat and extend the experiment to include more samples, 
using a more robust sequencing platform would be valuable in exploring the 
extent to which infection by Toxoplasma gondii has an effect on host cell 
microRNA expression.  
 
5.1.1 Normalisation 
Given that my data were of much greater depth and quality, I was able to 
take advantage of better and more robust statistical methods to normalise my 
data and thus obtain more trustworthy results. While RNASeq analyses are 
free from the issues of uneven hybridisation and dye-effects that can plague 
microarrays, the data still require thorough normalisation, to account for 
variation in library size and composition. Several methods of RNASeq 
normalisation have been proposed and, in the past few years, compared. The 
most commonly-used normalisation methods for NGS data are summarised 
below: 
1. Count-per-million: This is perhaps the simplest method of normalisation, 
where counts are scaled to library size, and library size only. 
2. Total Count: The total count method adds a step, by, following the size 
adjustment, scaling all libraries by a common factor, usually the mean or 
median library size.  
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3. Upper-Quartile Scaling: This adjusts for a large number of low- or zero-
count tags, by only considering the upper-quartile of non-zero counts, instead 
of the total count. 
4. Median: Rather than the upper-quartile, the median value of tags across 
samples is used to scale each library’s counts 
5. DESeq, the normalisation method implemented within the DESeq package 
(150, 151). First, the data are scaled according to the median of 
observed:geometric mean ratio for all tags (in all libraries). Following this 
scaling, the data are modelled according to a negative binomial distribution. 
This normalisation method relies on the assumption that most tags (genes) 
will not be differentially-expressed. 
6. Trimmed Mean of M- values: Like the DESeq method, TMM also assumes 
that most genes are not differentially-expressed, but, also takes into account 
the RNA composition of libraries. Robinson et al (152) argue that, while the 
‘simple’ count-based normalisations (1-4 in this list) might be appropriate for 
scaling between replicates, they are inadequate for looking at biological 
differences. This is due to what they call “sequencing real estate”: the idea that 
if libraries are sequenced to similar depths, differences in library composition 
will have a large effect on tag counts. The overcome this, TMM first assigns 
as “reference samples” those observations whose expression is close to the 
mean expression of all tags. The remaining samples (the “test” ones) are 
trimmed of observations with the highest log-fold changes (M-value of 30%) 
and absolute expression (A, of 5%) and then scaled. Then, the libraries are 
scaled based on the weighted mean of test:reference log-ratios. The fact that 
this method takes into account the fact that some reads will be highly-
sequenced (as, for instance let-7 miRNA family members) makes it the most 
appropriate for miRNA sequencing experiments. TMM is the method 
implemented in EdgeR (140). 
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A number of studies (153, 154) have conducted comparative analyses of 
these (and other, less commonly-used) methods on both real and simulated 
RNAseq data. While most of the methods, other than Total Count, resulted in 
somewhat similar stabilisation of library size across samples, DESeq and 
TMM performed far better in terms of lowering the coefficients of variance in 
the normalised samples. Importantly, following differential-expression analyses 
of libraries normliased by these methods, TMM and DESeq came out as clear 
winners, able to both control for false-discovery but also detect more DE 
genes.  	
5.2 Methodology 
5.2.1 Experimental Design 
I constructed the experimental design so as to correspond to a metabolomic 
study previously performed in the lab, which compared 1NMR profiles of 
Uninfected, RH-infected and ME49-infected NIH/3T3 mouse embryonic 
fibroblasts. These time points and MOIs were chosen in order to, as far as 
practically possible, keep parasite numbers comparable between strains and 
time points. The rationale behind this was to avoid cases where observed 
transcriptional effects might be attributable intracellular parasite numbers 
rather than to strain difference or the duration of infection. This MOI 
‘normalization’ was confirmed by infecting identical host cell monolayers at an 
MOI of 1.2 for RH and 3 for ME49. Twenty-four and 43 hours after infection, 
the monolayers were examined under the microscope to tally the number of 
infected cells for each condition. [This work was done with Dr Aysha Roohi]. 
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Figure 5.1. Infection Rates with RH and ME49. Cells were infected with either RH or ME49, 
at an MOI of 1.2 or 3 respectively. After 24 hours, infected cells were counted.  
 
To further guard against transcriptional differences arising from 
parasite numbers rather than strain-type or infection duration, the MOIs were 
also applied reciprocally. Ultimately therefore, the time points and MOIs 
chosen were as in Table 5.1. 
 
Table 5.1. The experimental set-up of infection. Numbers represent replicate wells of host cells 
either infected or washed with fresh medium at time 0. 
Strain ME49 RH Uninfected 
MOI 1.2 3 1.2 3 NA 
0h 0 0 0 0 3 
24h 3 3 3 3 3 
43h 3 3 3 3 3 
 
NIH/3T3 cells were seeded in 6-well plates, and allowed to adhere and 
grow for approximately 48 hours (33 sample wells, along with nine wells 
grown for host cell counting, in order to determine the appropriate number of 
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parasites to add to achieve the desired MOI). At this point, when host cells 
were ~70% confluent, purified parasite preparations were made (see 2.3.3) and 
the appropriate volume was added, in fresh, supplemented DMEM medium, to 
each well, so as to achieve the desired MOI. For the uninfected (or, ‘mock 
infected’) samples, this meant purely replacing the conditioned medium at the 
first time point.  
 
5.2.2 Protocol Refinement 
At each time point (0hpi, 24hpi and 43hpi), RNA was extracted using the 
Direct-zol method (described in 2.5). These extracts were then subjected to 
microfluidic electrophoresis using a Bioanalyzer 2100. This instrument 
evaluates the integrity of RNA samples according to four main features, each 
contributing to that sample’s RNA Integrity Number (RIN): 
1. 18S/28S:Total RNA Ratio, looking at the ratio of RNA under the 18S 
and 28S peaks to that under the rest of the plot 
2. Height of the 28S peak, whose degradation is the first sign of overall 
sample degradation 
3. ‘Fast’ area Ratio, looking at the area between the 18S and 5S peaks. 
Increase in this range indicates early signs of degradation. 
4. Large, diffuse peaks at short lengths, indicating severe degradation 
 
A critical feature in any RNA extraction is that of desiccating samples 
(especially if, as in my case, they are to be shipped abroad for library 
preparation and sequencing). The two main methods for drying are a) leaving 
tubes in a hood, or b) using a Speedvac. An initial protocol of leaving 
extracted RNA in a hood overnight (followed by shipment in RNAStable 
tubes) showed a great deal of degradation (Figure 5.2). 
	 88	
 
 
Figure 5.2. Microfluidic Analysis of 12 pilot RNA extracted from uninfected NIH/3T3 cells; 
Bioanalyzer 2100. 
 
Here, it appeared that, of 12 prepared samples, most had suffered 
degradation. It was postulated that the samples had not been sufficiently 
dried or perhaps had RNAses introduced during the drying period. As such, a 
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pilot experiment was designed to explore the impact of different drying 
methods on extracted RNA.  
Trizol-stored lysates from two biological replicates of NIH/3T3 cells 
grown to ~70% confluence in 6-well plates were used for this pilot analysis. 
RNA from these samples was extracte using the Directo-zol protocol, until the 
elution step (in 60uL RNAse-free water) each. At this point, the samples were 
split into 3 and treated as shown in Figure 5.3.  
 
 
Figure 5.3. Experimental Scheme to examine the effect of drying on RNA quality 
The RNA samples were treated according to different recommended drying protocols (as 
recommended by the manufacturers of the RNAStable storage and shipping tubes). The 
treated samples were analysed on an Agilent Bioanalyzer 2100 for RNA integrity. 
 
Two RNA Integrity analyses were performed per biological replicate, 
under the three storage/dessication regimes, yielding 12 analyses in total, as 
shown in Figure 5.4.   
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Figure 5.4. Microfluidic Analysis of the ‘drying pilot’ RNA samples as described in Figure 5.3. 
 
A drop in RNA Integrity (as measured by the RIN value) is apparent in all 
cases, as compared to the immediately-frozen (never dessicated) sample. In 
the first biological sample (A), dessication using the Speedvac resulted in no 
reduction in RIN value, and only a very modest reduction in RNA 
concentration (mean reduction by 6%), while overnight drying in a hood 
performed worse, resulting in reductions in both the RIN value (by 2.05 
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points) and RNA concentration (mean reduction by 7.1%). In Biological 
Sample B, the effect of the Speedvac is similar,  resulting only in modest RIN 
value reduction (by only 0.65 points) and loss of RNA (9.7%). The effect of 
hood-drying on Sample B’s RNA concentration is an undramatic 13.7% but 
the drop in RNA quality is precipitous: 7.7 RIN points. This is supported 
when looking at the electropherograms, where after hood drying, the clear 18S 
and 28S rRNA peaks disappear completely, revealing instead an 
overabundance of degraded RNA (large low-MW smear), 
 
5.2.3 RNA Extractions and Quality 
As a result of the potential variability in using hood-drying as a means of 
RNA dessication, the Speedvac protocol was used for all subsequent RNA 
extractions (that is, the 33 samples as described in Table 5.1). A summary of 
the integrity data (after drying and shipping) of the 33 samples is presented in 
Figure 5.5. 
 
Figure 5.5. RNA Integrity (RIN) Values of the 33 RNA samples. 
1-3: ME49 MOI 3 24hpi; 4-6: ME49 MOI 1.2 24hpi; 7-9: RH MOI 3 24hpi;  
10-12: RH MOI 1.2 24hpi; 13-15: Uninfected 24h; 16-18: ME49 MOI 3 43hpi; 
19-21: ME49 MOI 1.2 43hpi; 22-24: RH MOI 3 43hpi; 25-27: RH MOI 1.2 43hpi;  
28-30: Uninfected 43h; 31-33: Uninfected 0h 
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Figure 5.6. Concentration of the 33 RNA samples 
1-3: ME49 MOI 3 24hpi; 4-6: ME49 MOI 1.2 24hpi; 7-9: RH MOI 3 24hpi;  
10-12: RH MOI 1.2 24hpi; 13-15: Uninfected 24h; 16-18: ME49 MOI 3 43hpi; 
19-21: ME49 MOI 1.2 43hpi; 22-24: RH MOI 3 43hpi; 25-27: RH MOI 1.2 43hpi;  
28-30: Uninfected 43h; 31-33: Uninfected 0h 
 
While no standard cut-off exists for using RINs to decide whether to 
exclude or re-extract RNA samples, the higher the score, the more intact the 
sample. But, the RIN must be taken together with the electropherogram 
traces. Three samples stand out in these analyses: Samples 15, 29 and 31. In 
Sample 15, while distinct peaks can be seem at the 18S and 28S rRNA 
regions, an unexpected signal also occurs at the 5S region (~120nt). The 
presence of this peak triggers Agilent’s critical anomaly feature, which 
prevents the RIN from being calculated. However, the clear presence of the 
28S and 18S peaks indicates that this sample should still be usable. On the 
other hand, it is less clear whether Samples 29 and 31 are still intact enough 
for downstream processing. While sample 29 has a visible peak at, 18S, no 
distinct peak can be seen at 28S (hence the rRNA ratio of 0). For sample 31, 
the situation is worse still, with no distinct peaks, bar the marker, visible at 
050
100150
200250
300350
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33
ng
/μ
L
Concentration
Concentration
	 93	
all. That being said, these samples were still sequenced along with the others, 
pending exclusion from downstream processing, depending on what the 
sequencing results yielded. Luckily, these samples were also part of distinct 
replicate groups (Sample 29 being part one of the three ‘uninfected, 43hpi’ 
samples and Sample 31 part of the ‘uninfected, 0hpi’ group) and their 
eventual possible exclusion should still make differential expression analysis 
possible.  
 
Libraries were prepared from the 33 RNA samples, using Illumina’s 
TruSeq Small RNA Kit. [Library preparations and sequencing were performed 
by Mr Abhinay Ramaprasad, at the Pathogen Genomics Laboratory, 
KAUST]. 
 
5.2.4 Functional Analysis 
Given that many of the current enrichment analyses tools do not include 
miRNAs at all, or include them in a very limited capacity, the usual method 
that is followed is to generate lists of putative miRNA targets for each 
dysregulated miRNA and then perform enrichment analyses on these (KEGG 
or GO, for instance). I opted to use targets from the miRNet database (155), 
which aggregates experimentally-validated miRNA targets from a variety of 
large-scale target-finding experiments (such as HIgh-Throughput Sequencing 
of RNAs isolated by CrossLinking ImmunoPrecipitation, HITS-CLIP 
experiments) for my lists of dysregulated miRNAs. These experimentally-
validated target genes were then the input for use on the online tool 
WebGestalt (WEB-based GEne SeT Analysis Toolkit) (156, 157).  I used as 
my background the list of experimentally-validated targets from all the 
miRNAs currently in miRBase version 21 (80). 
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5.3 Results 
5.3.1 Quality of the Sequenced Libraries 
Characteristics of the sequenced libraries are presented in the tables below. 
Read counts are in Figure 5.7 and the collapsed read counts are in Figure 5.8. 
It is not an unusual feature of RNASeq for libraries to be of quite different 
sizes. As expected, the profile of read counts when collapsed is similar to that 
of the total reads and this can be seen in what I term the ‘diversity factor’ in 
Figure 5.9. 
 
Figure 5.7. Number of reads generated by the sequencer, per sample 
1-3: ME49 MOI 3 24hpi; 4-6: ME49 MOI 1.2 24hpi; 7-9: RH MOI 3 24hpi;  
10-12: RH MOI 1.2 24hpi; 13-15: Uninfected 24h; 16-18: ME49 MOI 3 43hpi; 
19-21: ME49 MOI 1.2 43hpi; 22-24: RH MOI 3 43hpi; 25-27: RH MOI 1.2 43hpi;  
28-30: Uninfected 43h; 31-33: Uninfected 0h 
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Figure 5.8. Number of ‘unique’ reads per sample 
1-3: ME49 MOI 3 24hpi; 4-6: ME49 MOI 1.2 24hpi; 7-9: RH MOI 3 24hpi;  
10-12: RH MOI 1.2 24hpi; 13-15: Uninfected 24h; 16-18: ME49 MOI 3 43hpi; 
19-21: ME49 MOI 1.2 43hpi; 22-24: RH MOI 3 43hpi; 25-27: RH MOI 1.2 43hpi;  
28-30: Uninfected 43h; 31-33: Uninfected 0h 
 
Figure 5.9. The ratio of collapsed to raw reads, per sample 
1-3: ME49 MOI 3 24hpi; 4-6: ME49 MOI 1.2 24hpi; 7-9: RH MOI 3 24hpi;  
10-12: RH MOI 1.2 24hpi; 13-15: Uninfected 24h; 16-18: ME49 MOI 3 43hpi; 
19-21: ME49 MOI 1.2 43hpi; 22-24: RH MOI 3 43hpi; 25-27: RH MOI 1.2 43hpi;  
28-30: Uninfected 43h; 31-33: Uninfected 0h 
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I then aggregated the 33 libraries of raw sequencing reads and 
subjected them to quality control using FASTQC (158). This tool is aimed at 
identifying any potential issues with the libraries’ qualities, whether arising 
from problems with the library preparation or from the sequencing itself.  
 
Per base sequence quality 
The threshold for sufficient quality is depicted in Figure 5.10 as the green box. 
Ordinarily, this quality check shows a box-and-whiskers plot of each base 
position along the read. Our sequences are of extremely high quality – all well 
within the ‘very good’ range of Phred scores above 28. The overall mean value 
is of 36.2. As indicated in Fig, the first five bases are of slightly lower quality 
(with only the first five bases having a mean quality of 32.8 as compared to a 
mean of 36.6 if these five are excluded). This value still places them well-
above the threshold for acceptable quality, and is likely due to the presence of 
barcodes. As has been noted, a lower start-of-read quality does not impinge on 
the usability of the reads and is likely due to a historical artefact of Illumina’s 
own quality control procedures (159).  
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Figure 5.10. Phred quality of all libraries taken as a batch, across read length 
 
On an individual level, most of the libraries exhibited this pattern, with 
mean and median qualities as well as lower whiskers still being well-within the 
highest (green) range. Two exceptions were 8913 and 8918, where lower-
whiskers dipped below the Phred high-quality threshold of 28. However, even 
for these libraries, the mean, median and inter-quartile quality range were all 
above this level, with only the lower-whisker reaching 27.  
 
Per sequence quality scores 
This analysis module computes the average quality per read, to indicate cases 
where subsets of reads have lower than average quality. In our case, the 
quality score distribution across the read population is excellent, with most 
reads having a high average quality, Figure 5.11. 
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Figure 5.11 – Per-Read quality, across all libraries 
 
This was also the case when looking at the libraries on an individual basis, 
with no exceptions.  
 
Per base N content 
This parameter flags instances where the the sequencer was unable to call a 
base, thus substituting “N” for the call. Indicative of successful base calls 
across the entirety of the reads is our extremely low levels of ambiguously-
called bases, <= 5% at any position (Figure 5.12). Similarly, the individual 
libraries also had extremely low levels of ambiguously-called bases.  
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Figure 5.12. Number of ambiguously-assigned bases, over all libraries 
 
Sequence Length Distribution 
This graph, with its single peak, indicates that all reads were of the expected 
size. This is obviously the expected result for libraries where the adaptors 
have not yet been trimmed, Figure 5.13.  
 
	 100	
 
Figure 5.13. Distribution of read lengths, for all libraries 
 
Per base sequence content 
In the ideal scenario, the base content for each of the 4 bases would be 
constant across the reads, according to the genomic distribution. This quality 
control parameter can be disregarded for small RNA sequencing, as it was 
designed with whole-genome libraries in mind. A library selected specifically 
for small RNAs will inherently have biased, non-uniform distributions of 
nucleotides across the read length. Moreover, the presence of barcodes and 
adaptors further confuses the issue, contributing to inconsistent traces, Figure 
5.14. 
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Figure 5.14. A/T/C/G content, per read position, for all libraries 
 
Per sequence GC content 
As before, deviation of the GC content from the expected normal distribution 
is a result of the inherent bias in small RNA library preparation as well as the 
inclusion of adaptor sequences.  
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Figure 5.15 – GC-content for all libraries 
 
Sequence Duplication Levels; Overrepresented Sequences; Kmer Content 
These parameters are all geared towards genomic libraries, which are not 
expected to either contain highly enriched sequences (be these full sequences 
or shorter Kmer fragments) or adaptors. A small RNA library is expected to 
have skewed distributions of both of these, and the distributions can be 
accounted for when looking at the FASTQC parameter that now follows.  
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Figure 5.16 – Sequence duplication, for all libraries 
 
Overrepresented Sequences.  
As expected with adaptor-containing, size-selected libraries (such as a small 
RNA library), a number of overrepresented sequences appear in this analysis. 
In fact, 112 such sequences were highlighted, with 59 of them accounted for as 
being Illumina primers and adaptors. Of the remaining, many of these fall 
within rRNA regions, again, as is expected from small RNA libraries. There 
were also a number of sequences (the most highly-overrepresented one, for 
example) mapping to T. gondii.  
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5.3.2 Preprocessing and Alignment 
5.3.2.1 Preprocessing 
The primary tool that I used for pre-processing and alignment of the libraries 
to the mouse genome was miRDeep2 (113), a tool that returns both quantified 
known miRNAs (as per the latest release of miRBase, v. 21) and detects novel 
ones. The miRDeep2 package is a multi-step tool, the usual workflow of which 
is as follows: 
1. Trimming of 3’ adaptors 
2. Collapsing of identical (trimmed) reads 
3. Alignment of the (collapsed, trimmed) to a supplied genome.  
 
While convenient as a ‘one stop shop’ for miRNA analysis, some of the 
(immutable) parameters applied by miRDeep2 in two of these steps are 
suboptimal, namely, adaptor trimming and alignment. 
  
Adaptor Trimming 
Within miRDeep2, only the 3’ adaptor is searched for and clipped. As seen 
both in the FASTQ results (where several other Illumina library preparation 
and sequencing adaptors appear among overrepresented sequences) and in the 
pilot study in Chapter 3, adaptor-contamination, including primer-dimers, can 
occur at other positions and with not just the 3’ adaptor. Moreover, within 
miRDeep2’s trimming algorithm, reads that do not contain any adaptor 
sequence at their distal end are “retained but not clipped” (129). Given 50nt 
read lengths, as with my 33 libraries, it is reasonable to assume that if a 
miRNA is contained within a particular read-insert, it will be contained in its 
entirety. As a result, the absence of 3’ adaptor following the miRNA is likely 
to represent not a true miRNA but rather a product of mRNA degradation or 
contamination with rRNA. To prevent the inclusion of such species within my 
sample, I therefore used a stand-alone adaptor trimming programme, cutadapt 
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(version 1.9.dev6) (125). This tool offers a number of options for read 
trimming, including 5’ and 3’ adaptors, as well as dimers thereof, at any 
location within a read. Moreover, a possible included option is to require the 
presence of a 3’ adaptor (following the miRNA) in order for a read to be 
retained. The results of the trimming process are shown in Figure 5.17.  
 
 
Figure 5.17. Uncollapsed (‘raw’) reads and the effect of trimming.  
Total Reads: The number of raw reads 
Trimmed Reads: The number of raw reads that contained the 3’ adaptor 
Too Short: Of the Trimmed Reads, the number of reads that were smaller than 18nt 
Remaining Reads: Reads used in downstream analysis 
 
After trimming, I checked the aggregate quality of the trimmed reads 
once again, using FASTQC. The overall per base and per base sequence 
quality remained high. Indeed, the only significantly changed FASTQC 
reports were, as expected, the sequence length distribution which now had a 
peak at 22nt (Figure 17), and the most over-represented sequences, which now 
no longer contained recognisable Illumina primer or adaptor sequences. 
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Figure 5.18. Distribution of read lengths after adaptor trimming, for all libraries 
 
Alignment 
miRDeep2 uses Bowtie to map trimmed and processed to the supplied 
genome. Of the numerous variable parameters permitted by Bowtie, only a 
few are modifiable within the miRDeep2 instance: whether or not to allow 
mismatches in the seed region and the length of the seed region. Most of the 
defaults set by miRDeep2 are as required for miRNA alignment, but one key 
restriction is of concern. As discussed in Chapter 3, in theory, there should be 
no limit to the number of times a read is ‘allowed’ to map to genomic 
locations, and miRNA-seq projects that limit this parameter often do so with 
little-to-no justification of the cut-off. That being said, the desirable 
alternative – reporting all legal alignments – is not possible within the 
instantiation of Bowtie implemented by miRDeep2, which requires instead 
that the user apply a discrete cut-off (i.e. if a read maps more than n times, it 
is to be discarded).  
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In order to examine empirically this parameter, I thus first performed 
an alignment of a single library, using the standalone version of Bowtie (118), 
allowing for all alignments to be reported.  
The largest number of mappings for a single read was 1,678,560 which, 
as expected, corresponded to a very low-complexity read 
(GAGAGAGAGAGAGAGAGAGA). Similar, dinucleotide runs emerged from 
several other extremely highly multi-mapping reads. While such reads would 
almost certainly be excluded from downstream analyses, their inclusion vastly 
increases the computing power necessary for these analyses and so, filtering 
them out at the outset is desirable. That being said, such extreme cases are 
rare: only 23 reads (of 7,144,900 trimmed reads that aligned anywhere) 
mapped to over 100,000 locations, with 10,532 (0.15% of aligned reads) 
mapping to more than 100 distinct locations. Using this cut-off (100 locations) 
did not noticeably increase the time taken for alignment but halved the rate 
of suppression due to multi-mapping. As a result, for the miRDeep2-wrapped 
mapping step, I applied a cutoff of 100 possible mapping locations for each 
read.  
With the case of mismatches, the maximum number of allowable 
mismatches  is one. In the pilot study (Chapter 3), I allowed for 2 mismatches 
in order to maximize the number of miRNAs detected, albeit with lower 
confidence. For this set of libraries however, the libraries were large and of 
high enough quality for this to not be necessary – sequencing errors are 
unlikely enough not to require more than one mismatch. 
 
5.3.2.2 Alignment 
Using these parameters, I then ran the miRDeep2 mapper module 
(mapper.pl), aligning each of the 33 libraries to the mouse genome (GRCm38). 
The resultant (proprietary and required for downstream analysis) .arf format 
files are the equivalent of SAM format, giving details about the location on 
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the reference genome, mismatches (edit distance) and strandedness of each 
alignment.  
Given the inevitable inclusion of parasite RNA in my libraries, I next 
attempted to identify putative T. gondii novel miRNAs from within my 
samples (5.3.4). Though of course any putative miRNAs of T. gondii origin 
would only be detectable in my infected samples, I thought it prudent to 
subject the uninfected samples to the same pipeline of discovery analysis as 
well, as a control. Thus, any novel miRNAs appearing only in the infected 
samples would have a greater confidence attached. For the same reason, 
though I used two different strains in my infections, I aligned all the libraries 
to both GT1 (version 13.0) and ME49 (version 13.0). GT1 is a Type I strain 
like RH, which was the strain used in the infections. Alignment results are 
shown in Figures 5.19 and 5.20.  
 
 
Figure 5.19. Alignment statistics to M. musculus, ME49 and GT1 – Raw trimmed reads 
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Figure 5.20. Alignment statistics to Mus musculus, ME49 and GT1 – Collapsed reads 
 
In all three alignment scenarios, the proportion of reads that mapped to the 
parasite roughly follow the expectation of the sample’s infection. That is to 
say, the highest proportion of ME49-mapping reads corresponds to libraries 
16-18, made from cells infected with ME49 at an MOI of 3, for 43h.  
 
The core miRDeep2 module consists of its ‘quantifier’ tool. This tool 
maps the known miRBase miRNAs to the precursor candidates and then 
intersects that with the mappings yielded by the sequencing reads.  
After the quantification has been performed, there is a possible bifurcation in 
next steps: analysis of known miRNA expression (5.3.5 onwards) or 
identification of putative novel miRNAs. (5.3.3 and 5.3.4). 
 
5.3.3 Potential novel microRNAs from Mus musculus 
At the highest scoring miRDeep2 tranche, 216 novel miRNAs were predicted. 
Of these, 18 had a seed sequence (2-8nt from the 5’ end) identical to an 
miRBase-annotated mature miRNA from Rattus norvegicus, which was 
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inputted as the closest related species in miRBase. One of the 216 triggered an 
‘rfam alert’ and was thus excluded. The full remaining list of novel putative 
M. musculus miRNAs in included in Appendix. 
I then identified putative novel miRNAs that were differentially 
expressed over time, per condition, using the R package maSigPro (160). 
Subsequent to the time course analysis, I used MR-micro-T (161, 162) to 
predict putative targets for the differentially-expressed miRNAs. Of the 
predicted targets, I took the top tranche (with scores greater than 0.95) and 
subjected them to functional analysis using Reactome data from Mousemine 
(163).   
 
Uninfected Sample – genes differentially expressed over time 
Three miRNAs were significantly differentially-expressed across the uninfected 
time course, with profiles shown in the plots below. Tables of enriched 
pathways from predicted targets are shown below the expression profile 
figures, where available.  
 
 
Figure 5.21. Expression Profile of putative novel miRNA s10_11_3926 – Uninfected 
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Table 5.2 Pathway enrichment of target genes for putative novel miRNA s10_11_3926 
Reactome Pathway adj p-value No. of genes 
Transcriptional regulation of white 
adipocyte differentiation 0.000351821 4 
Transcriptional Regulation of 
Adipocyte Differentiation in 3T3-L1 
Pre-adipocytes 0.000652876 4 
Mus musculus biological processes 0.024080493 4 
 
 
A total of 26 genes were predicted as putative targets for this miRNA. The 
four genes involved in all of the reactome pathways in Table 5.2 are: Ncoa1, 
Med19, Med27 and Ppargc1a.  
 
 
Figure 5.22. Expression Profile of putative novel miRNA s10_16_14002 – Uninfected 
 
No statistically-significant pathway enrichment was found for the 
predicted targets of miRNA s_10_16_14002. The targets themselves 
are Ammecr1, Edaradd, Foxp2, Kcna2, Ptprt (Protein Tyrosine 
Phosphatase, Receptor Type T), and Sos1. 
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Figure 5.23. Expression Profile of putative novel miRNA s10_8_40983 – Uninfected 
 
Again, no Reactome pathways were significantly-enriched for, but a 
GO term was enriched for: Organ growth. The genes that contributed to this 
process were: Gja1 (gap junction protein, alpha 1), Lats1 (large tumor 
suppressor), Mtor (mechanistic target of rapamycin (serine/threonine kinase)), 
Smad2 (SMAD family member 2), Tcf7l2 (transcription factor 7 like 2, T cell 
specific, HMG box), Tgfbr3 (transforming growth factor, beta receptor III) 
and Ttn (titin). 
 
ME49, MOI 1.2 – genes differentially expressed over time 
Three miRNAs were found to be differentially-expressed across the time 
course. MicroRNA s_16_14002 was also differentially-expressed in the 
Uninfected sample, but with a very different profile across time. Given that 
the prediction of putative targets does not depend on the pattern of 
expression, the targets and pathways are the same as above.  
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Figure 5.24. Expression Profile of putative novel miRNA s10_16_14002 – ME49, MOI 1.2 
 
 
Figure 5.25. Expression Profile of putative novel miRNA s10_7_38813 – ME49, MOI 1.2 
 
118 genes were predicted to be putative targets of miRNA 
S10_7_38813, but again, no Reactome pathways were enriched. That being 
said, the GO term analysis yielded several enriched terms, many having to do 
with metabolism and biosynthetic processes, Table 5.3. 
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Table 5.3 GO-term enrichment of target genes for putative novel miRNA s10_7_38813 
GO Term adj. p-value #genes 
regulation of nucleobase-containing compound metabolic process 0.001269326 41 
regulation of macromolecule biosynthetic process 0.001623246 41 
heterocycle biosynthetic process 0.001789389 41 
aromatic compound biosynthetic process 0.002052568 41 
regulation of cellular macromolecule biosynthetic process 0.002244811 40 
regulation of biosynthetic process 0.002964252 42 
regulation of transcription, DNA-templated 0.003021357 37 
regulation of nucleic acid-templated transcription 0.003463961 37 
regulation of nitrogen compound metabolic process 0.003510913 42 
regulation of RNA biosynthetic process 0.003675824 37 
nucleobase-containing compound biosynthetic process 0.003817873 40 
regulation of macromolecule metabolic process 0.004196736 51 
organic cyclic compound biosynthetic process 0.00437189 41 
transcription, DNA-templated 0.005541801 37 
regulation of cellular biosynthetic process 0.005803785 41 
nucleic acid-templated transcription 0.006323055 37 
macromolecule biosynthetic process 0.00693568 45 
RNA biosynthetic process 0.007090377 37 
negative regulation of cellular macromolecule biosynthetic process 0.008963633 22 
regulation of RNA metabolic process 0.009113422 37 
regulation of metabolic process 0.013500464 52 
regulation of primary metabolic process 0.019623559 49 
negative regulation of macromolecule biosynthetic process 0.020027057 22 
cellular nitrogen compound biosynthetic process 0.022624369 43 
organic substance biosynthetic process 0.02485083 49 
cellular macromolecule biosynthetic process 0.025721011 43 
regulation of cellular metabolic process 0.025785181 49 
cellular biosynthetic process 0.03765248 48 
negative regulation of cellular biosynthetic process 0.037890822 22 
regulation of gene expression 0.039640641 40 
biosynthetic process 0.040949275 49 
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Figure 5.26. Expression Profile of putative novel miRNA s10_8_42936 – ME49, MOI 1.2 
28 putative targets were identified, but neither GO Term nor Pathway 
enrichment yielded any statistically-significant results – this is likely due to 
the preponderance of “predicted genes” within the putative targets (over half). 
 
ME49, MOI 3 – genes differentially expressed over time 
 
 
Figure 5.27. Expression Profile of putative novel miRNA s10_11_3926 – ME49, MOI 3 
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As with predicted miRNA S10_16_14002, S10_11_3926 was also 
significantly differentially expressed in the uninfected sample, though with a 
visibly different temporal profile. 
 
 
Figure 5.28. Expression Profile of putative novel miRNA s10_8_42936 – ME49, MOI 3. 
 
5.3.4 Potential novel miRNAs from Toxoplasma gondii 
Neither T. gondii nor any closely relate species are included in miRBase (even 
the previously identified miRNAs from other studies). That being said, 
miRDeep2 recommends the inclusion of even distantly-related species (113), so 
I opted to compare the two approaches: once without comparisons, and once 
using miRBase miRNAs from Ectocarpus siliculosus, a filamental brown alga. 
In any case, given the absence of existing T. gondii miRNAs in 
miRBase for comparison, the scoring parameters that emerge from the 
miRDeep2 pipeline are slightly different than they were for the M. musculus 
samples. For instance, the estimated true/false positive score is based on the 
algorithm’s performance in detecting known miRNAs within a particular set of 
samples and then using that metric to inform the likelihood of a putative 
miRNA being a true or false positive. Without reference miRNAs, this 
calculation is omitted from the analysis.  
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Though I ultimately performed the T. gondii miRNA discovery analysis 
using only infected samples, I re-ran the analysis using only the uninfected 
libraries – to ensure that no spurious miRNAs arising from mouse-derived 
reads were included in the novel set. 
 
ME49 
At a cut-off score of ten, six putative novel miRNAs were identified. Of these, 
two did not map to the genome itself, rather to unassembled supercontigs. 
Given that the lack of genome positioning was a criticism levelled at other 
attempts at miRNA identification in T. gondii (108), I opted to exclude these 
from my set. A further putative miRNA (provisional id 13393) was found to 
be predicted from uninfected reads alone, so it too was excluded, resulting in a 
remaining total of four novel putative miRNAs from ME49.  
 
Table 5.4. Putative novel miRNAs from ME49 
Putative miRNA 13393 (stricken out in the table) was only found in uninfected samples, 
indicating that is unlikely to be a true miRNA from T. gondii 
T. gondii 
ME49 
provisional id 
Score with E. 
siliculosis 
Score w/out E. 
siliculosis 
T. gondii ME49 
Co-ordinates 
13523 433.5 434.1 VIII:1266109..1266167+ 
13393 48.1 48.7 VIII:702568..702626+ 
18892 17 17.6 X:2773287..2773347+ 
18365 15.1 15.7 IX:5990908..5990990- 
19667 9.7 10.3 X:6540009..6540050+ 
 
The inclusion of E. siliculosis neither improved the scores of putative 
miRNAs nor did it identify any new putative miRNAs with a score above 10. 
In fact, the only effect that this inclusion had was to identify one novel 
putative miRNA with the same seed sequence as an existing E. siliculosis 
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miRNA, but this putative T. gondii ME49 miRNA had a score of only three 
so was excluded from further analysis. 
The relative sequence contribution of each sample to each putative 
miRNA is given below, as well as graphical representations of frequency 
density plots of the alignment stacks and the predicted precursor RNA 
secondary structure. NB. The pie charts are for collapsed reads. That is to 
say, if a particular library contributed x reads to the alignment, but that read 
had been sequenced multiple times, that sample’s contribution would still be 
represented as x in the pie chart. 
 
Figure 5.29. Relative sequence contribution of each sample to the putative novel ME49 
miRNAs. Collapsed counts from each experimental samples were assessed for their 
proportional contribution to the putative novel miRNA. In all but one case, the 
preponderance of reads were contributed by ME49. 
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GT1 
At a cut-off score of ten, four putative novel miRNAs were identified, all of 
which could be positioned on the GT1 genome. 
 
Table 5.5. Putative novel miRNAs from RH. Putative miRNAs in green align exactly to 
putative miRNAs discovered in ME49, while putatuve miRNA 20653 was excluded from 
further anaysis since it’s score without including E. siliculosis was under ten. 
id 
Score with E. 
siliculosis 
Score 
without E. 
siliculosis 
T. gondii GT1 co-
ordinates 
14134 429.5 430.1 chrVIII:1260791..1260849+ 
28695 45.2 45.8 chrXII:6281695..6281774- 
28696 36.8 37.4 chrXII:6281758..6281799- 
19812 17 17.6 chrX:2684478..2684538+ 
20653 10.3 9.7 chrX:6429927..6429968+ 
 
	
Figure 5.30. Relative sequence contribution of each sample to the putative novel ME49 
miRNAs. Collapsed counts from each experimental samples were assessed for their 
contribution to the putative novel miRNA.  
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Given the possibility – however remote – of parasite miRNAs targeting 
mouse mRNAs directly, I used the algorithm above (MR-MicroT (161, 162) to 
predict putative M. musculus targets.  
 
Predicted M. musculus targets of putative ME49 miRNAs 
Provisional id 13523: 
No putative targets were predicted above a score of 0.95.  
 
Provisional id 18892: 
Of the nine putative targets predicted to be targeted by this putative miRNA, 
three were unestablished genes (e.g. predicted, or RIKEN cDNA probes). The 
remaining six were: Arl4c (ADP-ribosylation factor-like 4C), Cnot2 (CCR4-
NOT transcription complex, subunit 2), Erp44 (endoplasmic reticulum protein 
44), Peak1 (pseudopodium-enriched atypical kinase 1), Slc35f1 (solute carrier 
family 35, member F1) and Zfp938 (zinc finger protein 938). 
 
Provisional id 18365: 
Given the low-complexity nature of this miRNA (its sequence being 
UGUGUGUGUAUGUGUGUAUGUG), specificity in the prediction of targets 
is extremely difficult. As such, the list of putative targets is very large (298 at 
a score of >=0.95). 
 
Provisional id 19667: 
A single gene was predicted to be targeted by this putative miRNA, Nsrp1 
(nuclear speckle regulatory protein 1). 
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Predicted M. musculus targets of GT1 putative miRNAs 
Of the putative miRNAs identified by alignment to GT1, only two were not 
also found in the ME49 set.  
 
Provisional id 28695:  
A single predicted target was identified, Cadm2 (cell adhesion molecule 2). 
 
Provisional id 28696: 
Two putative target genes were identified, Map2kp (mitogen-activated protein 
kinase kinase 4) and Il1rapl1 (interleukin 1 receptor accessory protein-like 1)  
 
5.3.5 Differentially Expressed miRNAs 
While the miRDeep2 ‘quantifier’ module does yield count data for known 
miRNAs, it lacks the capacity for either normalization or statistically-sound 
differential expression analysis – it merely returns naïve/raw count data for 
each miRNA and each library. Given the vastly better quality of my libraries 
(as compared to the pilot study in Chapters 3 and 4), I opted to use EdgeR 
for both these analysis steps. Before normalising the data, EdgeR offers (and 
recommends) two filtering steps, the first being to filter out tags that have 
‘zero’ value across all conditions. A further filtering step also removes tags 
that are represented by fewer than one CPM (count-per-million) in fewer than 
two samples. This step ensures that only likely-expressed candidates are 
considered in downstream analyses, thus reducing the risks of multiple testing. 
Filtering on CPM, rather than raw read counts also provides some measure of 
scaling (given that library sizes can vary a great deal without much relation 
to the underlying biological reality). EdgeR utilises TMM normalisation and 
negative binomial distributions especially geared toward count data (rather 
than, for instance, microarray data).  
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A total of 274 microRNAs were found to be differentially expressed 
with regard to the uninfected sample, at any time following infection. How 
these were spread across strain, MOI and time point are presented as Venn 
diagrams in Figure 5.31.  
 
Figure 5.31. Intersection of host miRNAs identified as differentially expressed among all 
conditions. 
 
Only one miRNA (olive green with a white arrow in Figure 5.31) was 
found to be differentially expressed in ‘opposite directions’ over time (that is 
to say, underexpressed at 24h and then overexpressed at 43h, or vice versa); 
mmu-miR-425-3p. 
	 123	
I then examined the temporal pattern of miRNA differential expression 
(NB. I excluded mmu-miR-425-3p from these charts due to its atypical8 
biphasic pattern of expression upon ME49 MOI 3 infection). There are two 
different methods of examining this issue of temporal expression: 
 
1) Expression that is induced (or suppressed) at 24h and then may (or may 
not) be sustained through 43h 
2) Expression that is induced (or suppressed) only at 24h or 43h. 
 
Perhaps the more interesting case, is 2), which is what is represented in 
Figures 5.32 and 5.33. This could reveal where ‘waves’ of transcriptional 
initiation might be observed, i.e. looking at miRNAs whose 
induction/suppression was first observed at a particular time point (so, for 
instance, a gene that was induced at 24h and then sustained through 43h 
would be excluded from the 43h group). It would be too much to say that 
host miRNAs induced (or suppressed) by T. gondii infection follow a biphasic 
mode of expression, given that only two time points past zero were sampled, 
but this nevertheless suggests that they are not dysregulated ‘wholesale’, at 
the same time point.  
 
																																																								8 Atypical with regard to the rest of the dysregulated miRNAs in my dataset. 
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Figure 5.32. Timing of miRNA upregulation. microRNAs were scored and grouped based on 
the timepoint at which they first emerged as upregulated. The microRNA genes appear to 
follow ‘waves’ of transcriptional induction. 
 
 
Figure 5.33. Timing of miRNA downregulation. microRNAs were scored and grouped based 
on the timepoint at which they first emerged as downregulated. The microRNA genes appear 
to follow ‘waves’ of transcriptional induction. 
 
Given that (in both strains) the lower MOI showed a greater 
proportion of dysergulated miRNAs at the later time point, I thought that 
perhaps this might be due to parasite burden. There is an argument to be 
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made that a higher MOI might simply represent a higher (or lower) fold-
change in the same miRNA but with an ‘early onset’. To test this hypothesis, 
I looked at dysregulated miRNAs within each strain,  comparing ones that 
were dysregulated beginning at 24hpi in the higher MOI with those that were 
dysregulated at 43hpi (and no earlier) in the lower MOI. This hypothesis 
would imply that the higher MOI would be ‘one step ahead’ in terms of 
dysregulation, that is, that genes upregulated at the higher MOI at 24hpi 
would be followed by the same ones in the lower MOI, only later.  
 
RH – Delayed Onset 
For the Type I strain, of the 21 genes that were upregulated at 24h at MOI 3, 
five (24 per cent) exhibited a statistical ‘delayed’ upregulation (i.e. were 
overexpressed at 43 h and not at 24h). In the downregulated set of miRNAs, 
only 2 of the 22 genes downregulated at 24hpi were ‘followed’ by a similar 
downregulation at 43hpi in the lower MOI.  
 
ME49 – Delayed Onset 
In ME49, the ‘delayed onset’ hypothesis is strengthened, with over half of the 
24h, MOI 3 overexpressed genes being expressed later (and only later) at the 
lower MOI. Only 5 of the genes that were downregulated at MOI 3 24hpi (out 
of 42 in total) were downregulated only at 43hpi at MOI 1.2. 
 
5.3.6 Common Core of Dysregulated miRNAs 
Given the fact that the generalised host miRNA response to T. gondii 
infection has still not been well-characterised, I decided to then concentrate on 
those dysregulated miRNAs that were common to T. gondii infection as a 
whole, rather than related to strain-specificities. To do this, I intersected the 
genes that were upregulated at any time in both strains, at both MOIs, 
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resulting in 38 upregulated miRNAs and 55 downregulated ones (Tables 5.6 
and 5.7).  
 
Table 5.6. Mus musculus microRNAs upregulated in infection, by both strains 
mmu-miR-7081-3p mmu-miR-1934-5p mmu-miR-98-5p mmu-miR-146a-5p 
mmu-miR-877-5p mmu-miR-5121 mmu-miR-7650-5p mmu-miR-5103 
mmu-miR-7655-5p mmu-miR-6240 mmu-miR-677-5p mmu-miR-98-3p 
mmu-miR-582-5p mmu-miR-582-3p mmu-miR-1931 mmu-miR-132-3p 
mmu-miR-9-5p mmu-miR-1947-5p mmu-miR-295-3p mmu-miR-149-5p 
mmu-miR-101a-5p mmu-miR-1194 mmu-miR-217-5p mmu-miR-9-3p 
mmu-miR-1948-5p mmu-miR-708-5p mmu-miR-5099 mmu-miR-155-3p 
mmu-miR-708-3p mmu-miR-505-5p mmu-miR-188-5p mmu-miR-1191a 
mmu-let-7j mmu-miR-7042-5p mmu-miR-155-5p   
mmu-miR-3086-5p mmu-miR-1948-3p mmu-miR-1945   
 
Table 5.7. Mus musculus microRNAs downregulated in infection, by both strains 
mmu-miR-690 mmu-miR-299b-3p mmu-miR-671-3p mmu-miR-467b-5p 
mmu-miR-30b-3p mmu-let-7b-3p mmu-miR-299a-3p mmu-miR-503-5p 
mmu-miR-140-5p mmu-miR-466p-5p mmu-miR-92b-3p mmu-miR-199a-3p 
mmu-miR-574-5p mmu-miR-30c-1-3p mmu-miR-299b-5p mmu-miR-3072-5p 
mmu-miR-193b-3p mmu-miR-199a-5p mmu-miR-671-5p mmu-miR-382-5p 
mmu-miR-450b-3p mmu-miR-466k mmu-miR-328-5p mmu-miR-485-3p 
mmu-miR-5126 mmu-miR-134-5p mmu-miR-154-3p mmu-miR-467a-5p 
mmu-miR-6238 mmu-miR-410-5p mmu-miR-351-5p mmu-miR-411-3p 
mmu-miR-377-3p mmu-miR-187-3p mmu-miR-3068-5p mmu-miR-154-5p 
mmu-miR-135b-3p mmu-miR-134-3p mmu-miR-125a-3p mmu-miR-26a-2-3p 
mmu-miR-380-5p mmu-miR-379-3p mmu-miR-299a-5p mmu-miR-615-5p 
mmu-miR-199b-3p mmu-miR-129-5p mmu-miR-379-5p mmu-miR-1247-5p 
mmu-miR-666-5p mmu-miR-129-2-3p mmu-miR-193a-5p mmu-miR-574-3p 
mmu-miR-127-3p mmu-miR-466i-5p mmu-miR-466h-3p   
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5.3.7 Functional Analysis of the Dysregulated miRNAs 
While a number of well-characterised miRNAs appear in both lists (miR-155, 
miR-125, miR-146 and miR-92 for instance) the relatively large number of 
dysregulated miRNAs led me to perform a functional enrichment analysis 
bioinformatically, using WebGestalt (156, 157). I initially opted for a 0.05 
significance level (with Benjamini-Hochberg multiple testing correction) but 
relaxed this to 0.1 for the downregulated miRNAs, given that no significant 
results were found that this level.  
 
5.3.7.1 Downregulated miRNAs, Upregulated Targets 
The only pathway to be significantly enriched (even at a significance level of 
0.1) by this list of target genes was Sphingolypid Metabolism.  
 
5.3.7.2 Upregulated miRNAs, Downregulated Targets 
More pathways were significantly enriched using the set of targets from the 
downregulated miRNAs, they are shown in Table 5.8.  
 
Table 5.8 Enriched KEGG pathways for predicted targets of miRNAs upregulated by the 
common core of dysregulated miRNAs 
Osteoclast differentiation 
Toll-like receptor signaling pathway 
Jak-STAT signaling pathway 
Neurotrophin signaling pathway 
Hepatitis C 
Chemokine signaling pathway 
 
5.3.8 Profiles of Selected miRNAs 
Of the two miRNAs that were identified as being dysregulated in Chapter 4 
(mmu-miR-200b-3p and mmu-miR-3080-5p) only the former was present in 
my more comprehensive dataset here (not just the common core, but 
anywhere). To check whether the directionality of differential expression was 
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common between the two analyses, I plotted profiles of mmu-miR-200b-3p for 
each strain (Figure 5.34). Note that the Chapter 4 analyses were performed on 
NIH/3T3 infected with ME49 at an MOI of 5 for 24h.  
 
 
Figure 5.34. Profiles of mmu-miR-200b-3p 
 
 
 
Other noteworthy miRNAs are profiled below in Figures 5.35 to 5.38). 
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Figure 5.35. Profiles of mmu-miR-155-5p 
 
 
Figure 5.36. Profiles of mmu-miR-146a-5p 
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Figure 5.37. Profiles of mmu-miR-199a-3p 
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Figure 5.38. Expression profiles of miR-125 family members 
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Figure 5.38, continued. Expression profiles of miR-125 family members 
 
Given the known upregulation of MYC in T. gondii infection (21) and that 
MYC has been shown to directly and specifically suppress miR-23a/b (164), I 
also looked at those two miRNAs (Figure 5.39).  
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Figure 5.39. Expression profiles of mmu-miR-23a-3p and mmu-miR-23b-3p 
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5.4 Discussion 
My analyses report a number of host cell miRNAs dysregulated due to 
infection by Toxoplasma gondii, as well as a number of novel miRNAs, both 
host- and parasite-derived.  
 
5.4.1 Targets of miRNAs 
The nature of miRNA analysis – using miRNA targets as input for functional 
analyses by pathway enrichment – is inherently dependent on the quality of 
the targets. This becomes particularly crucial when looking at large lists of 
miRNAs that do not lend themselves to individual analysis.  
Though forward genetics have not been widely used to identify miRNA 
genes, their obvious advantage is that, at the very least, a scoreable 
pheonotype exists that can then be used to infer the function of the miRNA. 
Instead, we now find ourselves in the position where hundreds of miRNAs 
have been identified (and validated) in numerous organisms, but with 
relatively few functional annotations. Until relatively recently, most of the 
work in this area has concentrated on the computational prediction of miRNA 
targets. A miRNA’s characterstic mode of action relies on the formation of a 
duplex between the miRNA and the 3’UTR of its target. Unlike in plants, 
base-pairing between the miRNA and the target is usually imperfect, which 
obviously makes target prediction much more difficult.  
Since 2009, the process of target prediction and validation has been 
made far more reliable by the use of HITS-CLIP (165) (indeed, of the 39,534 
targets that I used as my background list for the WebGestalt analysis, over 
73% were validated using HITS-CLIP). HITS-CLIP works through UV 
crosslinking to purify RNA-protein complexes. Chi et al used this method with 
Argonaute protein, which binds to both the miRNA and its mRNA targets – 
which can then be precisely identified.  
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MR-MicroT (161, 162) is one of very few target prediction algorithms 
that allows the search of novel putative miRNAs’ targets (and even this 
programme is still in beta). To my knowledge, no independent validation of 
the process has yet been performed, and so those results must be taken as 
highly preliminary. Quite apart from the fact that the potential targets of 
these putative miRNAs are themselves ill-defined, the use of pathway 
enrichment on them to identify the potential function of putative novel 
miRNAs is extremely poorly defined. After all, no reasonable background 
correction is possible and so, these results must be taken with great 
reservations.  
 
5.4.2 Novel miRNAs – Mus musculus 
As with most classic model organisms, mouse miRNAs have, since their 
discovery, been well-studied: of 35,827 miRNAs in miRBase 21, 1,915 are 
mouse miRNAs, second only to human miRNAs (2,588 of which are listed). 
As a result, my expectation for my set of 33 libraries was that, were any novel 
mouse miRNAs to be detected, they would most likely appear as mouse 
miRNAs dysregulated specifically in response to infection by Toxoplasma 
gondii. At first this appeared to have been somewhat borne out by the fact 
that none of the novel miRNAs were predicted using uninfected samples alone.  
Overall, my analyses identified a total of 215 novel miRNAs. However, 
upon time course analysis, I then identified three novel miRNAs that were 
significantly differentially-expressed over the course of the 43h experiment, 
solely in uninfected NIH/3T3 cells. This indicates that these novel miRNAs 
could be dysregulated in response to confluence and contact inhibition. 
Indeed, of the three, though only one had predicted targets with significant 
pathway enrichment, these pathways corresponded to adipocyte 
differentiation. While NIH/3T3 are not known to spontaneously differentiate 
into adipogenic cells, given that most adipocyte research is conducted using 
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late-stage 3T3-L1 cell lines, it is not inconceivable that this particuar miRNA 
(identified in my analysis as s10_11_3926) has an impact on post-
proliferation processes in 3T3 or 3T3-like cells.  An important study of 
confluence and miRNA expression was conducted by Hwang et al (166), where 
a comparison was made of primary human fibroblast, NIH/3T3 and HeLa cell 
lines’ microRNA expression. Overall, they found that, in all three cases, 
growing cells towards confluence resulted in a global increase in miRNA 
biogenesis, an effect that they attribute to increased cell-cell contact (rather 
than, say, quiescence). Hwang et al. conducted northern blots to assess the 
presence of a battery of miRNAs and, following qPCR analysis, concluded 
that the increased biogenesis of miRNAs upon confluence was not 
transcriptional in nature (except for one case, miR-34a). However, the qPCR 
experiments were not conducted on NIH/3T3 cells. Even if the majority  of 
confluence-dysregulated miRNA biogenesis can be attributed to 
posttranscriptional processing, this does not preclude the possibility that a few 
specific miRNAs are transcriptionally dysregulated – including some that have 
not yet been discovered – when profiled across a long growth period, as my 
results indicate.  
 
5.4.3 Novel miRNAs – Toxoplasma gondii 
Far fewer novel miRNAs (or miRNA-like RNA species) were identified from 
the parasite. This is to be expected, purely from a technical standpoint, given 
the far lower alignment coverage. After all, parasite contribution to the RNA 
sample would have been small. The target gene predictions for these genes 
must be interpreted in an even more cautious fashion: while it has been 
hypothesised (112), there is no evidence at all that this might be the case.  
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5.4.4 Differentially Expressed Known Host miRNAs 
My results suggest that the host miRNA response to T. gondii infection is in 
fact rather modest – 274 miRNAs were found to be differentially expressed 
compared to the uninfected sample, at any time and by any strain/MOI. That 
being said, some of the most well-characterised miRNAs did emerge.  
There is some discussion as to whether analyses of differential 
expression are best performed considering lists of up/down-regulated 
genes/miRNAs separately or together. Single annotated networks (e.g. within 
KEGG) can contain genes – in this case miRNA target genes – that are both 
up and down-regulatory towards the pathway as a whole. That is to say, a 
particular KEGG pathway being enriched for may not necessarily indicate 
that that pathway is being driven “positively”. Rather, this may only indicate 
that several members of that pathway (whether positive or negative 
regulators) were disproportionately represented in the sample list. While some 
attempt has been made to quantify this in ‘simple’ gene expression analysis 
(167), no such study has been performed that takes into account the extra 
(‘inverted’) layer of complexity added by miRNA control and so this may 
represent a source of added complexity.  
That being said, a number of pathways that are known to be 
dysregulated by T. gondii infection did appear in the enrichment. The 
parasite is known to downregulate STAT1, though a miRNA component to 
that downregulation has not been explored. Toxoplasma gondii’s ability to 
interfere with the host cell cytokine pathways – many with NFKB 
implications - has also been examined but not in terms of miRNA regulation 
beyond the role of miR-146a, which I find in my dataset.  
Given the somewhat tentative nature of this pathway analysis, I focus 
instead on the well-characterised miRNAs that emerged from my list.  
Perhaps unsurprisingly, given its multiple and varied roles, the very 
‘famous’ let-7 pathway makes several appearances in my dataset. What is on 
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first glance very curious, however, is that members of this family appear both 
in the up- and downregulated lists: mmu-miR-98 and mmu-let7j are 
upregulated while mmu-let7b is downregulated (Tables 5.6 and 5.7).  
One of the difficulties in miRNA research is that, given the relative 
infancy of the field, very basic issues such as nomenclature and 
standardisation change rapidly and often. This means that early work on 
miRNA family members is often difficult to relate to current nomenclature: 
one can imagine a scenario9 where, for instance, early literature ascribes a 
particular function to let-7 without specifying which family member was being 
considered (M. musculus alone contains 12 different let-7 family members). 
Absent sequence information, it is therefore difficult to interpret that kind of 
experiment and decide which family member was being referenced.  
It is true also that members of a single miRNA family can have vastly 
different sets of target genes, and it is still unclear how these interactions are 
mediated, mechanistically. For the let-7 family, due at least in part to the 
nomenclature issue highlighted above, even despite it being the most well-
studied miRNA family, the exact similarities and differences between the 
family members is still poorly-understood. Of the family members in my 
dataset, mmu-let-7b and mmu-miR-98 are far better studied than mmu-let-
7j10 so I will concentrate on them. Wang et al found in 2011 that miR-98 
directly regulates Fas: miR-98 mimics decreased the levels of Fas-induced 
apoptosis in HeLa cells (and inhibitors increased it). Thus, its upregulation in 
infected cells is consistent with the observation that T. gondii-infected cells 
exhibit lower levels of apoptosis, including Fas-dependent (34).  
Given that my dataset included the well-characterised mmu-miR-125a, 
I generated profiles of other family members (Figure 5.38). Among the 
family’s roles is the regulation of NFkB. The potential mechanism that Kim et 																																																								9 Actually, one does not even need to “imagine” 10 A PubMed search for each revealed 126 and 299 results for “miR-98” and “let-7b” 
respectively, while “let-7j” yielded only a single paper – a survey of miRNAs in Nile tilapia. 
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all suggests is via targeting of TNFAIP3 (168).  That miR-125 is itself a 
target of NFkB adds another layer of complexity to an already complex 
regulatory mechanism. Another role for miR-125 is in the regulation of 
apoptosis, where the anti-apoptotic genes Bcl2 and Bcl2l12 were found to be 
direct targets. Again, a downregulation of the miRNA (and thus de-repression 
of the anti-apoptotic genes) is consistent with what we know about T. gondii 
interference with host pro-apoptotic pathways. The timing of some miR-125 
family members is curious with some appearing to be biphasic.  
The role of miR-155 in cellular processes is simultaneously well-studied 
but again the many layers of regulatory complexity mean that the results are 
not always very clear. This miRNA has been shown to be upregulated by 
inflammation (especially IL6) (169) but its downstream effects appear to have 
more to do with cancer metabolism, through an intriguing cascade effect. 
Transfection with the miRNA was found to result in an increase in 
Hexokinase 2 protein levels, but, rather than being a direct target of miR-155, 
it emerged that miR-155 repressed miR-143 and this latter miRNA was found 
to be a repressor of HK2 (170). Indeed, miR-155 was one of the miRNAs 
looked at by Cannella et al in the brains of mice. As I did (Figure 5.35), they 
found it to be upregulated by both strains (171).  
The other miRNA identified in that study was miR-146a. In my 
dataset, though it was statistically-significantly upregulated by all strains, it is 
clear that the miRNA’s upregulation at high MOI ME49 is far greater than 
the other strains and conditions (Figure 5.36).  
Another interesting miRNA to consider in my common core dataset is 
miR-199, which was downregulated by both strains, at both times (Figure 
5.37). This is a hypoxia-related miRNA, and in fact Hif1a appears to be one a 
direct targets (172). The presence of HIF1A has been described as being 
required for normal growth of T. gondii during hypoxia11 but the mechanism 
																																																								11 Though the data suggest this is also true at normoxia, see Chapter 6 
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for the stabilisation of HIF1A is much less clear. Signalling through the 
ALK4,5,7 system was shown to be a possible route (173) but the exact 
mechanism remains unknown. In Spear et al’s hands, transcript levels of Hif1a 
did not rise upon infection at normoxia12 which is consistent with targeting by 
a miRNA. Thus it is possible that at least part of the stabilisation of HIF1A is 
via the downregulation of miR-199a.  
Finally, I opted to look at miR-23a and miR-23b, given that they are 
known (suppressed) targets of MYC (164) and that they are known to 
suppress the expression of glutaminase (see Chapter 6). Thus, the expectation 
was that the overexpression of MYC known to occur during infection would 
suppress their expression here. Confoundingly, the opposite was true for miR-
23b, while miR-23a had an unclear profile, seemingly not very different from 
the uninfected sample (Figure 5.39). It will be interesting to see what other 
mechanisms might control the expression of these miRNAs during infection 
and how that impinges on the expression of downstream genes like 
glutaminase. 
																																																								12 Though it did in mine, see Chapter 6	
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VI. Effects of Toxoplasma gondii Infection on Host Cell 
Metabolism 
 
6.1 Introduction 
6.1.1 Toxoplasma gondii infection and host cell gene expression 
Large-scale efforts have been conducted in characterising the genome and 
transcriptome of Toxoplasma gondii itself, using 5-prime SAGE tags, 
microarrays and, of course, RNASeq (including ChIPSeq). Many of these 
studies have looked at either the difference between strains or at how 
expression of parasite genes changes as differentiation proceeds from 
tachyzoite to bradyzoite. These studies have largely been collected and 
published on ToxoDB which, at the time of writing, hosts some 137 datasets 
characterising the parasite and closely related species (such as Neospora 
caninum) and of these, 49 involve transcript or protein expression of T. gondii 
(174). In contrast, only three such datasets exist for HostDB13, the analogous 
database for host cell infected with the parasite, though admittedly this 
database in still very much in beta (175). While one of these studies describes 
host cell transcriptomic changes in response to infection by 25 different 
strains, the analysis of these data has focussed entirely on parasite gene 
expression (12). A large-scale proteomics study is also cited but again, the 
analysis is entirely parasite-centric (176). Of course that is not a true 
reflection of the study of host-cell transcriptomics in response to infection; a 
great many have looked at host cell gene expression changes in response to 
infection by T. gondii.  
An early time course study was conducted by Blader et al (177) who 
found a roughly biphasal transcriptional programme elicited by T. gondii 
infection. This experiment looked at HFF cells infected with the Type II PDS 																																																								13	The current URL for HostDB is: http://beta.hostdb.org/hostdb.b28/showApplication.do 
	 142	
strain (an ME49-clone), and used arrays to assay host cell gene expression at 
1, 2, 4, 6, and 24h following infection or mock-infection. The authors found 
that, early in infection (1-6h), pro-inflammatory immune-related genes were 
differentially-expressed, including chemokines, cytokines (such as Il6 or Il1b). 
At 24h following infection, genes involved in glycolysis were highly 
upregulated, but those involved in the citric acid cycle (TCA) were not. 
Cholesterol biosynthesis was also upregulated, especially via mevalonate 
metabolism while, as the authors note, T. gondii’s method of acquiring sterols 
from its host is thought to be by subverting LDL-trafficking in the host. It 
may be then that parasite scavenging depletes host stores which must then be 
replenished via the mevalonate pathway. Unfortunately, probably due to the 
relatively high MOI employed in this study (up to 10), the researchers did not 
follow infection beyond 24h.  
It is clear, however, that timing has a large impact on host cell gene 
expression. A 2006 study by Okomo-Adhiambo et al (178) profiled host cell 
gene expression via microarray in porcine kidney epithelial cells (PK-13) over 
a time course of 72h. To achieve this, the researchers used an unprecedentedly 
(to me) low MOI (1/6), and employed a temperature-sensitive derivative of 
RH – TS-4 – which grows more slowly at 37° C. PK-13 is a relatively rarely 
used cell line14 and currently has a note on the supplier’s site (ATCC), which 
states that this particular cell line “is neither produced nor fully characterized 
by ATCC.” (179) Their choice to use GAPDH as a control housekeeping gene 
for normalisation is also somewhat unfortunate, given known transcriptomic 
and proteomic evidence of its upregulation during infection (177, 180), 
especially when the given justification for this choice was based on ‘normal’ 
kidney epithelial cell expression rather than T. gondii infection15.  																																																								14	While obviously not comprehensive or definitive as a test, a search for the terms “PK13” or 
“PK-13” on 16/08/2016 yield only three PubMed references.	15	Despite these data, Gapdh is a commonly-used reference in T. gondii-host interaction 
studies. 	
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Nevertheless, a number of pathways were identified in this study as 
being differentially-expressed, including early upregulation of pro-apoptotic 
factors and late-stage downregulation of TCA-related genes. The authors 
attempt a comparison with the earlier Spear study (177) but do not make a 
case for either overwhelming similarity or difference that may have arisen 
from either the difference in parasite strain (Type II versus Type I), host cell 
species (human versus porcine), MOI (5-10 versus 1/6) or timing. It is difficult 
therefore to make generalisations about the timing of host cell responses to 
infection using these data.  
The early transcriptional (largely immune-related) response to T. 
gondii infection was further investigated in 2007, when Kim et al used 
microarrays to look at the effect of IFNG on infected cells (181). The type II 
Prugniaud strain was used to infect HFFs and the cells were treated with 
IFNG 18h post infection (or mock-infection). Remarkably, unlike the 
uninfected controls, where most genes known to be transcriptionally IFNG-
responsive were differentially-expressed following treatment, the infected cells 
did not show IFNG-based dysregulation. Thus, the use of large-scale 
transcriptional profiling paved the way for a greater understanding for how 
the parasite is able to survive a robust host cell immune response and persist 
through to bradyzoite differentiation. Microarrays were used more recently in 
a similar manner – focussing on a specific, rather narrow pathway or host cell 
phenomenon – to identify the MYC-related genes that appeared upregulated 
upon infection of RAW macrophages with RH for 24h (21). 
Microarrays have also been used to explore the difference in virulence 
between the three canonical strains, by looking at variations in gene 
expression that differed between types II and III, and then examining host cell 
effects that segregated in the progeny of the type IIxIII cross. This work was 
crucial in determining the role of ROP16 and STAT3/STAT6 activation in 
the virulence differences between the types (182). Broadening the range to 29 
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different strains (including non-canonical ones), Melo et al performed RNASeq 
on bone marrow-derived macrophages infected at a variety of MOIs, for 20h. 
Again, this study was aimed at clarifying the differences between the strains – 
such as the activation of a Type I interferon response by ‘atypical strains’ – 
rather than on the commonalities of T. gondii infection (183).  
Another common use of large-scale transcriptomics in T. gondii 
infection is when studies concentrate on the difference in host cell response 
between infection with mutant or wild type parasites, as was done in the case 
of GRA15  to identify a potent effect on host-cell NFkB and NFkB-regulated 
genes (17). A similar study – albeit RNASeq, rather than array-based – is 
currently underway by Bo Shiun Lai (personal communication), seeking to 
characterise the role of ROP13 on host cell gene expression.  
In vivo transcriptomics have tended to use mice as the animal model of 
choice and these studies have focussed on particular organs. For instance, in 
2016 He et al performed transcriptional profiling of mouse livers following a 
six-day infection by the PYS strain (184). Perhaps unsurprisingly, several 
immune response pathways were upregulated, such as IFNG and IL1B. Given 
the liver’s function in drug metabolism, the authors of the study concentrated 
on the potential implications of infection on adverse drug reactions. A 
proteomic analysis of infected mouse livers followed, from the same laboratory 
(185). Interestingly, they reported a downregulation in fatty acid metabolism, 
via an apparent suppression of the peroxisome proliferator-activated receptor 
(PPAR) signalling pathway. 
The same laboratory also conducted transcriptional profiling studies in 
spleens from mice infected with the Type I strain RH (186). This revealed a 
number of changes to splenic organelles, including a generalised 
downregulation of mitochondrial genes.  
 In terms of metabolism, curiously, while hexokinase 2 (hk2) was found to be 
upregulated (suggesting to me an increase in glycolytic processes), so was 
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pyruvate dehydrogenase kinase, which normally acts to inhibit the entry of 
pyruvate into the citric acid cycle (TCA) by inhibiting pyruvate 
dehydrogenase. The authors did not further examine the metabolic impact of 
RH infection in the spleen, choosing instead to focus on endolysosomal 
processes and antigen presentation. 
An obvious limitation of microarrays to study gene expression is that 
they can only profile what has been spotted on them. RNASeq thus provides a 
huge advantage in that it assays what has been transcribed and so 
interpretation of the results then becomes a question of computational power 
and the quality of existing annotation. A large-scale RNASeq study has been 
conducted in porcine PK-15 (kidney epithelial) cells: a time course of infection 
using RH, at an MOI of 5 . In my hands, that level of MOI with a Type I 
strain almost always causes host cell lysis shortly after 24h, and so it is 
unsurprising that the researchers concluded their time course at 24hpi. The 
fact that the researchers simultaneously profiled parasite and host 
transcriptomics is rather unique, although no attempt was made to correlate 
the two organisms’ expression profiles. The researchers found that the largest 
difference in parasite gene expression occurred in the first few hours of 
infection, and that large-scale host cell transcriptional changes were 
comparatively delayed. The main thrust of the analysis here, however, was 
based on GO-term analysis (which yielded such revealing terms as “cellular 
processes” being enriched). The KEGG-based analyses are far more 
informative, with specific pathways being described as enriched. Among those 
were several cancer-related pathways, along with “p53 signaling pathway” 
which raise interesting questions about the modulation of the host response 
that may be related to tumorigenic processes, especially given the known 
interaction of parasite GRA16 with this pathway (19). However, these issues 
were left unexplored in that study.  
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In this chapter, I seek to investigate host cell responses elicited by two 
strains of T. gondii – RH and ME49 – in a global manner. Given the plurality 
of conditions (host cell type, strain, MOI, timing of infection) used in previous 
host cell transcriptomic studies, I concentrate here on the cellular pathways 
and processes that appear to be shared, regardless of strain, MOI or, to an 
extent, timing of infection. I then focus on a particular feature that emerges as 
highly significant – that of aerobic glycolysis – and show additional functional 
results that support the hypothesis that infection with T. gondii elicits a 
remodelling of host cell metabolism towards a cancer-like, Warburg 
phenotype. 
 
6.2 Methods 
6.2.1 RNASeq 
Thirty-three RNA extractions were performed, as described in Chapter 5, 
dried as in 5.2.2-5.2.3 and shipped to the sequencing facility at KAUST, where 
libraries were prepared using Illumina’s TruSeq stranded mRNA (187) 
protocol, and where they were sequenced on a HiSeq 2000. Libraries and 
sequencing were again performed by Mr Abhinay Ramaprasad. 
I aligned the 33 RNA libraries to the Mus musculus (Ensembl 
GRCm38) using TopHat2 (188), which uses the alignment algorithm of 
Bowtie2 (119) and then puts resultant alignments through splice-site analysis, 
using the Ensembl annotation GTF file corresponding to the GRCm38 
annotation. I employed a mate-inner-distance of 80bp, and the default value 
for mate standard deviation (as recommended by Abhinay Ramaprasad, 
personal communication). 
The percentage of each library that aligned in concordant pairs is 
shown in Figure 6.1. 
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 Figure 61: Concordant and overall alignment rate of all 33 samples. NB. Samples are labelled 
StrainInitialTime_MOI_replicate, e.g. R43_3b is the second biological replicate of cells 
infected with RH, MOI 3 for 43h while U24_0a is the first biological replicate of uninfected 
cells at 24h. 
 
Tables of counts were generated using the htseq-count function of the 
Python library HTSeq (189), which tallies up the reads mapping to a 
particular feature (genes, as provided by the Ensembl GRCm38 GTF 
annotation file). I performed the next steps, the differential expression 
analysis, using EdgeR (140). As suggested by the EdgeR User Manual, I 
filtered the libraries for genes that a) did not exhibit zero expression across all 
samples, and b) that corresponded to greater than 1 count-per-million in at 
least 3 samples. I then performed TMM normalisation, as described in 
Chapter 5.  
Principal Component Analysis of my 33 samples following 
normalisation shows good separation of the different conditions along the 
second dimension (Figure 6.2).  
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Figure 6.2. Principal component analysis of A) unnormalised and B) TMM-normalised 
libraries. Sample labels as previous. 
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6.2.2 KEGG Pathway Enrichment 
After identifying genes that were dysregulated either in comparison to the 
control or to time, I then performed an enrichment analysis of the KEGG 
pathways contributed to by the genes in each of these profile groups, using 
the STRING database, version 10.5 (156, 157). This database contains 
interaction data from over 9.6 million proteins and employs an algorithm to 
enable the analysis of large gene-lists, akin to the erstwhile popular DAVID 
(190) tool for microarrays (though it has been updated much more recently 
than DAVID). Importantly, it allows user-submitted background population 
lists, which can help avoid bias often found in such enrichment tools (191). 
For RNASeq it appears that separating gene lists based on directionality can 
yield more biologically-relevant results (167) and so I assessed functional 
enrichment in each group separately. I applied a Benjamini-Hochberg multiple 
test adjustment of 0.05. 
 
6.2.3 Transcriptional Profiles of Individual Genes 
Following KEGG pathway enrichment analysis, I selected a number of 
functionally-related or highly-dysregulated genes and plotted profiles of their 
transcription over time, using MaSigPro (160). 
 
6.2.4 Western Blotting 
Given the apparent importance of Hif1a to several of the dysregulated genes, 
the next step was to perform western blots on key metabolic or cancer-related 
genes, using cell lysates from HIF1A-KO or HIF1A-WT MEFs infected or 
mock-infected with ME49. The conditions of infection were MOI 3, for 43h. 
 
6.2.5 Lactate Assay 
I performed lactate assays on extracellular medium taken from NIH/3T3 cells 
infected (or mock-infected) with ME49, at an MOI of 3 over a time course.  
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6.3 Results 
6.3.1 Pairwise Differential Expression  
I first examined the RNASeq in a parwise fashion, comparing the infected 
strains at each time point to the corresponding uninfected time point. I used 
EdgeR (140) to calculate which genes were differentially-expressed in each of 
these conditions, at a Bonferroni-Hochberg adjusted p-value of 0.01. For the 
RH strain samples, an MOI of 1.2 was used, which, as shown in Chapter 5, 
corresponds (in terms of parasite infection levels) to the ME49-infected 
samples at an MOI of 3. Several genes were found to be differentially-
expressed between the infected and control samples; plots of the log-fold 
changes are shown in Figure 6.3.  
 
 
Figure 6.3. Expression plots for each of the infected samples. For each infected sample, 
differentially-expressed genes, with respect to the uninfected control at the corresponding 
timepoint were plotted using R. Red lines represent a log2fold change of 2, blue lines represent 
a log2fold change of 1. 
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As expected, there appear to more many more differentially-expressed genes at 
the later time-points of infection; this is explored further in 6.3.2, which looks 
at differences across the time course as a whole. The full lists of differentially-
expressed genes at each time point between each infection condition and the 
corresponding control samples are in Supplementary Folder 1. The number of 
differentially-expressed genes in each pairwise comparison are shown in Table 
6.1 and Figure 6.4. 
 
Table 6.1. Differentially-expressed genes in each infected sample, as compared to the 
uninfected sample at the corresponding time-point. DE genes were filtered for an adjusted p-
value of less than 0.01 and a log2 fold change of at least 1.5 
Strain and 
MOI 
Upregulated at 
24hpi 
Upregulated at 
43hpi 
Downregulated at 
24hpi 
Downregulated at 
43hpi 
ME49, MOI 3 132 516 188 393 
RH, MOI 1.2 104 461 4 195 
 
Figure 6.4. Differentially-expressed genes at 24hpi and 43hpi.  
Differential expression was calculated between the infected samples and the corresponding, 
time-matched uninfected controls. They were filtered on an adjusted p-value of 0.01 and a 
log2FC of 1.5. 
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In order to then better understand the interactions of these differentially-
expressed genes, I constructed venn diagrams to uncover patterns between the 
different strains and time-points (Figures 6.5 and 6.6). Given that more genes 
were dysregulated at the later time point, regardless of the strain used, it 
could be feasible that those dysregulated at 43hpi include those dysregulated 
at the earlier time-point. However, it does not appear that this is the case: 
several genes were uniquely dysregulated at 24hpi, which suggests a 
potentially-‘phased’ mode of gene expression following infection. The 
dysregulation of genes across time following infection is further explored 
further in this chapter. 
 
 
Figure 6.5. Venn Diagram of up- and down-regulated genes following infection with ME49. 
Differentially-expressed genes from the ME49-infected samples were intersected, based on 
whether they were up- or down-regulated compared to the uninfected control sample. 
 
 
Figure 6.6. Venn Diagram of up- and down-regulated genes following infection with RH. 
Differentially-expressed genes from the RH-infected samples were intersected, based on 
whether they were up- or down-regulated compared to the uninfected control sample. 
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In the RH-infected samples, only a single gene was downregulated both at 
24hpi and 43hpi, lymphocyte antigen 6 complex, locus C2, a gene that has not 
been explored in the context of Toxoplasma gondii infection. 
Given that my interest is in discovering host cell gene expression effects upon 
infection as a whole, I think intersected the genes that were dysregulated by 
both strains, at both time-points. This proved possible only for the 
upregulated genes, given that the sole gene downregulated at both 24hpi and 
43hpi by RH was not downregulated (nor upregulated) at any time by ME49 
infection. As such, I obtained a ‘core set’ of 29 genes that were upregulated at 
both time-points, by both strains – a marker of common infection-regulated 
genes. These genes are shown in Table 6.2 where it is already apparent that 
several genes known to be related to Toxoplasma infection are represented, for 
instance members of the NFkB family, chemokine ligands and interleukins. 
 
Table 6.2 All the different infections conditions and time-points were interescted. A list of 29 
‘common core’ genes were found to be upregulated. 
Gene 
Symbol Gene Name 
Mmp9 Matrix metallopeptidase 9 
Traf1 TNF receptor-associated factor 1 
Nfkbia Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha 
Rnf19b Ring finger protein 19B 
Nfkb2 Nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100 
Ccl5 Chemokine (C-C motif) ligand 5 
Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 
Dcn Decorin 
Stra6 Stimulated by retinoic acid gene 6 
Acpp Acid phosphatase, prostate 
Egr1 Early growth response 1 
Nfkbie Nuclear factor of kappa light polypeptide gene enh 
Lif Leukemia inhibitory factor 
Ubxn2a UBX domain protein 2A 
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Egr2 Early growth response 2 
Mfsd2a Major facilitator superfamily domain containing 2A 
Slc7a11 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 
Cd200 CD200 antigen 
Homer1 Homer homolog 1 (Drosophila) 
Dusp4 Dual specificity phosphatase 4 
Tmem45a Transmembrane protein 45a 
Il23a Interleukin 23, alpha subunit p19 
Gfpt2 Glutamine fructose-6-phosphate transaminase 2 
Cxcl1 Chemokine (C-X-C motif) ligand 1 
Saa3 Serum amyloid A 3 
Tnfaip3 Tumor necrosis factor, alpha-induced protein 3 
Cyp4f40 Cytochrome P450, family 4, subfamily f, polypeptide 40 
Dennd2d DENN/MADD domain containing 2D 
Tslp Thymic stromal lymphopoietin 
 
Using this list of genes, I then examined the relationships between them, using 
STRING (192), a database of protein interactions. Using the authors’ 
recommended settings, I constructed a network diagram of the genes up-
regulated by both strains. The main protein interactions that were found in 
the ‘core upregulated’ set of differentially-expressed genes in both strains and 
both timepoints is shown in Figure 6.7. The major nodes are well-known genes 
differentially-expressed in infection, including NFkB family-members and 
known markers of infection such as CCL5 and Interleukin-23. One interesting 
cluster that emerged from this analysis was that containing the SLC7A11 
protein, which is a cystine/glutamate antiporter known to be upregulated in 
several cancers (193). 
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Figure 6.7. Protein interactions of genes found to be differentially-expressed in both strains, at 
both times. The core set of 29 genes found to be upregulated in all conditions were mapped 
and their interactions plotted. The colours of the nodes are simply to distinguish them from 
each other and do not hold any particular meaning.  
 
 
STRING (192) also performs KEGG pathway enrichment for a inputted set of 
genes. The enriched pathways are shown in Table 6.3 alongside the false 
discovery rate for that enrichment. Clearly, there are several expected 
pathways, such as the NFkB signalling pathway and the TNF pathway. 
However, some other more curious pathways emerge, such as several that 
implicate cancer-like mechanisms. These patterns are explored further by 
addressing the individual gene contributions to these enrichments (6.3.3). 
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Table 6.3. The core set of upregulated genes (upregulated by each strain and at both time 
points) was analysed for KEGG pathway enrichment using the STRING database. Genes 
contributing to the enrichment groups are presented in Supplementary Folder 1. 
#pathway 
ID pathway description observed gene count false discovery rate 
4668 TNF signaling pathway 7 1.86E-08 
4621 NOD-like receptor signaling pathway 4 0.000116 
4064 NF-kappa B signaling pathway 4 0.000363 
5169 Epstein-Barr virus infection 5 0.000363 
4060 Cytokine-cytokine receptor interaction 5 0.000773 
5134 Legionellosis 3 0.00249 
5203 Viral carcinogenesis 4 0.0045 
5166 HTLV-I infection 4 0.0122 
4630 Jak-STAT signaling pathway 3 0.0217 
5020 Prion diseases 2 0.0217 
5161 Hepatitis B 3 0.0217 
5200 Pathways in cancer 4 0.0217 
4062 Chemokine signaling pathway 3 0.0322 
5168 Herpes simplex infection 3 0.04 
 
 
As well as this core set of commonly dysregulated genes, I also wished to 
explore some of the differences between the strains. I thus then filtered my 
gene lists to retain only those that were unique to either strain, either time 
point, Figures 6.8.   
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Figure 6.8. Genes that were dysregulated at either time point were intersected, to obtain 
lists of dysregulated genes unique to each strain.  
 
Overall, it appears that more genes were uniquely dysregulated in ME49. In 
the upregulated geneset, 35.6% were unique to ME49, while 25.6% were 
unique to RH. The situation for the downregulated was even more extreme, 
with approximately seven times more genes being uniquely downregulated by 
ME49. 
 
Enrichments were once again performed on each of these gene sets using 
STRING. I also performed a network analysis, though with higher 
stringencies, due to the larger number of genes involved. Networks that 
emerged as being unique to ME49 upregulation are shown in Figure 6.9. 
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Figure 6.9. Protein interactions of genes found to be differentially-upregulated only in ME49-
infected cells, at either time. The 277 genes found to be upregulated only in ME49-infection 
were mapped and their interactions plotted using STRING. The colours of the nodes are 
simply to distinguish them from each other and do not hold any particular meaning. 
 
While fewer genes were found to be unique to dysregulation by RH, when I 
performed a similar network interaction analysis, several more obvious nodes 
were revealed (Figure 6.10). For instance, a clear JUN-signalling node 
emerges, with correlations to NF-kB family members. Similarly, the KEGG 
enrichment analysis also reveals more enriched pathways (Table 6.4). 
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Figure 6.10 Protein interactions of genes found to be differentially-expressed only in RH-
infected cells, at either time. The 199 genes found to be upregulated only in RH-infection were 
mapped and their interactions plotted using STRING. The colours of the nodes are simply to 
distinguish them from each other and do not hold any particular meaning. 
 
Given the long lists of genes involved in these KEGG pathways, these are 
shown in Supplementary Folder 1. Table 6.4 shows the KEGG pathways 
themselves, and whether those pathways are enriched in both strains or in 
either one of them uniquely.  
 
Table 6.4. KEGG pathways uniquely enriched in infection by either strain 
Pathways Unique to ME49 Pathways Unique to RH Pathways in Common 
Ribosome biogenesis in 
eukaryotes MAPK signaling pathway TNF signaling pathway 
Colorectal cancer 
Cytokine-cytokine receptor 
interaction HTLV-I infection 
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Cell cycle Rheumatoid arthritis Pathways in cancer 
Epstein-Barr virus infection 
Inflammatory bowel disease 
(IBD) Osteoclast differentiation 
DNA replication Jak-STAT signaling pathway MicroRNAs in cancer 
ErbB signaling pathway Mineral absorption Hepatitis B 
RNA transport PI3K-Akt signaling pathway 
 Aminoacyl-tRNA biosynthesis HIF-1 signaling pathway 
 Prolactin signaling pathway Leishmaniasis 
 Endometrial cancer Renal cell carcinoma 
 Thyroid hormone  
signaling pathway   
Arginine and proline metabolism 
  Prostate cancer 
  Influenza A 
  Purine metabolism 
  Hepatitis C 
  Pyrimidine metabolism 
  Fc epsilon RI signaling pathway 
  Biosynthesis of amino acids 
  Mismatch repair 
 Toxoplasmosis 
  Metabolic pathways 
  Fanconi anemia pathway 
  Progesterone-mediated oocyte 
maturation   
Small cell lung cancer 
  Homologous recombination 
  Acute myeloid leukemia 
  Proteoglycans in cancer 
  Circadian rhythm 
  FoxO signaling pathway 
  Estrogen signaling pathway 
  Toll-like receptor signaling  
Pancreatic cancer 
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Interestingly, several pathways were found to be enriched by both strains, 
despite those enrichments deriving from genes unique to each infection case. 
Moreover, several recurring pathways, even when unique to a particular 
strain, refer to metabolic pathways, cancer of various types and, of course, 
parasitology (Toxoplasmosis, and Leishmaniasis). The component genes of 
many of these pathways, as well as those highlighted as key nodes in the 
network analyses are profiled individually in 6.3.3, where their strain and 
MOI-specific patterns are further discussed.  
 
 
Figure 6.11 Protein interactions of genes found to be differentially-downregulated only in 
ME49-infected cells, at either time. The 325 genes found to be downregulated only in ME49-
infection were mapped and their interactions plotted using STRING. The colours of the nodes 
are simply to distinguish them from each other and do not hold any particular meaning. 
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Though a few networks emerged from the STRING analysis of genes uniquely 
downregulated in ME49-infected cells (Figure 6.11), these did not correspond 
to functional enrichment via KEGG pathway analysis – no pathways were 
found to be enriched. That being said, some genes of interest that emerged 
were Cish and Stat2, both of which have been implicated in ME49-infection 
and are discussed further in relation to Figure 6.17. The situation for genes 
uniquely downregulated in RH was even worse in terms of functional 
classification. No significant networks of protein interactions emerged, neither 
did any KEGG pathway enrichments.  
 
6.3.2 Differential Expression over Time 
The analysis in 6.3.1 considered each infected sample as compared to its 
corresponding uninfected control, such that, for example, the sample infected 
by ME49 for 24 hours was compared to the control. However, given that these 
infections were performed over time, one can also measure differential 
expression over the full 43 hours. For this analysis, I again used EdgeR with 
an adjusted p-value of 0.05. I first looked at genes that were differentially-
expressed between infected samples at 24hpi and the zero hour control and 
then between those in which infection had been allowed to proceed for 43h 
and the previous (24hpi) time point. Given the extremely large number of 
genes that emerged as being differentially-expressed over time (more than can 
be usefully handled by most enrichment algorithms), I opted to select the 
genes with the 100 lowest adjust p-values at either time comparison to analyse 
for functional significance, again using STRING for protein interaction and 
KEGG pathway enrichment. 
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Figure 6.12. A network of protein-interactions from the 100 most significant differentially-
expressed genes across time in each ME49-infected samples. The 100 genes from each time 
comparison (24hpi vs 0h and 43hpi vs 24hpi) were collated and subjected to protein 
interaction analysis. 
 
Several key nodes that have already been implicated in ME49-infection emerge from 
the networks shown in Figure 6.12. Notably, members of the NF-kB family are present, as are 
metabolism-related genes such as Enolase 2. Apoptosis-related genes also appear to vary over 
time in these ME49-infected samples, with a Caspase-Fas association being present in the 
results. The KEGG pathway enrichment for these same genes provides slightly more context, 
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where intriguing pathways such as carbon metabolism and TNF signalling are 
overrepresented. The contributing genes are in Supplementary Folder 1. 
 
Table 6.5 KEGG Pathway enrichment for the top 100 genes from ME49-infected samples 
over time. The top 100 DE-genes across time (at both time comparisons) were examined for 
pathway enrichment. 
#pathway 
ID pathway description 
observed 
gene count 
false 
discovery 
rate 
4668 TNF signaling pathway 10 3.92E-06 
1200 Carbon metabolism 7 0.00313 
4060 Cytokine-cytokine receptor interaction 9 0.0136 
1230 Biosynthesis of amino acids 5 0.0208 
1120 Microbial metabolism in diverse environments 7 0.022 
5134 Legionellosis 4 0.0497 
 
 
Though the number of genes used for functional analysis of RH-infected 
was the same as for ME49, more protein-interactions appear in the network 
(Figure 6.13). As well as the apoptosis-related pathways, a clear cell-cycle 
cluster appears, containing nodes such as PLK1 and CCNA2. Members of the 
JAK-STAT pathway also appear, with a connection to the glycolysis-related 
protein HK1. 
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Figure 6.13. A network of protein-interactions from the 100 most significant differentially-
expressed genes across time in each RH-infected samples. The 100 genes from each time 
comparison (24hpi vs 0h and 43hpi vs 24hpi) were collated and subjected to protein 
interaction analysis. 
 
This is echoed in the KEGG pathways analysis (Table 6.6), where those 
pathways are clearly enriched for. Additionally, as expected, parasitology-
related pathways also emerge, such as that for Leishmaniasis, as well as 
generalised infection.  
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Table 6.6 KEGG Pathway enrichment for the top 100 genes from RH-infected samples over 
time. The top 100 DE-genes across time (at both time comparisons) were examined for 
pathway enrichment. 
#pathway 
ID pathway description 
observed 
gene count 
false 
discovery 
rate 
4060 Cytokine-cytokine receptor interaction 15 3.20E-07 
4668 TNF signaling pathway 9 2.77E-05 
4630 Jak-STAT signaling pathway 10 3.13E-05 
5200 Pathways in cancer 12 0.000665 
4115 p53 signaling pathway 5 0.00713 
5161 Hepatitis B 7 0.00713 
5168 Herpes simplex infection 8 0.00713 
4920 Adipocytokine signaling pathway 5 0.00783 
5133 Pertussis 5 0.00783 
4380 Osteoclast differentiation 6 0.012 
4062 Chemokine signaling pathway 7 0.0137 
5203 Viral carcinogenesis 7 0.0235 
1200 Carbon metabolism 5 0.0313 
4151 PI3K-Akt signaling pathway 9 0.0313 
5140 Leishmaniasis 4 0.0313 
4110 Cell cycle 5 0.047 
4917 Prolactin signaling pathway 4 0.047 
 
6.3.3 Individual Gene Profiles 
The pathways signified as being enriched in these analyses appeared to 
contain several common pathways and genes. Therefore, I profiled them 
individually, grouping them into functional categories beyond KEGG 
association (that is, by looking at their interactions in the literature). This 
section presents the gene profiles with basic context for their inclusion in my 
examination – I delve more deeply into the way in which they interact in the 
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context of Toxoplasma infection in the Discussion portion of this chapter, 6.4. 
In the following profiles, the colour scheme is as shown in Table 6.7. 
 
Table 6.7 Colour scheme for the profiles throughout 6.3.3 
Colour Red Green Dark Blue Light Blue Pink 
Label Control, 
Uninfected 
ME49,  
MOI 1.2 
ME49, MOI 
3 
RH, MOI 1.2 RH, MOI 3 
 
Parasitology-Related Genes  
The KEGG pathways that were obviously related to parasitology included 
Leishmaniasis and, of course, Toxoplasmosis. Many of the contributing genes 
were also contained within other categories (Interferon gamma receptor 2, 
Ifngr2, for instance is discussed in the chemokine/cytokine and receptors 
section and Birc2 forms part of the apoptosis pathway). Two interesting cases 
within this category are the adhesion-related genes Vascular cell adhesion 
protein 1 (Vcam1) and Intercellular adhesion molecule 2 (Icam1).  
  
Figure 6.14. Expression profiles of Icam1 and Vcam1. 
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Figure 6.14, continued. Expression profiles of Icam1 and Vcam1. 
 
Host Immune Response 
It is difficult to assay the host immune response in non-immune cell culture 
systems lacking exogenous addition of cytokines – especially in the case of T. 
gondii where, for instance, (IFNG) is such a key player in mediating 
immunity. In vivo, infection by T. gondii sets in motion a cascade  
of proinflammatory processes whereby recognition of the parasite by toll-like 
receptors (TLRs) or chemokine (C-C motif) receptor 5 (CCR5) lead to the 
secretion of IL12 (via the NF-kB or MAPK pathways) by dendritic cells. 
Interleukin-12 in turn recruits NK cells which secrete IFNG and thus begins a 
programme of immune resistance to the parasite. While of course IFNG itself 
would not be expected to be detected transcriptionally in my dataset (and 
indeed it is not, data not shown), its receptor (a heterodimer of IFNGR1 and 
IFNGR2) is upregulated in all strains, relatively early in infection though 
Ifngr1 expression in RH MOI 3 plummets after this time point. Differential 
expression of the receptor has not been researched in the context of T. gondii 
infection but decreased transcription has been implicated in Mycobacterium 
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tuberculosis-infection as a potential mechanism of immune evasion (194). 
Conversely, treatment of a human breast cancer cell line (MCF-7) with indole-
3-carbinol was found to increase Ifngr1 and resulted in concomitant 
augmentation of the IFNG response, showing that transcriptional regulation 
of this receptor is possible and perhaps underexplored as a means of immune 
response regulation (195).  That I see expression in fibroblasts is consistent 
with an earlier observation that while IFNG is secreted by NK cells (and T 
lymphocytes), its receptor is able to be expressed in all cells except 
erythrocytes (196). 
 
 
Figure 6.15. Expression profiles of Interferon gamma Receptor 1 and 2  
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Normally, activation of the IFNG pathway then activates a 
transcriptional programme mediated by STAT1. However, T. gondii is able to 
disrupt this programme, though the mechanism and breadth of how this is 
achieved appears to be at least in part strain-specific. For instance, it is 
thought that activation of IRF1 by GRA15 in Type II parasites might induce 
a specific subset of IFNG-related genes (197). Similarly, the suppressor of 
cytokine signaling family of proteins – Socs1, Socs3 and Cish – have also been 
implicated in the abrogation of IFNG-responsive gene expression in T. gondii-
infected cells at least in part in a strain-specific manner (Figure 6.16 and 6.17).  
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Figure 6.16. Expression Profiles of signal transducer and activator of transcription 1 and 3 
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Figure 6.17. Expression Profiles of STAT-related genes 
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Figure 6.17, continued. Expression Profiles of STAT-related genes 
 
Cell Cycle 
When I looked at the list of genes that were dysregulated over time it emerged 
that several were related to the cell cycle – a process that is also disrupted by 
T. gondii infection. The mechanism of this disruption, and how it fits into 
host cell metabolism, is discussed in 6.4. Cdc25a appears elevated throughout 
the time course in all strains, consistent with its role in S-phase promotion; 
which the parasite also elicits. Perhaps more dramatic is the profile of Cyclin 
1 (Ccne) exhibiting a strong and sustained upregulation throughout infection. 
Other cell-cycle related genes that are thought to be modulated by the 
parasite include Uhrf1 (148) and Rb1 which, curiously, functions as a tumour 
suppressor gene. A gene not usually identified with T. gondii-mediated cell 
cycle interference is Pcna, which is necessary for DNA polymerase action and 
appears also to be upregulated in infection. 
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Figure 6.18: Expression Profiles of genes dysregulated in the uninfected sample and cell cycle-
related genes.  
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Figure 6.18, continued: Expression Profiles of genes dysregulated in the uninfected sample and 
cell cycle-related genes.  
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Figure 6.18, continued: Expression Profiles of genes dysregulated in the uninfected sample and 
cell cycle-related genes.  
 
 
 
	 177	
 
Figure 6.18: Expression Profiles of genes dysregulated in the uninfected sample and cell cycle-
related genes.  
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Figure 6.18, continued: Expression Profiles of genes dysregulated in the uninfected sample and 
cell cycle-related genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 179	
Hypoxia 
It has been observed that T. gondii is able to stabilise HIF1A and that in fact 
HIF1A is necessary for proper rates of intracellular parasite growth (144). 
Hypoxia induced factor 1, alpha subunit is the component of the dimer that is 
oxygen-regulated. 
 
Figure 6.19. Expression profiles of Hif1a and Arnt/Hif1b. 
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Glycolysis and Cancer-Related Genes 
The most striking profiles of glycolysis-related genes that were differentially-
regulated in the infection timecourse were Ldha and Hk2, with both being 
highly upregulated as compared to both time and the uninfected control. 
These genes have been highly implicated in cancer processes – a metabolic 
pathway that emerged several times within the KEGG enrichment analyses. 
 
 
Figure 6.20. Expression glycolysis-related genes 
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Figure 6.20, continued. Expression glycolysis-related genes 
 
 
 
 
 
 
 
	 182	
 
 
Figure 6.20, continued. Expression glycolysis-related genes 
 
Vdac1 is thought to be part of the mechanism by which Hk2 is able to remain 
mitochondrially-associated in highly-glycolytic conditions (198) and it also has 
potenti anti-apoptotic functions (199) and thus it is unsurprising that it 
should be elevated in all infection conditions. However, how these two 
mechanisms interact with each other is still unclear and is discussed further in 
6.4. 
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Transporters 
A number of transporters were shown to be differentially-regulated throughout 
the course of infection. Figure 6.12 shows the profiles of the lactate importer 
Slc2a1 and Mct1, a lactate exporter. All strains clearly show an elevation of 
these transcripts, even from the 24hpi onwards. 
 
 
Figure 6.21. Expression genes encoding transporters 
 
	 184	
Sirtuins 
While still relatively understudied, Sirtuins have been implicated in the 
control of processes that are known to be parasite-disrupted, such as apoptosis 
and glycolysis, perhaps through mediation of HK2. The role of Sirtuins in 
glycolysis and cancer is a controversial one, that is examined in 6.4. Few 
generalisations emerge from their profiles (Figure 6.22). 
 
 
Figure 6.22. Expression profiles of sirtuin and sirtuin-related genes 
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Figure 6.22, continued. Expression profiles of sirtuin and sirtuin-related genes 
 
Glutamine-Related Genes 
The repeated reference to “glutamine metabolism” in so many of the 
enrichment lists led me to look not just at this phenomenon but other aspects 
of cellular glutamine function. Gls, for instance encodes Glutaminase, which is 
seen to be upregulated in all the infected samples. This is also the case for 
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glutamine transporters Slc7a5 and Asct2, both of which have been implicated 
in increased glycolysis in cancer cells.  
 
 
Figure 6.23. Expression profiles of genes with functions related to glutamine and 
glutaminolysis 
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Figure 6.23, continued. Expression profiles of genes with functions related to glutamine and 
glutaminolysis 
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Figure 6.23, continued. Expression profiles of genes with functions related to glutamine and 
glutaminolysis 
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Glutathione and ROS-related 
Many of the genes to do with the “glutamine metabolism” pathways had to do 
with the replenishment of glutathione – a potent protector against ROS. 
These include from uncoupling proteins (Ucp2), transporters (Slc7a11) and 
metabolic enzymes (Idh1). 
 
Figure 6.24. Expression profiles of genes with functions related to glutathione and ROS 
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Figure 6.24, continued. Expression profiles of genes with functions related to glutathione and 
ROS 
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Figure 6.24. Expression profiles of genes with functions related to glutathione and ROS 
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Nucleotide Biosynthesis 
Given T. gondii status as a scavenger and an auxotroph, I profiled several 
genes from nucleotide synthesis pathways, especially since this had emerged as 
a significanltly-enriched KEGG pathway as well. 
 
Figure 6.25. Expression profiles of genes related to nucleotide biosynthesis 
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Figure 6.25, continued. Expression profiles of genes related to nucleotide biosynthesis 
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Fatty Acid Synthesis 
T. gondii is well-known to scavenge lipids from the host cell, including 
cholesterol (40) and palmitate (200). Host cell synthesis of these could require 
upregulation of the genes involved in fatty acid synthesis. The time-profiles of 
these genes is quite curious, with pyruvate dehydrogenase (Pdha) exhibiting a 
sustained elevation as compared to the control sample, whereas the gene for 
fatty acid synthase, Fasn, appears to peak earlier in infection. The two genes 
profiled for malonyl decarboxylation and transacylation (Mlycd and Mcat, 
respectively) both seem to be downregulated in all infection conditions as 
compared to the uninfected control. 
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Figure 6.26. Expression profiles of genes related to fatty acid synthesis 
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Figure 6.26, continued. Expression profiles of genes related to fatty acid synthesis 
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Myelocytomatosis oncogene (Myc) and Myc-related 
This potent oncogenic transcription factor is known to be upregulated 
(translationally) by T. gondii infection (21). It’s binding partner Max appears 
to be dysregulated in a strain-dependent manner, which is discussed in 6.4. 
Other related genes, Jnk and Jun which both act to regulate Myc in contrast 
are upregulated in all infection conditions.  
 
Figure 6.27. Expression profiles of Myc and Myc-related genes 
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Figure 6.27, continued. Expression profiles of Myc and Myc-related genes 
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Apoptosis-Related Genes 
Apoptosis is a process that the parasite is able to effectively evade, and it is 
mediated by both pro-apoptotic and anti-apoptotic factors. Apoptosis and the 
mechanisms by which T. gondii modulates this pathway is discussed further in 
6.4, especially in relation to the NFkB family. 
 
Figure 6.28, continued. Expression profiles of genes related to apoptosis 
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Figure 6.28, continued. Expression profiles of genes related to apoptosis 
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Transformation-related protein 53 (Trp53) and Trp-related 
Akin to MYC, TRP53 is a potent transcription factor in the realm of cancer, 
except that it is an tumour suppressor. There are also numerous reported 
interactions with the Myc. Given the current lack of clarity surrounding T. 
gondii’s effects on this pathway, I looked at both Trp53 expression and that of 
related regulators.  
 
Figure 6.29. Expression profiles of genes related to Trp53. 
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Figure 6.29, continued. Expression profiles of genes related to Trp53. 
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NFkB Pathway 
Given the somewhat confusing picture that emerges from NFkB in T. gondii-
infected cells (see Chapter 1) and reports that, in Type II strains at least (17) 
upregulation of NFkB is wholly dependent on a secreted parasite factor 
(GRA15), I sought to look at the transcriptional profiles of all NFkB subunit 
family-members. Moreover, members of this family appeared numerous times 
in the functional analysis performed in 6.3. 
 
Figure 6.30. Expression profiles of NFkB family members 
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Figure 6.30, continued. Expression profiles of NFkB family members 
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Figure 6.30, continued. Expression profiles of NFkB family members 
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“Reverse Warburg” 
While researching concepts surrounding metabolism in cancer (see 6.4, 
Discussion) I came across the intriguing concept of the “Reverse Warburg” 
effect, the primary mediator of which is Caveolin 1 (Cav1). 
 
 
Figure 6.31. Expression profiles of caveolin 1 
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6.3.4 Lactate Assays 
Seeing as many of the genes and pathways that were upregulated related to 
cancer or glycolysis, I performed a biochemical lactate assay on extracellular 
medium taken from infected (ME49, MOI 3) or uninfected cells, over a time 
course of 30h (blanked against unconditioned HG-DMEM). A chart of the 
results is presented in 6.32 
 
Figure 6.32. Time course of extracellular lactate. Cells were either infected with ME49 at an 
MOI of 3 (red) or left untreated (blue). Over the course of 30h, the extracellular medium was 
removed and assayed for lactate. 
 
After a short a time as 24hpi, there is a clear significant difference in the 
extracellular lactate levels between the infected and control cells, with the 
former exhibiting a far greater level of lactate. 
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6.3.5 Western Blots 
Given the fact that Hif1a is known to be of particular interest in T.gondii-
infected cells and is a known mediator of aerobic glycolysis, I infected Hif1a 
WT and Hif1-/- MEF cells with ME49, at an MOI of 3 for 43 hours, and 
prepared cell lysates. Then, I extracted lysates from these, with which Bo 
Shiun Lai performed Western Blots. The aim here was to look at expression of 
a few key proteins (Figure 6.33). Beta-tubulin was used as a loading control.  
  
Figure 6.33 HIF1A WT or KO MEFs infected with ME49, MOI3 for 43h. 
Loading Control was β-tubulin. Wester blots of the infected samples indicate an abrogation of 
C-MYC protein expression in the absence of HIF1A, as well as a clear upregulation of HK2 
and LDHA, both of which are abated though not totally, in the absence of host cell HIF1A. 
 
As expected, HIF1A levels are completely absent in the KO cell lysates. 
Similarly, LDHA and HK2 appear higher in the infected cells, though this is 
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only partially dependent on HIF1A. GLS2 did not appear to vary much 
between uninfected and infected samples, though its epression was completely 
abrogated in the absence of HIF1A. If SAG1 expression is taken to be a 
surrogate for parasite numbers (either through differential replication or 
invasion), then it is clear that, the parasite contribution is notably lower in 
the KO cells. While MYC overexpression in infection has been described 
before (21) and is recapitulated here, perhaps the most surprising result from 
this series of immunoblots is the total lack of MYC protein in the KO cells.  
 
6.3.6 Methyl Jasmonate 
As the first step in glycolysis (aerobic or not), hexokinase 2 is clearly an 
important enzyme in the host cell metabolic programme initiated by T. gondii 
infection. And, while it is usually cited as being a gene under the 
transcriptional control of Hif1a, it is clear from the western (6.3.5) that this is 
not the entire story. Indeed, the difference in HK2 protein levels between 
infected and uninfected cells does not appear to depend on the Hif1a status of 
the fibroblast. For that reason, I decided to look more directly at the effect of 
downregulating the effects of HK2 in a more direct manner, using methyl 
jasmonate. Methyl jasmonate is a plant stress hormone that has important 
implications for HK2’s role in cancer.  
 
6.3.6.1 Effects of Methyl Jasmonate on Host Cell Numbers 
I treated uninfected monolayers grown on coverslips (at 70% confluence) with 
the same dose of methyl jasmonate as the infected cells, and fixed and 
mounted them, as in 2.9. Three fields of view from two coverslips were viewed 
per condition, and DAPI-stained host cell nuclei were counted. Though there 
appears to be a slight reduction in cell number in the treated cells, this is still 
within the SEM.  
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Figure 6.34. Effect of 50 µM methyl jasmonate on host cell numbers.  
n = six fields of view from two replicate coverslips/wells. Error bars represent SEM. Cells 
were seeded with NIH/3T3 cells and treated with methyl jasmonate. No statistically-
significant difference emerged between treated and untreated cells.  
 
A representative image that was used for cell counts is shown in Figure 6.27. 
 
Figure 6.35: Uninfected host cells A) with methyl jasmonate treatment, B) without methyl 
jasmonate treatment 
 
6.3.6.2 Effects of Methyl Jasmonate on T. gondii-Infected Cells 
I treated cells infected with either RH, MOI 1.2 or ME49 MOI 1.2 with 50 µM 
methyl jasmonate and allowed them to grow as usual for 43 hours.  
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I had hoped to be able to make a quantitative assessment of the effect that 
methyl jasmonate had on parasite numbers (two coverslips were collected per 
sample), but the characteristics of the result made this very difficult.  
Representative images from coverslips of each condition are shown in Figures 
6.36 and 6.37.  
 
     
A      B 
Figure 6.36. RH-infected cells A) without methyl jasmonate treatment, B) with treatment 
In the presence of methyl jasmonate, overall parasite numbers appear lower, and 
parasitophorous vacuoles appear tighter and less diffuse, perhaps indicating less egression.  
 
     
A      B 
Figure 6.37. ME49-infected cells A) without methyl jasmonate treatment, B) with treatment. 
In the presence of methyl jasmonate treatment, ME49-containing parasitophorous vacuoles 
appear smaller, and fewer individual parasites are visible. 
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When methyl jasmonate treatment was combined with infection with 
RH, it is clear that a reduction in both PV size and number resulted. 
However, there was also a large reduction in overall parasite numbers – these 
may have been from newly-lysed PVs in the untreated sample. This difference 
in whether parasites appear to be free (in singletons or doublets), within 
clearly-defined PVs or fully filling the host cytoplasm makes statistical 
analysis difficult.  
In the case of ME49, interpretation is even more difficult. The GFP 
signal appears extremely diffuse with a few punctae, but no discernible 
crescent-shaped parasites. Nor where there any visible PVs, of any size. For 
that reason, I used a higher magnification on the ME49-infected cells to see 
whether any parasites could credibly be made out but the situation remains 
very uncertain, Figure 6.38. Nevertheles, given the drastic difference from the 
untreated sample, it is clear that methyl jasmonate is having an effect – 
perhaps even a more potent one in ME49 than in RH. A variety of 
interpretations of these results are discussed in Chapter 7. 
 
 
Figure 6.38. ME49-infected cells treated with methyl jasmonate. 
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6.4 Discussion 
It is clear that there a number of different ways to look at transcriptional 
data, when considering time-courses of several samples. For a start, genes may 
be dysregulated across each sample’s time course, but they may also be 
dysregulated between the samples. Of course, combinations of these cases are 
also possible, and care must be taken not to let any one of these factors 
confound the overall picture. For this reason, I opted to analyse gene 
expression in my libraries in different methods (over time, between samples) 
to obtain a broad sense of induced or repressed systems and then looked at 
them in a more detailed manner by looking at individual gene profiles.  
These results that I have shown in 6.3 largely point towards the 
phenomenon of glycolysis being upregulated as a consequence of infection by 
T. gondii. Notably, this upregulation occurs under normoxic conditions – 
glycolysis is traditionally thought of as a metabolic phenomenon arising from 
a restriction in available oxygen. While clearly striking, this is not an unusual 
phenomenon and, in line with my other observations about numerous cancer-
related pathways being upregulated under infection, it is in fact a well-known 
feature of tumors: the propensity to engage in aerobic glycolysis, even in the 
presence of plentiful oxygen, the Warburg Effect. The fact that this appears 
to happen in infection, that is to say in the absence of host cell proliferation 
and in the absence of host cell genetic transformation, makes it even more 
striking.  
The first inkling that infection by Toxoplasma gondii might have 
effects on host cell metabolism came with one of the first array analyses of 
infected host cells (177). These experiments were performed using HFFs 
infected with a Type II strain (PDS, cloned from ME49). In this study, the 
authors found that late-stage host cell transcriptional perturbation in infected 
cells included many genes related to metabolism, notably glycolysis. The 
authors note a “specific up-regulation of transcripts involved in anaerobic 
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glycolysis[…]” [emphasis mine], but do not comment on the fact that this 
apparently ‘anaerobic’ glycolytic signature of gene expression was being 
elicited in standard cell culture conditions where oxygen is plentiful. As a 
result of this apparent contradiction, as well as later studies looking at HIF1A 
and its interaction with T gondii, I examined the phenomenon of aerobic 
glycolysis further, through transcriptional profiling of several key genes. In the 
following discussion, I first look at the genes that emerged from ‘parasite-
specific’ KEGG pathways, and then those that came from uninfected cells 
(though there is crossover here in terms of cell-cycle regulation). I then turn 
my attention to the various different facets of aerobic glycolysis that emerge 
from my data. 
 
6.4.1 Gene and Protein Expression  
6.4.1.1 Adhesion and Migration 
As well as within parasitology-related pathways, Intercellular adhesion 
molecule 1 (Icam1) and Vascular adhesion cell molecule 1 (Vcam1) they were 
also represented within pathways to do with NK cell mediated cytotoxicity. 
Interestingly, these genes appear to be highly differentially expressed between 
the two strains (Figure 6.14), with higher expression levels being achieved in 
ME49-infected cells. Icam1 has been looked at largely in the context of the 
ability of T. gondii to cross so-called non-permissive boundaries (such as the 
blood-brain barrier), given ICAM1’s known role in mediating migration of 
immune cells. Barragan and Sibley note that there exists a strain difference in 
the ability of Type I and II strains to move across epithelial barriers both in 
vitro and in ex vivo matrix simulations, with RH having a far higher 
migratory capacity (201). This was extended into the observation that Type II 
strains result in an earlier and greater upregulation of ICAM1 in brain 
endothelial cells 	
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Vascular adhesion cell molecule 1 has not been studied anywhere near 
as thoroughly, though it does appear to mediate differences in the 
inflammatory response observed between C57BL/6 and BALB/c mice, which 
are described as having different inflammatory cell migration in response to T. 
gondii infection (202). While no causation is shown, this difference is 
correlated with differential expression of Vcam1, with C57BL/6 exhibiting 
both increased CNS-inflammation, and higher Vcam1 expression. This study 
was performed using ME49 only, so strain differences were not possible to 
compare.  Overall, it appears that the differential expression of these two 
adhesion factors may mediate differences in infection-related immune cell 
migration, as well as strain-specific inflammatory responses.  
 
6.4.1.2 Cell Cycle 
Perhaps unsurprisingly, a number of cell-cyle-related genes were found to be 
downregulated in the uninfected sample, especially at 43h, at which point 
contact inhibition will have occurred (Figure 6.18). These are consistent with 
previous transcriptional studies of contact inhibition (203) and include 
Cdc25a, Plk1, Ccnd1 (also known as Cyclin D1) and Ccna2 (also known as 
Cyclin A). Upregulated genes that have been associated with contact-
inhibition include Cdkn1b (p27) and Rb1.  
Toxoplasma gondii is known to have an effect on the cell cycle of its 
host cell (148, 149), though the exact mechanisms of how this is achieved have 
not yet been elucidated. Both of these studies point towards a parasite-
mediated ‘push’ towards S-phase. This also appears to be the case in my data. 
For instance, Ccne2 is strongly upregulated in both strains as compared to the 
uninfected sample and is required for progression into S-phase. Both studies 
point to an arrest in cell cycle that prevents infected host cells from 
proceeding into mitosis, which makes the uptick in S-phase-related processes 
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intriguing: this is occurring in the absence of cell division and therefore 
proliferation.  
An important gene that I find highly upregulated in all strains at 24hpi 
(and that is not mentioned either in the T. gondii cell cycle studies or in the 
contact-inhibition study) is Pcna, an important mechanistic cofactor for the 
processivity of DNA synthesis (Figure 6.18) (204). That it is downregulated in 
uninfected cells is consistent with these being in a state of contact-inhibition 
while being upregulated in the infected cells, which exhibit an increase in S-
phase-related gene expression. Indeed, ectopic overexpression of Pcna in 
contact-inhibited NIH/3T3 cells has been shown to result in unregulated 
proliferation (205). While obviously infected cells do not engage in 
unregulated proliferation, it is possible that the parasite-driven ‘push’ towards 
S-phase has yet another gene mediating it, that I have identified in the above 
study.  
 
6.4.1.3 Toxoplasma gondii and Hypoxia inducible factor 1 
Often called the master regulator of the hypoxic response Hif1 has numerous 
roles in tumorigenesis, even when oxygen is plentiful. The usually 
consistutively-expressed alpha subunit (HIF1A) under normoxic conditions 
has a very short half-life. This is accomplished by the oxygen-dependent 
action of prolyl hydroxylases (PHD1-3) which hydroxylate the subunit on one 
or both of it’s proline residues. Upon this hydroxylation, HIF1A is targeted for 
proteosomal degradation, via the E3 ubiquitin ligase (and tumor suppressor) 
VHL, the von Hippel-Lindau protein. The PHDs that mediate this 
degradation are themselves sensitive oxygen sensors (absolutely dependent on 
oxygen as well as iron) and so, in hypoxic conditions, they can no longer 
hydroxylate HIF1A. Absent this proteosomal targeting, HIF1A is then free to 
translocate to the nucleus. There, it can dimerise with its stably-expressed 
partner HIF1B. The heterodimer, along with cofactors from the p300/CBP 
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family, then mediates the transcription of a number of hypoxia response 
element (HRE)-containing genes.  
Another hydroxylase also controls the activity of HIF1A, the 
asparaginyl hydroxylase FIH1 (Factor Inhibiting Hif1), which was indentified 
by a yeast two-hybrid screen in 2001 (206). It too is oxygen-regulated, but 
instead of targeting HIF1A for proteosomal degradation, hydroxylation by 
FIH1 instead inhibits association of the subunits with their p300/CBP 
cofactors. That each of these hydroxylases depends absolutely on molecular 
oxygen, renders them (and therefore HIF1A) sensitive monitor of cellular 
oxygen levels. However, they also respond to other cues, which may be 
important indicators of the cell’s metabolic state including, importantly, α-
ketoglurarate, the first product of reductive glutamine metabolism, often then 
used for lipogenesis (207, 208). These other interactions (including those with 
Myc) are discussed later on. 
The first few transcriptional targets identified as being under HIF1A 
control were glycolytic enzymes, such as PGK1 and PKM2 (209). Since then, 
both functional studies involving HIF1A null cell lines, as well as 
computational studies using the identified “NCGTG” HREs have yielded 
numerous other genes thought to be at least partially under Hif1a control 
(210, 211).  
While having identified glycolytic processes as being upregulated 
following T. gondii infection in their array experiment, Spear et al did not 
concentrate on the aerobic conditions under which this appeared to occur, 
focussing instead of the specific role of Hif1a under “physiological conditions” 
(i.e. hypoxia16). As such, they proceeded to investigate this transcription 
factor and its possible role in infection further (144). Here, they discovered 
that the parasite was able to modulate the stability of HIF1A: protein levels 
were increased upon infection, and appeared to do so in a time-dependent 																																																								16 Though, apart from within large tumor masses it is often very difficult to assess what 
“physiological” actually represents in terms of oxygen tension. 
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manner. A later study from the same lab (138) showed, via northern blot, 
that Hif1a RNA was also increased upon RH infection. While the authors’ 
conclusions were focused almost entirely on these effects in hypoxic conditions 
(less than 3% O2), the data themselves show a significant HIF1A stabilisation 
at normoxia (21% O2) as well. Most significantly, the replication defect that 
was observed in HIF1A-KO cells under hypoxic conditions could also be seen 
(although more modestly) at 21% O2, though this was not commented upon in 
the publication. This supports the transcriptional data that I have analysed, 
which show that the phenomenon of aerobic glycolysis is a strain- and MOI-
independent phenomenon – suggesting therefore that it is a more generalised 
feature of tachyzoite infection.  
Taken with the Spear microarray data (144), it is then likely that the 
aerobic glycolysis phenomenon is at least in part responsible for permitting T. 
gondii replication within host cells. Similarly, if SAG1 expression in my 
western blots (Figure 6.33) are taken as indicative of parasite replication in 
HIF1A-KO cells, it is clear from my results that the parasite burden in cells 
lacking HIF1A is much lower – even under conditions of normoxia. 
From my study, the HIF1a-regulated genes of particular interest are 
Hk2, and Ldha, key modulators of glycolysis (though both have also been 
implicated as targets of MYC possibly in co-operation with HIF1A (212, 
213)). Both are highly upregulated upon infection with either strain of T. 
gondii, regardless of MOI, and this is reflected at the protein level too 
(Figures 6.20 and 6.33). Notably, the B-isoform of lactate dehydrogenase 
(Ldhb) was found to be highly downregulated in infection – a result that is 
entirely consistent with its role in catalysing the reverse reaction of lactate 
back to pyruvate (Figure 6.19). Interestingly, in the case of infection, these 
two genes appears not to be wholly under the control of HIF1a: even in MEFs 
knocked-out for that transcription factor, an upregulation at the protein level 
(though abated) is still apparent (Figure 6.33). This suggests other 
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mechanisms for the control of one or more of the battery of genes I have 
identified as being important for aerobic glycolysis during T. gondii infection. 
Along with Hk2 and Ldha, several transporters crucial to glycolysis are also 
upregulated in infection (Figure 6.21): Slc2a1 (also known as Glut1), which 
facilitates entry of glucose into the cell, and Slc16a3 (also known as Mct4) 
which mediates export of lactate that is produced as a result of glycolysis. 
Both are frequently upregulated in several cancers and they are considered to 
be potential drug targets (193, 214, 215). While the regulation of Mct4 
appears to be wholly dependent on HIF1A (216), this is not necessarily the 
case for Glut1. While a role for HIF1A-dependent transcription has been 
implicated even under normoxia (217), it is unlikely to be the only regulator. 
Instead, the expression of Glut1 has also been shown to be a directly target of 
MYC (218) and also the TRP53 (commonly known as P53) protein, the latter 
of which apparently mediates its transcriptional repression (219). Notably in 
my dataset, Trp53 is itself highly downregulated – perhaps echoing the fact 
that this tumor suppressor is frequently mutated in cancer – and Myc is 
highly transcriptionally upregulated in the infected samples (Figure 6.27). 
Interestingly, while the lactate exporter Slc16a3 is under direct HIF1A 
control, its family member Slc16a1 (also known as Mct1, another potent 
lactate exporter) does not appear to be, given that it lacks an HRE in its 
promoter (216). Instead, Slc16a3 has been shown to be a direct target of MYC 
(220), indicating yet another point where MYC and HIF1A may be acting in 
concert to promote a programme of metabolic reprogramming towards 
glycolysis. 
 
6.4.1.4 Hexokinase 2 and Sirtuins 
For Hk2, a great deal can be learned from the cancer literature, especially the 
work of the Pastorino, Guha and Pedersen groups. This enzyme catalyses the 
first step of glycolysis, the phosphorylation of glucose upon entry into the cell. 
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At least four isoforms of this enzymes have been identified and characterised: 
HK1, HK2, HK3 and HK4. While all are capable of phosophorylating glucose 
and are inhibited by the product of this glycolysis (glucose-6-phosphate), they 
vary in terms of their affinities, cell type expression and localisation, and it 
has been postulated that the localisation and activity of these isozymes have a 
large part to play in regulating cellular glucose metabolism. HK1, HK2 and 
HK3 have been reported as having a far higher affinity for glucose (221) with 
HK4 (also termed Glukokinase) being largely expressed in non-tumorigenic 
liver and pancreas but upon tumorigenisis, being silenced, yielding instead to 
higher expression of the other three hexokinases. In my dataset, only Hk1 and 
Hk2 were found to be significantly differentially expressed. Hexokinase 2’s 
prevalence in numerous tumors and cancer cell types (222–226), as well as its 
specific importance to aerobic glycolysis have led to it being termed the 
“cancer hexokinase”, while Hk1’s role has most often been described in terms 
of its interactions with Akt.  
One of the first experiments identifying hexokinase as important for 
aerobic glycolysis in cancer metabolism was conducted in rat hepatoma cells 
(222), where – in a stunningly elegant experiment - the authors found that, 
upon growth in galactose medium (rather than the usual glucose), the 
formation of lactate was highly reduced, despite those cells’ ability to grow 
well in medium supplemented by either hexose. The authors concluded that 
this was due to the ability of galactose to bypass the hexokinase step 
altogether, and notably, that this hexokinase was enriched in mitochondrial 
fractions. Importantly this and subsequent studies indicated a lack of glucose-
6-phosphate inhibition, but only when HK2 is bound to the outer 
mitochondrial membrane – this is thanks to its N-terminal hydrophobic 
domain. In ascites carcinoma cells, the localisation of HK2 was also found to 
preferentially access mitochondrial ATP (rather than having diffused to the 
cytosol) also contributing to the rapid breakdown of glucose to lactate. 
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Hexokinase 2 is localised to the mitochondrial voltage-dependent anion 
channel 1 (VDAC1) whose expression itself is increased at the transcriptional 
level in all infection states that I assay above. The interaction between HK2 
and mitochondria is also thought to be mediated by Peptidylprolyl isomerase 
D (more commonly known as Cyclophilin D), which is also overexpressed in 
HEK293 and glioma C6 cells. The role of cyclophilin here may be related to 
apopotosis as well as glycolysis, as it has been shown that siRNA knock-down 
of Cycliphilin D releases HK2 from mitochondria, with concurrent increase in 
apoptotic markers. So, as well as access to ATP and increased glycolytic 
pathways, it may be that HK2’s strategic positioning in cancer cells may 
function as an anti-apoptotic actor too – some postulate by physically 
blocking access of actors such as BAX to the mitochondria (227). Confusingly, 
nuclear localisation of HK2 has also been described in HeLa cells, a 
localisation which appears to increase upon blockage of enzymatic activity 
(by, for instance, treating cells with the non-metabolizable glucose analogue 2-
deoxyglucose). The purpose of this localisation remains as yet unknown, as do 
the mechanisms of translocation (though nuclear exportins have been 
implicated) (228).   
Whether this is the case in T. gondii-infected cells has been explored by 
Menendez et al, but only in the context of the Type I strain, RH (229). Here, 
it appeared that – unlike in cancer – infection did not correlate with 
mitochondrial localisation of HK2, which may suggest a separate mechanism 
for hexokinase 2 action here. However, that work was conducted solely in 
Type I RH. Intriguingly, Type II strains are known to themselves be 
mitochondrially-associated so it will be critical to examine the mitrochondrial 
localisation of Hk2 in Type II-infected host cells. Moreover, nuclear 
localisation has not been addressed at all.   
Another important actor in the role Hk2 also emerges from the cancer 
literature: sirtuin 3. Sirtuin 3 is one of seven sirtuins, which are class III 
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NAD+ dependent histone deacetylases. Sirtuin 3 is localized to the 
mitochondrial matrix, and activates acetyl-CoA synthetase 2 and glutamate 
dehydrogenase (GDH), an example of its role as an enhancer of TCA. In a 
echo to Bustamante et al’s early experiments, Shulga et al (230) examined the 
growth of a variety of cells in galactose (rather than glucose). This resulted in 
a gradual change of Hk2 localisation (as assessed through western blots of 
different cellular fractions) from mitochondria to the cytosol, as well as a 
concurrent increase in the expression of mitochondrially-associated SIRT3. 
Through siRNA experiments, the authors found that this effect was mediated 
by Sirt3, via the deacetylation of Cyclophilin D. Additionally, when Sirt 3 is 
knocked-down by siRNA, the usual reduction in membrane potential that 
follows the transfer of cells to galactose-medium is also abrogated.  
Indeed in MEFs, a loss of SIRT3 (via a null mutation) has been found 
to exhibit an increased glycolytic profile, as assessed by a battery of tests 
including cell proliferation, lactate production and LC-MS (231). The authors 
then explored the interplay between Sirt 3 and Hif1a, by looking at HIF1A 
protein expression in nuclear extracts of SIRT 3 null cells. Increased 
expression in this case was obvious, and even more pronounced under hypoxia. 
Conversely, upon SIRT3 overexpresson, Hif1a was not as overexpressed, under 
hypoxic conditions. Further experiments point to the PHDs as the locus of 
SIRT3 regulation of HIF1A.  
On the other hand, Sirt3 is also cited as a mediator of apoptosis (232), 
by blocking BAX translocation to the mitochondria (albeit in a mechanism 
different to that proposed for HK2), in non-transformed cardiomyocytes (233). 
So, it will be curious to understand the localisation and actual end effect of 
SIRT3 in T. gondii-infected cells between its pro-oxidative phosphorylation, 
anti-glycolytic, ROS-protective and anti-apoptotic functions.  
In my data, while Sirt3 is ultimately underexpressed in both strains 
compared to the uninfected host, there appears to be a difference between the 
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strains and MOIs, with ME49-infected cells exhibiting a definite 
downregulation at 24hpi (especially MOI 3) whereas RH seems to ‘recover’ 
transcription (Figure 6.22). The role of Sirt3 in cancer is still quite 
controversial, and thus may undertake different functions under infection by 
the different strains.  
More clear is the pattern found looking at Sirt6 transcription in 
infection (Figure 6.22), where an upregulation is seen in uninfected cells, but 
in none of the infection scenarios. Unlike Sirt3, Sirt6 is nuclearly-localised, and 
acts as a histone deacetylase on H3K9. This has resulted in reports of NF-kB 
target silencing. Zhong et al (234) found that, in SIRT6 KO MEF cells, 
glucose uptake was heightened, via the overexpression of the glucose 
transporter Glut1.  Importantly, the authors found co-precipitation of SIRT6 
and HIF1a, indicating a potential co-repression by that particular sirtuin (this 
interaction was not found with, for instance, SIRT1). Given the incomplete 
picture of Hif1a regulation in T. gondii-infected cells, it may be that the 
sirtuins (3 or 6, or other less-well-characterised ones) may have a part to play. 
Interestingly, Sirt2, whose primary roles are to do with cell-cycle control, not 
the Warburg effect, followed a similar pattern to the uninfected cells for both 
strains.  
 
6.4.1.5 The role of Glutaminolysis, Fatty Acid Synthesis, Pentose Phosphate 
Pathway 
As well as increased glucose uptake, another facet of the Warburg effect is a 
concurrent uptake in the non-essential amino acid glutamine. In my dataset, 
this is supported by the increased expression of, for instance, the glutamine 
transporters Slc1a5 (also known as Asct2), Slc7a5 (also known as Lat1) as 
well as both glutaminase genes, Gls and Gls2 (Figure 6.23). Both metabolise 
glutamine (routinely supplemented in cell culture medium and also reportedly 
the most abundant extracellular amino acid in vivo (235)) into glutamate and 
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ammonia. Their tissue localisation have been the source of some debate (for 
instance the GLS2-encoded “liver type” isoforms were first thought to be 
restricted to hepatic tissues until they were identified in human pancreas and 
brain tissue(236)) and so obviously, their expression profiles must be 
considered with care in a cell culture system. That being said, there is 
evidence of at-times seemingly antagonistic roles in cancer, with the MYC-
regulated GLS being associated with increased proliferation and glutaminolysis 
in the service of macromolecular synthesis in gliomal tumors, and GLS2 
isoforms – under TRP53 control and co-operation – acting as tumour 
suppressors to suppress ROS (237), a feature that has also been noted in 
human lung and hepatocarcinomas (238, 239). That being said, these roles of 
glutaminase in infected cells – where the host cell is cell cycle arrested but 
where nevertheless the “machinery” of proliferation (macromolecular synthesis 
etc) must be carefully unpicked. Moreover, it is imperative that the genes’ 
transcriptional signatures be related to both protein expression and enzymatic 
activity – as well as the timings of these – in order to properly assess 
glutamine uptake and deamidation, given that in my hands at least, the 
transcriptional increase in Gls2 was not followed by a substantial change in 
protein level (Figure 6.33). In Chapter 6, I profiled two microRNAs that have 
been shown to both be under MYC suppression and that themselves suppress 
GLS and GLS2. I would therefore have expected those miRNAs to have been 
underexpressed but in my dataset, this was not the case. Indeed, while miR-
23a’s profile was not striking, miR-23b seemed to be upregulated. This 
highlights that there may be many mechanisms by which GLS and GLS2 are 
regulated, and that there may be crosstalk between several pathways.  
Interestingly, as shown in the western blot, GLS2 appears to be 
expressed even in uninfected WT cells – that is, even in the absence of MYC 
expression (Figure 6.33). This further supports the idea that, under conditions 
of infection, it is likely that Myc and (miR-23a/b) are not the only – or even 
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the major – means of regulating Gls2. On the other hand, removal of Hif1a 
does have a large effect on GLS2. This is particularly curious, since in at least 
two previous studies which sought to computationally identify hypoxia-related 
target genes (based on analysis of conserved binding sites and prediction of 
promoter motifs) did not identify Gls2 as a potential HIF1A-responsive target 
(210, 211). That being said, the latter of these studies did identify Gls but 
noted that it did not have a consistent response to hypoxia across the datasets 
the authors were considering and so did not take it further for study). 
In tumor cells it is clear that there is a large need for anapleurotic 
reactions – be these for nucleic acid synthesis, or fatty acid or lipid synthesis. 
It is this requirement that underpins the idea that glutaminolysis and the 
production of NADPH as a reducing agent, are key drivers of anapleurosis, 
with increased glycolysis acting as a source of intermediates, an effect often 
referred to as “glutamine addiction”. The routes for glutamine following import 
into the cell are several: towards nucleotide synthesis, that of non-essential 
amino acids (alanine and aspartate), the provision of reducing equivalents 
and, importantly, the glutathione maintenance. 
DeBerardinis et al (240) found, through 13C-NMR labelling experiments 
that, in the glioma cells they were looking at, glutamine was taken up and 
shuttled through towards biosynthetic pathways (such as towards aspartate, 
and oxaloacetate as an anapleurotic carbon within TCA), yes, but that this 
was greatly in excess of being able to provide the building blocks for such 
processes themselves. Rather, excessive glutaminolysis, the authors suggested, 
could be in the service of generating large amounts of NADPH, the electron 
donor for fatty acid synthesis, but also other anapleurotic processes.  
This model suggests a co-operative mechanism by which glucose and 
glutamine both contribute to the anapleurotic processes of highly proliferating 
cells. Of course, parasite-infected cells are well-known to be cell cycle arrested 
(148, 149), and so the macromolecular requirements of the host cell will 
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clearly be quite different. That being said, despite host cell quiescence, there is 
of course a highly-proliferative cell within – the parasite itself, within its 
parasitophorous vacuole. Thus, it may be that T. gondii acts as a sort of 
intracellular tumor, pushing its host cell towards increased anaplerosis, as a 
means of itself scavenging the necessary intermediates for replication and 
growth. The role of glutamine may play an important part here, as it appears 
to do in cancer. For instance, as calculated by Vander Heiden et al (241), the 
metabolic requirements for the synthesis of fatty acids, amino acids and 
nucleotides are far greater in terms of reducing equivalents than just ATP: 
there is “35-fold” asymmetry in the NADPH:ATP ratio. As such, the 
“efficiency” of oxidative phosphorylation does not come to bear in this unique 
anabolic scenario, and this is largely dependent on glutamine. 
While the two glutaminases and the glutamine importer Slc1a5 were 
clearly transcriptionally upregulated, another transporter – Slc7a11 – points to 
yet another important role of glutamine: control of ROS (Figure 6.24). 
Glutamine is one of the key components of glutathione, which acts as a potent 
intracellular buffer against oxidative stress. While glutamine is crucial to this, 
it is in great excess in the cellular context (even physiologically), whereas 
cysteine/cysteine is the limiting component of GSH and can only be imported 
via the SLC7A11 glutamate/cystine antiporter. Thus, it appears that high 
levels of glutamine can be imported into the cell and then metabolised into 
glutamate, which itself is then exported, in exchange for cystine. Then, 
cysteine (from reduced cystine) together with excess intracellular glutamate 
can form GSH, via the rate-limiting glutamate-cysteine ligase (GCLC) whose 
transcript, as with the glutamine and glutamate/cystine transporters is 
upregulated in infection. As well as these cues that seem to point towards 
glutamine uptake and glutathione synthesis, the converse pathways appear to 
have been unequivocally downregulated in infection. For instance, the 
“Glutathione Metabolism” KEGG pathway made an appearance in nearly all 
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infection scenarios, with the constituent genes being largely glutathione S-
transferases (GSTs), which act as detoxification enzymes coupling the 
metabolism of xenobiotics to GSH. Notably, the majority of cancer research in 
the area of GSTs has to do with increased expression contributing to 
chemoresistance of tumors (242) but, in the context of T. gondii infection, it 
may be that transcriptional downregulation of these enzymes contributes to 
protecting the cellular pool of GSH from spurious (or baseline) GST-mediated 
depletion. 
Another controversial actor in this area is Isocitrate dehydrogenase 1, 
which was also very significantly downregulated in all infections, as well as a 
repeated contributor to the “Glutathione Metabolism” KEGG pathway17. The 
enzyme encoded by Ihd1 catalyses the conversion of isocitrate to  
α-ketoglutarate, in an NADP+-dependent fashion. Mutations in Idh1 are 
commonly-associated with gliomas, but much of the discussion here has been 
centered around the neomorphic character of these mutations, enabling the 
enzyme to reduce α-ketoglutarate to the potential oncometabolite R(-)-2-
hydroxyglutarate. Indeed, inactivating mutations – arguably the most 
analogous situation to the downregulation that I observe in T. gondii infection 
(Figure 6.24) – have not been described in cancer (243, 244). That being said, 
dominant negative Idh1 mutations have been seen, with the observed effect of 
stabilising HIF1A (245). This is almost certainly due to the fact that the 
product of IDH1 catalysis, α-ketoglurarate, is required by the PHDs that, 
under normoxic conditions, act to promote the degradation of HIF1A. Thus, 
with lower levels of α-ketoglutarate available, the PHDs are not able to 
hydroxylate HIF1A. The regulation of Idh1 expression itself remains 
underexplored, although it may be that Idh1 downregulation is a consequence 
of the other processes that surround tumorigenesis (or indeed parasitism): 																																																								17 The fact that, in ‘normal cellular metabolism’ IDH1 is normally thought of as contributing 
to the pool of NADPH that protects again reactive oxygen guards against overinterpretation 
of KEGG pathways without a further examination of their constitutive genes. 
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Robbins et al (246) reported that treating mouse epidermal JB6 P+ (tumor 
promotable) cells with tumorigenic levels of 12-O-tetradecanoylphorbol 13-
acetate (TPA) or UVC radiation reduced IDH1 protein levels as well as 
activity. It is not inconceivable that a similar process may be happening upon 
T. gondii infection. In any case, the downregulation of Idh1 in infection is 
consistent with a preservation of cytosolic citrate – which can feed directly 
into the fatty acid synthesis pathway.  
How might the parasite accomplish this broad-based re-modelling of 
host cell metabolism? Partly through stabilisation of HIF1A as described by 
others (144), but also via a programme of interference with host cell signalling 
networks, including protooncogenes and tumor suppressors.  
Wise et al suggest MYC as a key effector of glutaminolysis in human 
gliomas (247). In their study, increased glutaminolysis was dependent upon 
MYC expression, via an upregulation of LDHA which in turn redirected 
glucose towards exiting the cell as lactate (rather than as a lipid precursor). 
As a result, the authors found, instead of ‘usual’ TCA processes, Myc-
transfected cells were instead dependent on glutamine as a substrate for 
mitochondrial intermediates of anapleurosis. Though the authors did not 
explore a possible Hif1a connection, it is possible, as I find below, that this 
programme of Myc-related glutaminolysis is somehow interconnected with a 
broader hypoxia-like environment resulting from the stabilisation of HIF1A.  
 
6.4.1.6 Myelocytomatosis oncogene (Myc)  
A striking feature of infection is the high upregulation of Myc in response to 
infection, both at the transcriptional and protein level. As a b-HLH 
transcription factor, it interacts with its binding partner MAX (whose half-life 
is thought to be longer, which is consistent with my transcriptional data) to 
effect a large transcriptional programme with broad implications for 
development, differentiation, apoptosis and immune function. Most often, it is 
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highly overactive in transformed cells, with one estimate being that it is 
overexpressed in 70% of human tumours (248). Many of the pathways 
upregulated by MYC are to do with anabolic pathways, for instance fatty acid 
synthesis, nucleotide synthesis with mitochondrially-sourced intermediates. In 
this sense, MYC operates on a dual armed system: promoting an increase in 
glycolysis to yields a rapid source of ATP, as well as the ability to synthesise 
important anabolic intermediates. I will focus here on its interactions with 
metabolism (via cooperation with Hif1a) and its role in glutamine metabolism 
(looking later at its interaction with Trp53). 
Overexpression of Myc has previously been shown in cells infected with 
all three strains, in a variety of cell types, at the protein level as early as 1hpi 
(though their assay of transcription was only performed at 24hpi) (21). 
Though the timing may differ – the earliest time point I assayed was 24hpi 
either for transcription or western blot – these results are consistent with what 
I have found in terms of transcriptional and protein-level induction. The 
authors of that work also characterise further a potential route for Myc 
induction via MAPK8 (more commonly known as JNK) by treating cells with 
a JNK-inhibitor and finding that this abrogated Myc expression, as assayed 
by western blot. In my results, Jnk expression also transcriptionally increases, 
which may indicate that this is indeed a possible mechanism, but the western 
blots show another possible route – one that has not previously been 
described, involving Hif1a.  
Very surprisingly, my infection of HIF1A-KO cells resulted in total 
abrogation of MYC protein expression, suggesting a potentially-novel means 
of regulating this transcription factor, at least in cells infected with T. gondii 
(Figure 6.33). In most studies, Myc has always thought of as being an 
upstream regulator of Hif1a, though my result shows that the situation is 
clearly more complex, perhaps involving many routes of positive and negative 
feedback. While Hif1a and Myc have been known to exhibit antagonistic 
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effects, particularly in the realm of cell cycle control (249, 250), this has not 
been shown in terms of a reduction in MYC protein levels, rather by 
antagonistic effects on MYC target genes themselves (via, for instance, 
displacement on MYC’s classic E-Box binding sites due to the sequence 
overlap between these sites and HIF1A’s HREs). In the latter of these two 
studies, Koshiji et al used a normoxia-stable HIF1a (Adenovirus-ΔODD) and 
found no difference in the transcription of Myc. On the other hand, MYC has 
been reported to have effects upon HIF1a, most notably post-transcriptionally, 
by stabilising the protein (251). Clearly this relationship, and its impacts on 
target genes downstream of one or both of these transcription factors, needs 
careful disentangling and is more complex than has been previously 
understood.  
 Another cellular regulator that has important implications for both 
cancer and T. gondii infection is TRP53, which has been shown to be 
dysregulated in infection at least in part by the dense granule protein GRA16 
(19). The mechanisms of TRP53 are unclear: While infection with wild-type 
T. gondii results in a robust decrease in TRP53 protein levels, infection with 
parasites where Gra16 had been ablated resulted in even lower protein levels. 
Thus it appears that GRA16 acts to stabilise TRP53, indicating a role for 
other factors in the overall reduction of TRP53 protein seen in infection.  
Usually, the control of TRP53 levels is examined in the context of 
ubiquitination and degradation. One pathway for the control of TRP53 is via 
ubiquitination by Mouse double minute 2 homolog (MDM2) which 
subsequently leads to degradation. Ubiquitin specific peptidase 7 (USP7, also 
known as HAUSP) on the other hand acts to stabilise TRP53 by de-
ubiquitination it (252), and so it at first appears curious that Usp7 transcript 
levels also appear elevated in infection, although fairly modestly (which 
mimics USP7 protein levels in Bougdour et al’s GRA16 data (19)). However, 
the situation is not as simple as MDM2 and USP7 acting in antagonistic 
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directions. The deubiquitination activities of USP7 also act upon MDM2 and 
so a certain baseline level of USP7 is almost paradoxically necessary for the 
ubiquitin-mediated degradation of TRP53. How this precise balance of USP7 
activity is achieved is not yet fully understood. Yet another mechanism of 
TRP53 regulation is in fact transcriptional, via BCL6 binding specific Trp53 
promoter sites, though the control of BCL6 itself appears to be post-
transcriptional (253). A number of studies have shown that the regulation of 
TRP53 is complex and involves autoregulation by MDM2, where Mdm2 is 
itself transcriptionally-activated by TRP53 (254). In my dataset, Mdm2 is 
upregulated – despite the downregulation of Trp53. It must also be 
remembered, however, that this important tumor suppressor can also be 
regulated by miRNAs such as miR-125b, and miR-504 (255). 
 
6.4.1.7 Apoptosis 
It is well-known that infection by T. gondii acts potently against host cell 
apoptosis – an obvious advantage for an intracellular parasite. That these 
same processes are also affected in tumorigenesis should also not come as a 
surprise, given the uncontrolled and unchecked proliferation of transformed 
cancer cells. In my dataset, I was able to replicate the transcriptional results 
found by Kim et al, who noted downregulation of Bax (256). However, it is 
clear that the regulation of apoptosis depends not simply on the 
transcriptional regulation of the various actors but also post-transcriptional 
modifications such as phosphorylation and cleavage (for instance of caspases). 
Thus, it is perhaps more fruitful to look at apoptosis through the lens of the 
signalling pathways that modulate it. 
One mechanism for this is likely to be via NfkB, where it has been 
documented that protection from apoptosis in infected cells is absolutely 
dependent on this pathway. The role of NfkB in T. gondii-infected cells is 
itself controversial, where contradictory effects have often been observed, 
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likely due to the plurality of host cell types used, the timing of assays, the 
strain of parasite as well as, as noted by Rosowski et al (17), the fact that 
many such experiments use as their ‘baseline’ nuclear translocation of RELA 
(P65) in response to LPS or TNFA, which may mask more subtle activation, 
as they themselves found in Type I strains. It must also be borne in mind, 
that Nfkb has a multitude of effects, many of which could be to an 
intracellular parasite’s advantage at different stages of infection. For instance, 
blocking NfkB to avoid immune detection is potentially desirable in early 
infection, while inducing NFkB’s anti-apoptotic effects would clearly allow for 
increased parasite survival. While the identification of GRA15 in Type II 
strain Toxoplasma gondii (17) shows that strain-specific activation (or 
increase in activation) is indeed possible, other studies show activation (albeit 
modest in comparison to Type II) in Type I strains such as GT1 at 24hpi 
(257). Moreover, studies involving Myc suggest a broader role for NFkB in all 
three strains (21). In my own dataset, I see a broad upregulation of all NFkB 
family-members, with the curious phenomenon that RELA and REL appear to 
be strain-specifically upregulated (Figure 6.30).  
 
6.4.1.8 Reverse Warburg Effect 
A different take on the Warburg effect has been proposed by Michael Lisanti 
and colleagues (258, 259) in epithelial cancers. Their work suggests a role for 
the stroma in promoting the metabolic changes associated with Warburg. 
They argue that the changes that accompany increased aerobic glycolysis in 
epithelial cancer actually take place in the non-transformed stromal cells, as a 
result of signalling events from the tumour cells themselves. In this model, the 
stromal fibroblasts are effectively turned into factories for the tumour, 
exporting lactate and pyruvate to the tumour microenvironment, for 
subsequent uptake by the tumour cells thus allowing for their own 
unrestricted proliferation. This hypothesis came from the observation that 
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caveolin 1 expression was vastly downregulated in several cancer-associated 
fibroblasts. Proteomic analysis of CAV1-ablated stromal cells and co-culture 
experiments of breast cancer MCF7 and fibroblasts (260) further revealed the 
upregulation of eight glycolytic enzymes (including lactate dehydrogenase A 
and pyruvate kinase M2). Such a model might be applicable for the case of T. 
gondii-infection. After all, even at high MOIs, not every cell in culture will be 
host to a parasitophorous vacuole, leaving a proportion of uninfected 
fibroblasts. If these are taken to be equivalent to the “cancer-associated 
fibroblasts” described by Lisanti, it is possible that the transcriptional changes 
associated with the apparent Warburg phenomenon in infection actually 
results from changes in the uninfected population. Indeed, the experiments 
that I have performed, be they transcriptomic, proteomic or of lactate output 
always assay the mixed population of infected and uninfected cells. It cannot 
therefore be ruled out that the increased lactate output may indeed come from 
uninfected “infection-associated” cells. Indeed, the severe transcriptional 
downregulation of Cav1 (Figure 6.31) might indicate that this is indeed the 
case, given that it is impossible to distinguish whether this transcriptional 
difference arises from the uninfected or infected cells from the same 
experimental well. One clue might be the role of MOI here: one might think 
that, if the ‘Reverse Warburg’ effect is in operation with transcriptional 
differences arising from uninfected cells, then those samples with the broadest 
infection rate (highest MOI) would exhibit the least transcriptional changes, 
given that the population of uninfected cells in those wells would be lesser. 
While this does not appear to be the case, this hypothesis ignores any 
‘magnitude effects’ that might arise: if indeed Cav1 downregulation arises in 
uninfected cells as a result of signalling events in neighbouring infected ones, 
the magnitude of transcriptional dysregulation might also be affected. 
Interaction between T. gondii and host cell CAV1 was briefly looked at while 
examining the establishment of the parasite moving junction during 
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invasion(13). Immunofluorescence experiments in this study showed that, 
while CAV1 was selectively excluded from the parasitophorous vacuole while 
remaining visible in the surrounding host cell. However, no adjacent 
uninfected were shown in those images, thus leaving the question of CAV1 
expression there open.  
 
6.4.2 Methyl jasmonate as an anti-parasitic 
A chemical effector that is thought to have an effect on HK2 in cancer is the 
plant hormone, methyl jasmonate. I initially decided to look at this compound 
due to its reported effects on HK2 (261), my hypothesis being that methyl 
jasmonate-mediated disassociation of hexokinase from VDAC might mediate a 
reduction in aerobic glycolysis (and thus parasite replication). However, while 
the localisation of host HK2 in infected cells is not definitively mitochondrial 
under normoxic conditions (229) it has also emerged that methyl jasmonate 
may mediate a whole host of anti-tumour phenomena, including anti-
proliferative, pro-apoptotic, ROS-generating effects. It had been known to 
affect cancer-cell mitochondria since at least 2005 (262, 263), had its 
mechanism more fully elucidated in 2008 by Goldin et al (261). These 
researchers found that treatment of CT26 rat carcinoma cells promoted the 
selective detachment of HK2 from mitochondria. This is thought to have two 
effects: first, the disruption of aerobic glycolysis in these cells, and secondly, 
the triggering of apoptosis in those cells (and those cells only), likely to an 
increase in ROS levels. My experiments (Figures 6.35 – 6.38) present an 
intriguing first look at the effect that methyl jasmonate may have on T. 
gondii but the very preliminary nature of these results cannot be stressed 
enough. Far more characterisation is required before beginning to unpick the 
jasmonate’s role here, and this is discussed in Chapter 7. 
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VII. Discussion and Future Directions 
 
7.1 Toxoplasma gondii and microRNAs 
While microRNAs have been studied for over a decade now, their functions 
are only now being characterised – a process made more difficult by the 
multiple roles that they can play, under different cellular contexts. Most often, 
they have been looked at in the context of development or cancer18 and a 
handful of studies have now examined the issue from the perspective of T. 
gondii infection. My results in Chapter 4 and Chapter 5 recapitulate many of 
these (for instance miR-146a) and also give a broader look at the host cell 
miRNAs modulated by both RH and ME49. While RNASeq technology like 
Illumina has undoubtedly been a boon to miRNA research, one of its pitfalls is 
the sheer volume of data that is produced – and that makes functional 
interpretation rather difficult. To that end, pathway enrichment is often used 
as a kind of ‘filtering’ step, helping to narrow down the vast experimental 
space. This filtering however depends entirely on the quality of the pathway 
data available, and those have not been optimised to deal with the role of 
miRNAs as suppressors of genes. So, enrichment might mean repression, and 
vice versa.  
Of the miRNAs identified in my study as dysregulated by infection, a few 
warrant special mention. The family of miR-199 was found to be highly 
suppressed in all strains at all times when compared to the uninfected control. 
That this miRNA family has elsewhere been implicated in the control of 
hypoxia (172) renders it all the more intriguing, given that the question of 
how T. gondii infection mediates HIF1A stabilisation has not been fully 
resolved (138). Useful experiments here would be to overexpress the miRNA 
and perform analyses of HIF1A and its target genes.  																																																								18 Though this may be an artifact of the likelihood that these are the two most-studied 
aspects of biological science 
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 The interplay between what ‘is known’ in T. gondii infection and non-
T. gondii-related processes that may be mediated by miRNAs also call for 
special attention. An example here is the case of miR-23a/b which, given its 
documented suppression by MYC (164), I would have predicted to also be 
suppressed in infection. That this wasn’t the case raises questions about other 
means of regulating this miRNA, as well as of regulating MYC.  
 
7.2 Toxoplasma gondii infection and the Warburg Effect 
As described in Chapter 6, many of the pathways and genes identified as 
being dysregulated during infection had to do with the phenomenon of aerobic 
glycolysis. While Otto Warburg’s seminal paper On the Origin of Cancer 
Cells (264) is the publication most famously associated with the phenomenon 
of aerobic glycolysis, the years preceding its publication saw several labs 
(including Warburg’s own19) already examining the unusual features of cancer 
metabolism. As early as 1929, for example, Crabtree looked at the energy 
consumption of eight different type of transplantable mouse tumour and saw 
an elevation in aerobic glycolysis in all of them, noting “The constant factor is 
the possession of a high aerobic glycolysis, which, though not specific for 
tumour tissue, is a source of energy available for uncontrolled proliferation.” 
(265) Warburg however was the one who extended his findings into a 
hypothesis, postulating that this was due to a defect in these cells’ 
mitochondrial function, but in the intervening years, this has been shown not 
to be the case. Rather, the increase in aerobic glycolysis is independent of 
mitochondrial misfunction and indeed, mitochondria do not overwhelmingly 
exhibit any real defects in cancer cells. Between 1958 and 1964, Wasley D. 
Yushok published a series of papers (266–268) in which he examined the 
effects of different metabolisable sugars on the respiration rates of ascites, 
																																																								19 For example his 1924 paper Über den Stoffwechsel der Carzinomzelle , On the Metabolism 
of Cancer Cells (283) 
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with the observation that the ability of hexokinase to differentially 
phosphorylate them was a key point of potential control.  
 
The difficulty in much of the cancer literature to do with metabolism 
and the Warburg effect is the inherent genetic heterogeneity that causes 
tumorigenesis. As such, different tumors will almost certainly have different 
metabolic needs and so, hypotheses seeking to explain the Warburg effect 
abound. A few of these include the impact of glutaminolysis, protection from 
ROS and/or apoptosis, autophagy, mitophagy and, of course, immune-related 
functions. This leads to an attractive idea: the use of T. gondii as a proxy for 
tumorigenesis that is able to decouple the metabolic effects from the genetic 
transformation or dysregulated proliferation that is exhibited in cancer.  
A preliminary model for the regulation of host cell metabolism by T. 
gondii is shown in Figure 7.1, where the parasite has effects in targeting 
particular signalling netwkorks and transcription factors.  
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Figure 7.1. A schematic of the key requirements that T. gondii has upon intracellular 
infection of the host cell. Some of the key signalling networks that are known to be modulated 
by the parasite are noted, as well as potential ‘reasons’ why it these might promote parasite 
survival. NA = nucleic acids; FA = fatty acids; AA = amino acids. Adapted, with permission, 
from Dr J. Ajioka. 
 
This follows from the obvious need that an intracellular parasite has for 
certain key cellular ‘commodities’ such as nucleic acids, fatty acids and amino 
acids. Moreover, there is a great need for reducing equivalents, and so more 
complex processes such as glutamine metabolism and ROS-protection may 
also be tweaked. Indeed, it is likely that the parasite is able to modulate the 
host resulting in changes both at the level of gene expression and metabolite 
levels. Preliminary studies have looked at metabolite levels in infected cells 
using 1NMR (Roohi, personal communication) and those results have been 
used to supplement the gene expression information revealed during my 
analyses in a more detailed model of intracellular infection, highlighting 
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differentially-modulated genes and metabolites. Such a model can help form 
the basis for future experiments on specific pathways. 
 
 
Figure 7.2. A schematic of some of the genes and metabolites modulated during T. gondii 
infection. Gene expression data from Chapter 6 were combined with data communicated to 
me personally by a colleague regarding the modulation of metabolites. (Adapted, with 
permission, from Dr. A. Roohi). 
 
That being said, it is increasingly clear that a rather limited number of 
transcription factors are at the root of this metabolic reprogramming, though 
these are interconnected in often non-obvious ways. As Yeung et al note “The 
regulation of energy metabolism can be traced to a "triad" of transcription 
factors: c-MYC, HIF-1 and p53.” (269) – and T. gondii infection appears to 
modulate all three. While MYC (20) and TRP53 appear to have regulatory 
parasite secreted factors identified the situation is still not clear cut – after all, 
GRA16 appears to have a stabilising role on TRP53, unlike the wholesale 
decrease in mRNA that I see, or the protein decrease that Bougdour 
themselves note (19). It may be that at least some of these effects are 
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mediated via the NFkB pathway but the parasite effector associated with that 
regulation is strain-specific (19), and it appears that the overall upregulation 
in glycolytic/cancer-like processes are not. What is clear is that we need a 
better understanding of how these signalling pathways intersect under 
conditions of infection. One of the most striking results from my data suggest 
that HIF1A may have a regulatory role on MYC (251), whereas the 
relationship between them has thus far been described as the reverse. As such, 
a sequential dissection of these three key transcriptional networks, using 
classical genetics, siRNAs or overexpression studies, will be crucial in 
understanding what nexuses of control are likely targeted by T. gondii.  
 
7.3 Specific Future Directions	
7.3.1 Mitochondrial Localisation and Activity of Hexokinase 2 
Given the upregulation of hexokinase 2 in infection, taking a page from the 
cancer literature and exploring its localisation would be a useful path to 
explore. It has been proposed that, apart from being the ‘cancer hexokinase’ 
upregulated as part of the generalised Warburg phenomenon, its localisation 
to the mitochondria is key to this effect (227, 270, 271). In certain cases, 
growing cells in medium where galactose is the central carbon source (instead 
of glucose), has been shown to result in the dissociation of HK2 from 
mitochondria (222, 272).  
The steps to undertake this experiment would be as follows: 
1) Ascertaining the growth rate of host cells in the galactose medium, 
versus the glucose medium to ensure that any growth defect is controlled for.  
2) Ascertaining the expression and cellular localisation of HK2 during 
infection and whether that changes upon growth of infected cells in galactose. 
3) Ascertaining the metabolic state of these cells. Ideal for this is a piece of 
equipment called the Seahorse XF (273), which simultaneously and in real 
time analyses oxygen consumption (OCR) and extracellular acidification 
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(ECAR. In a sense, this is a modern interpretation of the biochemical lactate 
assay that I have performed, but also includes oxygen electrode experiments.  	
7.3.2 Carbon Labelling Experiment 
Apart from specifically assaying particular enzymes such as HK2, a more 
global picture of host cell metabolism upon T. gondii infection could be gained 
by performing, as Deberardinis et al did with glioma cells (274), 13C-NMR 
labelling experiments. By measuring which particular carbon is labelled, one 
can then ascertain the eventual ‘destination’ of the increased glucose taken up 
during infection – whether it is to supply the parasite directly, to supplement 
depleted host nutrients or a combination of both. Not only that, it can – 
through the proportion of differentially-labelled products - give an idea of the 
rates of the different routes through central carbon metabolism, and how these 
are altered upon infection.  
 
7.3.3 Methyl Jasmonate 
My results in 6.3.6 provide a very preliminary glimpse into a potential role for 
methyl jasmonate as an anti-parasitic, and this may give useful insight into 
the mechanisms by which T. gondii reshapes its metabolic host cell niche. Of 
course, my result in and of itself is inadequate to make any such claims, but 
there are a number of experiments that could be undertaken to clarify what 
methyl jasmonate’s action is here. For a start, it is crucial to attempt to 
separate the drug’s effects on the host and on the parasite. While it does not 
seem that methyl jasmonate had a noticeable effect on host cell numbers, live-
dead staining (using for instance trypan blue) would confirm that this was 
indeed the case. Moreover, it will be important to look at the metabolic state 
of treated cells – this is true of both infected and uninfected cells.  
Given that my preliminary results suggest lower numbers of PVs and 
parasites in treated cells, it is then necessary to examine what the 
disadvantage actually is: is it a block on invasion? A replicative disadvantage? 
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This can be sorted out to an extent by modifying the ‘order of operations’ of 
such an experiment. These would be the steps to do this: 
1. Apply parasites to a host cell monolayer in ‘normal’ medium 
2. Allow the parasites to invade for an hour 
3. Rinse the monolayer with PBS to remove parasites that have not invaded 
4. Replace the medium with either fresh medium or fresh medium containing 
methyl jasmonate. 
A tight time course following treatment would then follow the timing of 
replication of the parasites that had been able to invade – distinguishing 
between PVs containing different numbers of parasites at each time point. 
Further, if the ‘PBS-rinse’ were centrifuged and any resulting pellet examined 
one could also examine the parasites that had explicitly not invaded. Another 
necessary control is to pre-treat parasites with methyl jasmonate (or fresh 
medium) for a few hours before using them to infect the monolayer. This is 
always a little tricky given the obligate intracellular nature of parasites, but it 
is a reasonable compromise as long as it is well-controlled. Finally, the 
differentiation potential of treated cells would also need to be controlled as it 
is possible that by altering host or parasite metabolism, the transition to 
bradyzoite is promoted. This could be done with simple staining using 
bradyzoite antigen 1 (BAG1) antibody at different times following.  
 
7.4 Toxoplasma gondii and the Warburg Effect: Clinical Implications 
7.4.1 Chemotherapy 
While methyl jasmonate may (or indeed ultimately may not) exhibit 
metabolism-based anti-parasitic effects, it is not the only compound to have 
been considered in both the context of cancer and T. gondii infection. In 
several cancer studies, the compound 3-Bromopyruvate has been employed as 
an HK2-inhibitor. Interestingly, in one study looking at the effect of this 
compound in T. gondii-infection, the authors found a dose- and time-
	 243	
dependent reduction in parasite proliferation following treatment of infected 
LLC-MK2 (rhesus monkey kidney) cells; 3BP treatment had no effect on host 
cell proliferation (275). While de Lima et al attribute this effect to direct 
action on parasite metabolism, they do not address at all the possibility that 
3BP may instead modulate metabolism of the infected host cell instead, as it 
appears to do in cancer. It would be interesting to examine this further, 
through one of the metabolic studies proposed above.  
In a clinical context, though, care must be taken using such newly-
characterised drugs : 3BP has recently found itself at the centre of a tragic 
controversy, where its use in an unlicensed alternative therapy clinic is 
thought to have caused the deaths of three patients (276). The full connection 
between these deaths and the use of 3BP is still being investigated but the 
case highlights the need to fully characterise these types of metabolic drugs 
extremely carefully – their effects are likely to be broader than simply 
targeting a single metabolic pathway and even if they do, the central position 
of cellular metabolism (including, for instance the brain’s requirement for 
glycolytic metabolism) makes this a particularly challenging pathway to target 
therapeutically.  
 
7.4.2 Diagnosis 
18F-FDG-PET has, since the 1980s, been a commonly-used technique for the 
visualisation of tumors in vivo (277). It rests on the use of the non-
metabolisable glucose analogue 2-fluoro-2-deoxy-D-glucose (F-18), and 
subsequent visualisation using Positron Emission Tomography – a direct 
result of the Warburg Effect whereby tumours take up glucose at highly 
increased rates. This technique has been shown to be useful in distinguishing 
between lymphoma and toxoplasmosis in patients with AIDS (278). Central 
Nervous System (CNS) lesions arising from either condition are near-identical 
in appearance when evaluated through traditional contrast-based imaging 
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methods such as CT or MRI  (279). Drawing upon previous studies (REF) 
which showed that CNS lymphoma, like most cancers, accumulate 18F-FDG at 
a high rate, Hoffman et al demonstrated that it was possible to use this 
hypermetabolic feature of lymphoma in 18F-FDG-PET, to discriminate 
between CNS lesions arising from malignancy or from infection. Indeed, 
lesions arising from non-malignant pathologies were shown not to accumulate 
18F-FDG as much as those resulting from lymphoma. As a result, 18F-FDG-
PET has become, at least in patients with AIDS, a valuable tool to resolve 
the often confusing differential diagnoses of CNS lesions. However, as Hoffman 
et al themselves acknowledge, this method is imperfect. In their study, seven 
of the 11 patients were at the time receiving treatment for toxoplasmosis, 
though only four of them were eventually diagnosed with it. This is due to the 
widespread clinical practice of ‘empirical treatment’ where patients with AIDS 
who exhibit characteristic neurological symptoms are pre-emptively prescribed 
an anti-toxoplasma regimen, even in the absence of serological evidence of 
parasitic infection. Only if symptoms prove refractory might other avenues, 
such as an FDG-PET scan be pursued. As such, the FDG-PET profile of T. 
Gondii infection in the absence of treatment remains unknown. Moreover, the 
majority of toxoplasmosis cases in patients with AIDS results from the 
reactivation of encysted parasites, a situation which may present a different 
metabolic profile (and thus a different FDG-PET reaction) to acute primary 
infection.  
The clinical FDG-PET response of acute Toxoplasma infection in HIV-
negative populations is difficult to assess, since most primary infections are 
asymptomatic and would not require even a visit to the doctor, much less a 
PET scan. As a result, any clinical metabolic information in this regard comes 
from patients for whom an FDG-PET was indicated for other reasons. At 
least two cases are noteworthy in this respect. In 2001, Sandherr et al 
reported the case of a patient apparently in remission from Hodgkin's 
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Lymphoma, whose follow-up full-body FDG-PET scan revealed a splenic locus 
of high FDG uptake. The presumptive diagnosis was of a recurrence of the 
lymphoma but, after numerous serological tests, the patient was eventually 
diagnosed with, and successfully treated for, toxoplasmosis. Importantly, 
though the authors do not make note of this, the method of diagnosis 
(positive igm-antibodies rather than igg characteristic of chronic infection) 
would suggest that this was a primary infection (280). 
Spieth et al's patient exhibited enlarged lymph nodes, more than a year after 
undergoing a wide resection of a scalp melanoma (281). As in the previous 
case, a full-body FDG-PET was indicated and its results “further 
strengthen[ed] the presumptive diagnosis of lymph node metastases”. However, 
after histological examinations pointed to toxoplasmosis, acute infection was 
diagnosed immunologically. In this case, the infection was left to ‘run its 
course’ (as is advised in most non-immunocompromised patients) and, six 
months later, an FDG-PET scan revealed no unusually hypermetabolic loci. 
Furthermore, serial igm measurements reflected a marked attenuation of acute 
primary T. gondii infection. 
In a clinical context, these studies serve primarily to emphasise the 
need for care when interpreting FDG-PET scans but the bio-energetic picture 
that they hint at is much less clear. Sandherr et al speculate that the FDG-
PET false-positive they observed might be due to “increased glycolysis of 
activated granulocytes and macrophages” but this remains conjecture and 
Spieth et al offer no explanation for their result. Either way, the idea that 
acute primary T. gondii infection (as distinct from chronic infection) may, in 
vivo, mimic present with the same, and most characteristic, metabolic feature 
as cancer is intriguing, and perhaps plant the seeds for parasite-induced 
Warburg effect in vivo. 
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IX. Appendices 
 
9.1 Putative novel Mus musculus miRNAs from 3.4.1 
9.2 Putative novel Toxoplasma gondii miRNAs from 3.4.2 
9.3 Putative novel Mus musculus miRNAs from 5.3.1 
9.4 Gene lists from 6.3 are included in an external DVD, as Supplementary 
Materials 
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9.1 Putative novel M. musculus miRNAs, from 3.4.1 
 
provisional	
id	
miRDeep2	
score	
total	read	
count	
mature	
read	count	
loop	read	
count	
star	read	
count	 consensus	mature	sequence	 consensus	star	sequence	
1_1152	 68.1	 181	 180	 0	 1	 uaguuuuacauuuuuuauuuu	 aaauaaaaaauaauaauaua	
10_2483	 27.1	 66	 65	 0	 1	 uuuuacagucucauaaua	 auuaugaauacugcauuu	
11_2824	 9.9	 25	 21	 0	 4	 uuguauucucccuuccuu	 uggggggggggguuguuuuuuu	
17_8492	 9.9	 18	 14	 0	 4	 acucucucacucugcaugguuac	 ugacuuucguacggagagagagagaaa	
16_8372	 5.2	 35	 35	 0	 0	 auguguguguguauguguguau	 acacacauacauacacacauaa	
2_11921	 5.2	 192	 192	 0	 0	 ugagguagaaggcugugugc	 acacgccugcacucucggc	
12_3883	 4.8	 61	 61	 0	 0	 gaggguuggguggaggcug	 gcaccaccaugcccagcu	
X_20178	 4.7	 19	 19	 0	 0	 gggggugcagcucagugg	 acuuuccucacauaccccag	
14_6561	 4.5	 12	 12	 0	 0	 uguuauagauuccugcuc	 gugggaaacuuuggacauu	
10_1912	 4.4	 230	 230	 0	 0	 uuguacagugugaugcuc	 gcucugcuucugaag	
9_19150	 4.3	 10	 10	 0	 0	 uggcaguggaguuagugauugu	 aaucagcuaauuacacugccuac	
14_6034	 4.3	 17	 17	 0	 0	 agcagcauuccacagguc	 caaagguggagggcugugaa	
11_3513	 4.1	 13	 13	 0	 0	 ugagguaguugugugguu	 cuacauaccuagccucaua	
16_8320	 4	 1095	 1095	 0	 0	 uguuauagugugaggaga	 accauggcuuuaugacauc	
9_19433	 4	 14	 14	 0	 0	 uacauucauugcucucug	 augaguggagaaaguaag	
10_2617	 3.6	 816	 816	 0	 0	 ugagguaguggguuguuu	 uuaaccuccuccauuaga	
5_14886	 3	 548	 548	 0	 0	 uguuauagagugaguaua	 uucucacuaaugugauagu	
1_1519	 2.9	 9	 9	 0	 0	 cuauacagguguucuuccuuu	 cuagagagcuagcugucuuaguu	
6_15778	 2.1	 89	 89	 0	 0	 uucuccagucccgccguc	 cggcguggacguggugcu	
5_15035	 1.9	 39	 39	 0	 0	 uucuauggccuguucuuc	 ggaauuggcuagcagggc	
2_10828	 1.9	 20	 20	 0	 0	 ugagguaguauuuuguuu	 gcaaaaugcugguucuggu	
7_17481	 1.9	 30	 30	 0	 0	 uguuauagucucauaauc	 ugauguagauuugaaaggauggu	
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7_17484	 1.8	 260	 260	 0	 0	 ggggguguagcucagugguaga	 agccccugccuagaaucccccag	
13_4913	 1.8	 20	 20	 0	 0	 uucuacaucccuccccuc	 ggggggggagcguguuggg	
4_14431	 1.7	 551	 551	 0	 0	 uucuaaagcccaccgucc	 cuggugggaggagug	
10_1721	 1.7	 21	 21	 0	 0	 cugugcucuccauuccuc	 ggaagcggagccgcacagug	
2_11195	 1.7	 144	 144	 0	 0	 cgcuacaguccgccgagc	 ugggcggcucugugguggc	
5_15644	 1.6	 424	 424	 0	 0	 agcucuacagucagaagcuc	 gcucagcugugcagucag	
13_5378	 1.6	 195	 195	 0	 0	 uuuuauagucugaggcuc	 gccugagucuguggcg	
7_17091	 1.6	 1073	 1073	 0	 0	 uucuauagugugaggaga	 uccuuguguaggaca	
12_4157	 1.6	 115	 115	 0	 0	 uucuacauucccuccugc	 aggagugggcaggc	
7_17622	 1.6	 13	 13	 0	 0	 ugauauagccaagcccgacugua	 cagucaggcugcuggcuauauuccagg	
17_8931	 1.6	 37	 36	 1	 0	 uucuccagccccccauuc	 uuuaggggugggagaagu	
8_18839	 1.5	 156	 151	 5	 0	 uuuuuuaaguucuaagauu	 ucccagcacucgggaagca	
14_6481	 1.5	 22	 22	 0	 0	 ggggauguagcucaguggcagag	 cagcccuagguuggaucccacg	
11_3196	 1.5	 33	 33	 0	 0	 uuugcaguaacagguguggacaucc	 guggucauguaugauacugcaaaca	
11_3031	 1.5	 84	 84	 0	 0	 uccuacaccccccccagc	 uggggggggggaag	
11_3226	 1.5	 97	 97	 0	 0	 uucagggauaaauggagucacaga	 ugugacuccugagcucuguucc	
3_12951	 1.5	 16	 15	 0	 1	 aguaccaccauacacagcuuuugu	 gagcugggugugguggcacaugc	
15_7353	 1.4	 18	 18	 0	 0	 uagagcuguacagucaua	 uugcauguaucagcucuugc	
5_15643	 1.4	 430	 424	 0	 6	 agcucuacagucagaagcuc	 agcuguacagucagaagc	
11_3385	 1.4	 51	 51	 0	 0	 ggggguguagcucagcggua	 cucuguguuauuugauccccag	
19_9928	 1.4	 94	 94	 0	 0	 ggggguguagcucagugg	 ccugaguucaaccac	
17_8647	 1.4	 126	 126	 0	 0	 agggggugggaaaaaaaa	 ggacuuuccacccuuagc	
3_13243	 1.3	 50	 50	 0	 0	 uucuaaggcccaccauuc	 uuauuggguuuugaacc	
14_6524	 1.3	 931	 931	 0	 0	 uucuccagucccacccuc	 ggaaggcuggagccag	
10_2398	 1.3	 513	 513	 0	 0	 aguuauagagucauaaga	 uuauguucugacugu	
19_10198	 1.3	 1276	 1276	 0	 0	 agggagggaacgcagucugagugga	 cauugaugaucguucuucucuccuucg	
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12_4373	 1.3	 34	 34	 0	 0	 uguuguaguagccuguguuc	 acugucaaacagguacugugacaau	
16_8393	 1.3	 25	 25	 0	 0	 uucugcuguccugugcuc	 gccagggcccuauggauug	
9_19001	 1.3	 30	 30	 0	 0	 uucugcagucugcaguuc	 ucugugacccaacugcaggauu	
X_20698	 1.3	 16	 16	 0	 0	 agggggaggcaaaaaaaaa	 ccuuucugccuccucugcc	
1_1253	 1.3	 43	 43	 0	 0	 ucagagagcuacaggucc	 acccagucucaaaggug	
7_17963	 1.3	 2511	 2511	 0	 0	 uucuacagugugaggauc	 gccucgccuuagaccagaguc	
1_715	 1.3	 91	 91	 0	 0	 uccuacugcuccaugcuc	 gcaggggcagguuccau	
16_8088	 1.3	 30	 30	 0	 0	 uuuuccagucccacccuc	 gggggagaaugagagacc	
6_16407	 1.2	 146	 146	 0	 0	 uucuaaagaccgaagagc	 ucagcgguuaaaag	
15_7116	 1.2	 325	 325	 0	 0	 uucuucaggcccaccauc	 uguuggggguugaggggga	
4_14426	 1.2	 12	 12	 0	 0	 auacagucuccaacaauc	 uuguuggaggaaguguauuu	
4_13891	 1.2	 732	 732	 0	 0	 uucuacagcccgaccucc	 aggaguggugcaggggg	
5_15620	 1.2	 238	 238	 0	 0	 ugaggcaguaccuuguuc	 acaguguauggcuugcagg	
1_716	 1.1	 91	 91	 0	 0	 uccuacugcuccaugcuc	 gcccgugggucuucuggaag	
10_1763	 1.1	 52	 52	 0	 0	 ugucauacagucccccgcuc	 guacuggacugguugacaga	
3_12945	 1.1	 29	 29	 0	 0	 ucguccucucccuuccuc	 gggggggggaagaucagu	
17_8834	 1.1	 11	 11	 0	 0	 ggaaggugggugcuaagggcuga	 aguucauagcaaccccccuuaagccug	
2_11126	 1.1	 21	 21	 0	 0	 uucuccauucccaugcuc	 gcuugagaguggacagca	
5_15110	 1.1	 16	 16	 0	 0	 ugagugugugugugugauuguga	 auuuuggaugugcauacaugugug	
1_1307	 1.1	 153	 153	 0	 0	 uucuauaguguuauuauc	 aaguaauacuagaagaacu	
X_20633	 1.1	 20	 20	 0	 0	 ugcuaucuuccuuccuuc	 gggcaggaagcagg	
10_2577	 1.1	 115	 115	 0	 0	 ugcuguagucuguuguuc	 augacagccuacuccaugcaac	
9_19633	 1.1	 39	 39	 0	 0	 uaguguucuccaucccuc	 gggguggauuugau	
1_1544	 1.1	 100	 100	 0	 0	 aguuauacaguuauaugaua	 ucauauacauauuugu	
11_3633	 1	 393	 393	 0	 0	 aucucuccagucccacucuc	 gagugaggcugggacccugg	
11_2654	 1	 271	 271	 0	 0	 ugaggcaggagguugugu	 ccagccaaugucaccaauc	
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1_310	 1	 11	 11	 0	 0	 cuguauccucccuuccgc	 gggagucagagggucucagag	
7_17974	 1	 120	 120	 0	 0	 uucugugcucucuugucc	 auaggggcaggacaga	
3_12577	 1	 81	 81	 0	 0	 uccuacucucccuuccuc	 gacagggacuggggcuuggagg	
10_1874	 1	 12	 12	 0	 0	 ugagggggagagagggug	 ccacaguuucccccucugu	
2_11512	 1	 58	 58	 0	 0	 uccuacugcuccaugucc	 acuugcuugccaguacaaggauu	
5_15253	 1	 230	 230	 0	 0	 uguuauacaguacgauga	 auugugcuaggacaca	
2_10551	 1	 133	 133	 0	 0	 ugcuauagugugagaauc	 gucuugacucaaauauaagauca	
10_2048	 0.9	 32	 32	 0	 0	 agggggugggggguuugg	 agcaaccucaucaacggg	
12_3832	 0.9	 27	 27	 0	 0	 ucguauugcuccauuucc	 aaauggggcagggaga	
9_19209	 0.9	 1713	 1713	 0	 0	 uucuacagccccuccauc	 uggaaaggaaaaugucaugaaga	
18_9407	 0.9	 19	 19	 0	 0	 cucuguucuccauuccuc	 gagagagagacagagag	
X_20069	 0.9	 47	 47	 0	 0	 ugaggcaggaggauguac	 acaugccuguaagc	
14_6021	 0.9	 29	 29	 0	 0	 acccagucuccaccaauc	 ucacuggggcuuugagguca	
4_13560	 0.9	 2165	 2165	 0	 0	 uuuuauagugugaggauu	 gccuugccuauggagga	
8_18786	 0.8	 158	 158	 0	 0	 uucuccaguccuccccuc	 ugugguaggaacaggaagg	
5_14733	 0.8	 12	 12	 0	 0	 uucuauguucucccuuuc	 ggcaugaaggaga	
15_6865	 0.8	 97	 97	 0	 0	 uuguauagcuuguuguuc	 acugugcaaguaugcuaug	
5_15628	 0.8	 53	 53	 0	 0	 uucuacagagccauaaua	 aaaugugcucuguagcaca	
8_18072	 0.8	 6566	 6566	 0	 0	 uuuuauagugugaugaga	 ugauuuguuuucacuguaacccu	
2_11711	 0.8	 1240	 1240	 0	 0	 uucuacccucccuccuuc	 ggggggggggguaguggu	
3_13001	 0.7	 12	 12	 0	 0	 uucuacacccucuuccuc	 ggacgagaggugugauau	
X_20208	 0.7	 11	 11	 0	 0	 uccuagaucuccauuauc	 caguggaggcugagguag	
6_16742	 0.7	 11	 11	 0	 0	 ucagacagcuccaccccc	 ggguggaggucagcca	
7_16877	 0.7	 75	 75	 0	 0	 aguucuacauccuacucuc	 ggauggaggugcuagaguca	
6_16639	 0.7	 594	 594	 0	 0	 ugcuacagacccaggauc	 uccugaucugugcaug	
2_11768	 0.7	 785	 785	 0	 0	 uucuaccaucccaccauc	 uggucugcaggaugggagaaga	
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16_7896	 0.7	 13	 13	 0	 0	 agaguucuacauccgauc	 cuggaagcagagccucaaa	
5_15531	 0.6	 25	 25	 0	 0	 ugcuacauucucuccuug	 gggagguggagauggcagu	
3_12752	 0.6	 41	 41	 0	 0	 auggagauagauauagauau	 guguauauauauguacauau	
7_17365	 0.6	 52	 52	 0	 0	 uguuauauaguuauuaua	 auguaacuguauagcuau	
7_17874	 0.6	 17	 17	 0	 0	 ugagguagggggcgguguuc	 uccugcguuccaaccacagc	
15_6958	 0.6	 9	 9	 0	 0	 aacugaguugaaggcaaaggua	 gcuuugccuucagcuuagucgu	
18_9202	 0.5	 215	 215	 0	 0	 uuauacauucagaauauc	 uaucuugggugcucagca	
11_2984	 0.5	 100	 100	 0	 0	 uuguacacuccauccuuc	 agugaucaugugcgcauug	
4_13571	 0.5	 80	 80	 0	 0	 uucucuaguccuccuauc	 uaugggggcuaguuauca	
14_6335	 0.5	 234	 234	 0	 0	 uuguauucuacuuuccuc	 ggaaagcuguggaccagcc	
19_10124	 0.5	 18	 18	 0	 0	 cagaagguuggccauuggggaa	 cccaaauggcucacccucuccu	
1_1075	 0.5	 875	 875	 0	 0	 uucuaaaaucccacgauc	 auggggagauagaagg	
13_5038	 0.4	 83	 83	 0	 0	 uaguucuacauuuugauc	 aggaaggaagaacaauc	
17_8704	 0.4	 128	 128	 0	 0	 auagguguguguguauguguguau	 acaguguauaggggugugugugc	
15_7325	 0.4	 1447	 1447	 0	 0	 uucuacagucccucccuc	 ggccuccccucuguggaguu	
12_3810	 0.4	 265	 265	 0	 0	 uucuauagagucagaaua	 uucugccuuagucuu	
1_1004	 0.4	 23	 23	 0	 0	 gggggugcagcucagugg	 auuggagauuaaccaucccag	
13_4924	 0.4	 58	 58	 0	 0	 uuuuauauugugcuuaua	 uggguaaauguguacagagua	
13_5389	 0.3	 83	 83	 0	 0	 uucucuacucucccaauc	 uugggagcugagaguuug	
3_12426	 0.3	 230	 230	 0	 0	 uuguacagugugaugcuc	 gcucugcuucugagg	
1_242	 0.3	 36	 36	 0	 0	 auagaugugugugcauguguguau	 gugcguaugugugugugucuguau	
19_10042	 0.3	 801	 801	 0	 0	 ugaggcaggagguuguuu	 accagccuccuccuugcu	
14_6308	 0.3	 1424	 1424	 0	 0	 uucuacacucccgccauc	 ugugaggagaugagaagc	
1_825	 0.3	 71	 71	 0	 0	 ugaggcaguacauuguac	 acgaccuguacuguccuugag	
6_15816	 0.2	 170	 168	 1	 1	 ucuuuucaguucuucuauu	 agagggagagagagagagagagaga	
18_9408	 0.2	 19	 19	 0	 0	 cucuguucuccauuccuc	 ggauuggaaaacagcaac	
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17_9030	 0.2	 58	 58	 0	 0	 ucccugagacccuuuaac	 cagaggugagggaga	
8_18550	 0.2	 97	 97	 0	 0	 uucagggauaaauggagucacaga	 ugugacuccugagcucuguucc	
10_2550	 0.2	 4401	 4401	 0	 0	 uucuacagucccucguuc	 augauguccuguguaug	
17_8435	 0.2	 8	 8	 0	 0	 uuauacauuuuuauucuu	 gauuaaaggcgugugcca	
8_18552	 0.2	 97	 97	 0	 0	 uucagggauaaauggagucacaga	 ugugacuccugagcucuguucc	
X_20518	 0.2	 109	 109	 0	 0	 ugcuccagacccacacgc	 gugugggacacuggaacugc	
5_14769	 0.2	 5	 5	 0	 0	 caccacagucccacgagc	 acguggcucuuugcugau	
10_2238	 0.2	 87	 87	 0	 0	 uuagacaguccauuguuu	 acaccugcagagu	
5_14785	 0.2	 1930	 1930	 0	 0	 uucuccaguccgacucuc	 gagucaaggcugugugacuc	
6_16084	 0.1	 67	 67	 0	 0	 uuguacucuacauugagc	 ucacuguugagaugucu	
18_9405	 0.1	 11	 11	 0	 0	 uugagcuguacagugauc	 uccugccuggcuuguga	
14_6353	 0.1	 463	 463	 0	 0	 aucuaccuuccgacgauc	 uuucuagcgaagaggc	
15_7030	 0.1	 80	 80	 0	 0	 uucuacucuaccuccauc	 ucagggugagaugcuaguaauu	
6_16174	 0.1	 305	 305	 0	 0	 uucuauucucccuuccuc	 gguagggugcuuagaaau	
1_1211	 0	 44	 44	 0	 0	 uucuauaguguuaggagc	 ugaaaauucuggaugaaa	
1_1543	 0	 100	 100	 0	 0	 aguuauacaguuauaugaua	 ucauauacauauuuguauaguaac	
7_17551	 0	 14	 14	 0	 0	 caugugugcauugaggaucuu	 gaucuguugcaaugggucacuggu	
14_6234	 0	 27	 27	 0	 0	 gggggugcagcucagugg	 accuggaguuugaucucuag	
6_15801	 0	 208	 208	 0	 0	 ugaggcaggcggaugauu	 uacugcuuaaauguucuagu	
11_2688	 0	 205	 205	 0	 0	 ucauauugcuccauguuc	 acauacuguaaugugauu	
18_9267	 0	 474	 474	 0	 0	 uuauauaguagguuguuu	 acaaccaagaauauauaaag	
3_12530	 0	 2440	 2440	 0	 0	 uucuacaguacuaccauc	 ugggcacugacuguaggccu	
X_20810	 0	 14	 14	 0	 0	 uuuucuauagugauuaua	 gaaucacgaggaaaug	
4_14417	 0	 230	 230	 0	 0	 uuguacagugugaugcuc	 gcucugcuucugagg	
9_19567	 0	 146	 146	 0	 0	 uucuauucuccuuuccuc	 ggugggggaauggaggc	
10_2191	 0	 26	 26	 0	 0	 ucuuuucccuccuucuauu	 ucugaggaauuaaagaug	
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9.2 Putative novel T. gondii miRNAs from 3.4.2 
	
provisional	
id	
miRDeep2	
score	
total	read	
count	
mature	
read	count	
loop	read	
count	
star	read	
count	 consensus	mature	sequence	 consensus	star	sequence	
TGME49_		
chrVIII_2086	 2.2	 36	 36	 0	 0	 uucuccauucccacacuc	 uagugggauuggagggcc	
TGME49_	
chrII_3466	 1.6	 16	 16	 0	 0	 uuguguuguacauuguuc	 augaagucaacaagauc	
TGME49_	
chrX_1032	 1.5	 11	 11	 0	 0	 ugcgacagacagucgauc	 ucguuuugugucugcauu	
TGME49_	
chrXII_519	 1.2	 10	 10	 0	 0	 aguucuucagucugccgagu	 acgagcagaagaacgaacugg	
TGME49_	
chrIV_3185	 1.1	 114	 114	 0	 0	 uucuccacaccgcugcuc	 gcggccuggaguccu	
TGME49_	
chrVI_2926	 0.2	 85	 85	 0	 0	 ucauauaucuacauguuc	 ccauguacguauauauau	
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9.3 Putative novel M. musculus miRNAs, from 5.33 
	
provisional		
id	
miRDeep2	
score	
total	read	
count	
mature	
read	count	
loop	read	
count	
star	read	
count	 consensus	mature	sequence	 consensus	star	sequence	
13_9745	 33140.4	 65011	 65010	 0	 1	 cugggcuacacauuuuua	 aaaaagcagagguagagcc	
3_28811	 5118.3	 10056	 10054	 0	 2	 ucccggguuucggcacca	 gaguuggaauuuugauggggauu	
7_39899	 3695.4	 7251	 7244	 4	 3	 ugagcugucuccuaguaccuauu	 aaaggacuagagacuaaa	
11_3926	 1703.7	 3373	 3361	 6	 6	 uggugggugcauauguuu	 aacucuaccuuccuaauuuu	
14_11408	 1406.2	 2758	 2680	 1	 77	 gaccgaguaacugcuagauccu	 agucuagcucuugcucuugcuc	
11_3345	 1401.6	 2757	 2680	 0	 77	 gaccgaguaacugcuagauccu	 agucuagcucuugcucuugcuc	
13_9832	 1310.8	 2564	 1696	 0	 868	 uagguagaccaggcugaucu	 uguagcccuggcuguccugga	
2_25682	 1204.4	 2367	 2358	 0	 9	 ucccgcggcuccugcucugcuc	 agcgaggggcggagagccgcgc	
9_44382	 939.5	 1836	 1797	 2	 37	 uagguagaccaggcugaucu	 auccuccugucucugccuucu	
3_29821	 922.2	 1818	 1816	 0	 2	 cuccauguaucuuugggaccugcc	 cagucucccuuccuagccaugg	
7_38813	 645.1	 1264	 1255	 0	 9	 aaagagagacagauagauagag	 cuaucuaucuaucuaucuaucugu	
8_42888	 642.8	 1266	 1251	 0	 15	 uguccgggggaccgacuuugcc	 auggagccgcgcuccgggacgcg	
4_31937	 444.1	 876	 874	 0	 2	 ucgcgggcugccgagcuccaggucc	 ccgggucccggcagcugcggccc	
10_1343	 388.3	 776	 766	 0	 10	 uuggcugagaaaaaugacugaauag	 uauucauauacuucuagccuaca	
3_29313	 362.5	 709	 343	 0	 366	 uccgagcuccgagccccgaggcag	 cccugggcucuggagcccgaga	
17_16347	 351.5	 681	 648	 0	 33	 uuggucugagcaucuuccagg	 gggaggaugucaggaugcagacug	
17_17490	 351.4	 681	 648	 0	 33	 uuggucugagcaucuuccagg	 gggaggaugucaggaugcagacug	
12_7670	 331.1	 648	 646	 0	 2	 uuaggaaugcuaggcuagugcu	 acuagcuugcuuuccugggg	
17_17246	 306.1	 591	 555	 0	 36	 aggccugcucugagccuccgccu	 gagggcccagagcagagguucu	
9_43646	 290.3	 561	 560	 0	 1	 uggcaguggaguuagugauugu	 aucagcuaauuacacugccuaca	
7_38735	 280.6	 550	 547	 0	 3	 ucugucuucucuugugccuauuc	 guaagcacaggaagccacaggcu	
15_12114	 269.9	 527	 526	 0	 1	 aacugaguugaaggcaaaggu	 gcuuugccuucagcuuagucgu	
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8_42936	 266	 513	 474	 4	 35	 aacucagaucugccugccucug	 aggcaagaaguucugagcuaga	
12_6448	 247.6	 484	 451	 0	 33	 ucagaacaaccugaccugccu	 ccagcacugaguuguucuguca	
10_1853	 237.1	 474	 375	 0	 99	 caugacugaaacucgacauccg	 agagucgggucucagccagucu	
12_7958	 236.5	 462	 427	 0	 35	 ucugaucccaacccuucugcccagc	 agggcagaagugagguuaggagc	
16_14002	 228.5	 455	 412	 0	 43	 agccaugacggaagacuguguu	 gacuguguucuguuguuggugc	
3_29798	 228.1	 446	 435	 0	 11	 ucugagccccgagacuguauuac	 uuacaguccgagcccugagacu	
14_11592	 219.6	 429	 413	 0	 16	 ucagccacuguguccccuccu	 cuugggggcagagguggcacggugu	
10_6	 218.1	 426	 249	 0	 177	 gagggacauacucaaugagaac	 ucuuauuguccaugucccugcc	
7_40090	 215	 428	 371	 4	 53	 acugccuccugccugcccugcaga	 ugacaggguggguggggcagccc	
2_25278	 210.7	 413	 412	 0	 1	 aacaccaggacugaaaacagccu	 uuguuucaucuccuggguuugu	
2_24316	 204.6	 400	 303	 0	 97	 uaaggcaugcaugcuucaggcu	 ucugugucaugcauuccacacu	
4_31673	 200.8	 392	 388	 0	 4	 uucaaaccucucuggcugcc	 caggccaaggugggauuuuugaggg	
6_36022	 194.1	 380	 375	 0	 5	 uuauggcccuucgguaauucacug	 ugaauucuaccagugccauaca	
11_4468	 188.4	 368	 285	 0	 83	 ucuguuggauccugugaggaca	 cccauaggauuuuaacagaacug	
11_3915	 184.2	 367	 365	 0	 2	 ugcacccuucugacccacuucuccu	 gaaggagguggggggcugcugug	
9_43534	 181.3	 354	 304	 0	 50	 ccaggcugcuggagucugggu	 ccagucuccaucugccuuccu	
4_31706	 174.3	 340	 335	 2	 3	 acuuucuagauguucccggaag	 cugggaacaucuacaaagugaagu	
X_46099	 168.6	 329	 317	 0	 12	 cugagcacccuggccccccaga	 aagggggaucagggauccaga	
19_19896	 167.3	 336	 234	 0	 102	 ugggcuccgccugugguccgc	 cugacuuccaggcccagcccugc	
17_16661	 155.8	 315	 293	 0	 22	 ugugggaugaauggcaccugg	 aggccuucuuucugucccaccca	
11_2468	 155.6	 315	 293	 0	 22	 ugugggaugaauggcaccugg	 aggccuucuuucugucccaccca	
2_26011	 155.5	 297	 251	 0	 46	 auauacauuaaauaagucaaug	 uugauuuauuuaauguauaug	
17_16779	 149.2	 297	 294	 1	 2	 cgggggggccggcggcggcg	 ugacuggcggcgcccgcgcagc	
8_41659	 140.7	 275	 264	 0	 11	 ggucccugauaucgaugcugugc	 ucggcaccgacacaaggauccug	
10_690	 132.2	 258	 230	 0	 28	 uuugguuccucugaccuuuugcu	 gccaggucucuggagccuuug	
3_29076	 131.3	 256	 255	 0	 1	 ucugugggucuguuuguccgucc	 aaggagacacaguccuugcaggc	
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10_711	 124.6	 251	 244	 0	 7	 augaccuggccuugcucauc	 guggguaagcugugguccuggccugu	
15_13237	 122	 238	 88	 0	 150	 cgaggcaucucacaggccgucu	 uugggcugucagagagaugg	
13_9699	 111.1	 218	 199	 0	 19	 cacucugaaaaugcagaugagcu	 uucauuguugauuuucgguggga	
10_1972	 106.4	 208	 206	 0	 2	 caagcuggacuccaggccccaga	 ugggcuuggauagccagccacgcc	
6_37662	 103.5	 192	 182	 0	 10	 ugacuggcagaggaagcucacc	 gugagcuuccucugccaguc	
7_40779	 101.3	 198	 171	 0	 27	 acucacucuguagaccag	 uggccucagacugagagaucu	
16_15096	 91.1	 176	 151	 0	 25	 ugccuguggaagucagaugagg	 cucuucuggccuucaugggcacu	
8_40983	 89.9	 183	 181	 0	 2	 uugcucugugcuguggaucaggagc	 ucccugagccucuggagagca	
1_23755	 88	 171	 148	 1	 22	 ucugaccccuggacucacugga	 agugacucucuaaggcaggacc	
4_30295	 87.1	 169	 156	 0	 13	 gaggaucugguucuguagcuc	 ugcuacaggaugagauccggucu	
3_29436	 78.6	 145	 143	 0	 2	 ugagcaccuccugcaccccaugg	 cuggggggugaggugggg	
2_24211	 77.3	 150	 64	 6	 80	 cuccaaagcucccagaggcuagg	 ugccucuggaagguuuggcagg	
11_3180	 76.7	 149	 87	 1	 61	 acagucugucaccugagccaaacu	 uuugcugcauuugacaggcacag	
2_24248	 76.5	 149	 131	 0	 18	 ucucuaucccuggccugcucuc	 gccuagguuuggggauacagagc	
11_6018	 75.7	 146	 138	 0	 8	 ucagccaugcuaaggccugc	 ugggcuggggcguggcucagc	
2_25073	 75.5	 159	 151	 0	 8	 acgugaccauuucugcccaauu	 cuggggagaauggccauuuca	
5_35384	 75.4	 154	 152	 0	 2	 ugccuaggugauagcggaucgcg	 agagccguuaucgguugggccuc	
11_3502	 75	 145	 127	 12	 6	 acugggcugcucugggcgagccgg	 cugcacaccuggagcccagauaa	
16_15400	 72.3	 140	 138	 0	 2	 uucugaucucuucccucccuccu	 gagggaggggaaagauaagaaaa	
17_17068	 71.9	 149	 145	 0	 4	 ugucuggaucugacccacaga	 uggugggcagagcucagucaguggg	
11_5359	 68.2	 132	 64	 0	 68	 gugggcaugcaguaguggaccagc	 agcuccacuguuguccccacagc	
5_34825	 67.8	 141	 79	 9	 53	 uaugaguucuaggcauugaaucu	 gucaaugcucugaacuccuaag	
15_13680	 66.1	 128	 109	 0	 19	 ccgaugccauucccccgccgccc	 aggcgggggguggcaaugc	
3_28397	 62.9	 127	 126	 0	 1	 ucugucauuuuucccaccu	 agugggaaaauugacauggauugu	
2_27003	 62.3	 122	 116	 0	 6	 ugucuguacaguucagguggga	 ucaaccccaacuguccagucgcu	
8_42162	 54.2	 107	 92	 0	 15	 aaacugucugucuguucauagc	 uaugagcagaccuccaguuuau	
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7_40715	 53.9	 117	 113	 0	 4	 uuggggaaggcaguacuuaugu	 auggguguccuccuucccaga	
10_600	 53.4	 103	 90	 0	 13	 acccaggaagcuggggcaggag	 cuaccucagucuccuugagcgc	
12_8133	 53.4	 103	 95	 0	 8	 uauguggauucucucacuagcc	 cugugggagagucuccagacu	
9_43572	 53.2	 97	 39	 0	 58	 cgcuacauugauuggacacuga	 aguggacaguucuguguggccu	
10_598	 51.2	 99	 97	 0	 2	 uaaacagaccaggcuggccuc	 gaucagcaugucucugcuucuc	
7_40058	 48.1	 100	 81	 0	 19	 acugguacaaggguugggagac	 ucccccaggccuguaccaggguc	
11_2710	 47.2	 93	 92	 0	 1	 ucugauccugugcaguacugga	 caguacuggucaggaucacc	
17_15871	 47.1	 90	 58	 0	 32	 cgggcacggggacacugacgug	 cccucaguguucccguguggcc	
2_24119	 45.6	 87	 84	 0	 3	 ugcaaugccuggaucugggcuc	 uucccaggcuuaggcauugcaca	
11_4107	 44.2	 85	 67	 0	 18	 uccugcccccuuucccuguaga	 uaaggguggauggggcagagcu	
12_6962	 43.7	 92	 84	 0	 8	 cuuccuccuugacugggucauc	 agcacccggagaaggagggcggac	
7_38181	 42.9	 83	 79	 0	 4	 ucuucucuuuccagucaucagc	 uggugccuggauuggaggaugaga	
17_15524	 42.9	 82	 80	 0	 2	 cuuccaagugcuggacuacaggc	 cugagggcaggacuuggagc	
15_12512	 42.7	 93	 71	 0	 22	 uuccagaucuacaagccagagcuu	 cccuagcuaguauaucuugaaucu	
9_44170	 41.2	 86	 64	 0	 22	 cgccgggguuggcccugagc	 cucucggccccgccccggcccu	
19_20413	 40.5	 91	 28	 19	 44	 guaagggaccagggcaggagga	 cgcucacccuucuccuuuccu	
2_25292	 40.4	 77	 76	 0	 1	 aauuacccaccaaaccccagaag	 uuuugggggggggggguauugu	
12_7318	 39.7	 84	 28	 0	 56	 cuuccuaccuuuuccuggcgg	 cccuaggaccagguaggaguugc	
1_22957	 39.1	 76	 40	 0	 36	 caaagcguuuuaagcggaaaugc	 cuuucgcuuccuucgcuuuggu	
7_40098	 37.6	 80	 67	 0	 13	 ucacgcuggcucccucucucugcag	 ugugggagagggcugugcgggag	
15_13560	 37.5	 72	 68	 1	 3	 cacccagaacugacagaccuagc	 agguuuuucagcuucugguugc	
5_33996	 37.2	 71	 63	 0	 8	 cagcacucagaggggcagaggga	 uccugcccucccugggcug	
10_465	 36.3	 76	 61	 0	 15	 gcucucgcucgcgggccgccucg	 ggcgcggcuccgggucgucgagc	
1_21565	 35.4	 69	 62	 0	 7	 ucuaagcagagguguuaguucc	 aacugcaccucuacuuccaga	
3_27907	 34.9	 59	 45	 0	 14	 ugucugcccccacccccacauc	 cugggggugggggggagacuac	
11_4932	 34.8	 62	 59	 0	 3	 aacagaacugaaggacauacga	 cucaugaccuucuggccugguuu	
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15_13527	 33.1	 62	 52	 0	 10	 ucuggcacaggggugucuaggga	 ucccacacacgccccuuugcccgc	
11_4625	 32.9	 62	 52	 0	 10	 ugacugaaucuuguuaaagaau	 ucuuuaacaagauucagucac	
10_506	 32.7	 63	 62	 0	 1	 acuuaaccguuucuccggccu	 ccuggaggagcgggagaga	
2_26397	 32.6	 76	 75	 0	 1	 uuccaugauguagcuuguucugaug	 auucuccagucaucuguggaau	
1_23614	 32.4	 62	 51	 3	 8	 cugcauggcucugcauggcucu	 uggcucugcauggcucugcaugg	
1_23325	 32.3	 70	 67	 0	 3	 gcuaaacuuccuucugaugcuc	 caacacaaggaaguuaggggcu	
10_683	 31.9	 60	 41	 0	 19	 cagccggcagcuggccgucgcagc	 gcuuuggccugcagccuggcugcc	
6_37833	 30.9	 59	 54	 0	 5	 aagggaagcaagcucugcaugggu	 uuugcagccugcaugcuacccucc	
2_25671	 30.8	 58	 33	 0	 25	 acaggagcauagggcgcaggcagc	 ugccuggcucccugcccucu	
2_24390	 30.7	 59	 43	 0	 16	 gguuaagaucgccuuguuaggg	 ucugacagugugauuuuaucug	
2_24354	 30.6	 58	 54	 0	 4	 uuggaucugguguuguccacagacc	 uguguggacacggcuccaug	
10_11	 30.2	 64	 52	 0	 12	 cgcccgcuccggacgcccuuggc	 cggggcuccggcgcgggaccgcu	
11_5908	 30.2	 57	 49	 0	 8	 ugcucagaaacucuguccucccc	 cgagacaguguagcugcggcag	
14_10938	 29.5	 66	 59	 0	 7	 ucaacauggaagagcuggaugacu	 cauugaacucuucugugugugc	
5_34887	 28.8	 56	 55	 0	 1	 aguggaccggcagacaugucu	 caucucuucggcccaaaucuaga	
19_19955	 28.8	 55	 54	 0	 1	 aagugggacaggaauaaagagc	 cuuugucucuguccucuc	
15_12254	 28.7	 56	 55	 0	 1	 uccugagagagagagaggaagu	 cuucuucuauccucucaugcac	
7_38567	 28.6	 61	 54	 0	 7	 uucccccgugcggggggcggcggc	 uccccguccccacucggcggg	
6_37681	 28.4	 54	 33	 0	 21	 uuaggguuuucauugcugugaac	 ucagagcaguagaaacucugacc	
10_2431	 28.3	 63	 59	 1	 3	 uugggaguaugagaaacgaaauuc	 auggguuucuccuguucccagg	
2_24275	 28	 53	 52	 0	 1	 acgugaccucugucucccucagg	 auggggaggcuggguguuauuugc	
12_7126	 28	 54	 50	 0	 4	 uccucagcaugucuucagaacucug	 aguucuaggaugcuuuggc	
6_38061	 27.4	 53	 22	 2	 29	 gucacacucaguagagcagaga	 uuugcuuacaugauugugcuca	
18_18282	 27.4	 45	 37	 0	 8	 gaaagccagguaacaggugcugu	 gguccugaaacuuggcuuugcc	
11_4442	 27.3	 52	 50	 0	 2	 ucaagccagacccagugagcucu	 ucucacugaggaugggcuuaagggc	
14_11452	 27.3	 51	 47	 0	 4	 aucgccuccucagagaccuguu	 aggucucugaggaggcgaucagu	
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6_37146	 27.2	 58	 54	 0	 4	 uucccccgugcggggggcggcgg	 cccgcccccacucggcggggc	
7_39103	 27	 59	 56	 1	 2	 uucccuccgucuuccuuccagg	 cgggaaggaaggaggcgggcuugacu	
4_30900	 26.8	 51	 43	 0	 8	 cagagccuggucaaggucacuc	 aguggucagggccaagccagaga	
7_39418	 26.6	 50	 39	 0	 11	 uuaggcugaccaguacugggcu	 accaguacugggcuagccucuggccu	
3_29829	 26.5	 62	 56	 0	 6	 ugguuuaucugaaauucugaacc	 ucaaaauaucagaugcaccgcu	
10_1016	 26.3	 58	 55	 0	 3	 ucuuggggaguugaugcucaga	 uuggcuucuucuccgcaaacag	
10_132	 25.9	 49	 26	 0	 23	 aaaaagaauuugcuccgaacu	 uucggagcaaguuccuuuuca	
11_3682	 25.7	 52	 50	 0	 2	 cagcccaucgacugcuguugcc	 caacaucagucugauaagcuauc	
8_42343	 25.7	 56	 24	 0	 32	 ccccgaagcuggucuaccucgagc	 gucggguggcgcccgcguuggggu	
14_10540	 24.9	 52	 50	 0	 2	 aaagaaaacucaggcugugga	 acauccugagcguuccuccau	
7_40082	 24.7	 41	 39	 0	 2	 ucugucccuucugccuuccagu	 cugggaagggacuuaggacagac	
11_4490	 24.5	 54	 36	 0	 18	 cgcuugaucuucucccucugcagg	 gugcggaaggacagauccugug	
15_12311	 23.9	 44	 40	 2	 2	 ugcgcgaguugaggcgggucuau	 cuccccgcugggccucgc	
2_23981	 23.6	 54	 52	 1	 1	 uauucugacucuaccuaacugga	 ucugcuagguagugguggaacu	
18_18957	 23.6	 46	 43	 0	 3	 uuuugagacaggcugaccugggau	 ccaggcugguuggucuucaacu	
8_42685	 22.9	 43	 25	 0	 18	 ccaacucugcauucuagcugcc	 cagggguuugcaggauuggaga	
4_30826	 22.8	 43	 41	 1	 1	 ucuuuuagaaggcguccaguaga	 ucuggaggccuucuuuuugg	
15_13669	 22.8	 43	 40	 0	 3	 uagacacuacuggccuucccagga	 cugauuggcugugguguccau	
11_5759	 22.2	 50	 47	 0	 3	 uguggaggaggagccugaggcu	 ucucacacacuuccuccagg	
15_13448	 21.9	 41	 40	 0	 1	 augcuuccaccucaugggcgggc	 cagcccaugggguggagcugcc	
8_42518	 21.6	 49	 32	 0	 17	 ugacugguguuccuuccgcaga	 ugcuggacaggugccauggacccu	
9_45310	 21.5	 40	 29	 0	 11	 caaggauguucgcgcggcuucu	 ccggccgccggauccccuuguc	
9_45230	 21.2	 40	 39	 0	 1	 cuccagcauuguuccucugcaaa	 ccagaggaaaaguugcaggccuug	
7_40712	 21.2	 48	 24	 0	 24	 auaccucacuucuacucuggcag	 uccaguagagaaguggcauga	
11_5310	 21	 49	 47	 0	 2	 aaagaggaggggguggac	 uaaccucuccuguagccc	
8_42029	 20.8	 39	 37	 0	 2	 ucccagacuuccucaggcuuuc	 agcucuguggaaguuggggugugu	
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5_34069	 20.8	 46	 37	 0	 9	 aucccccccgcaccccaacagg	 ucgggguggggguggggucugccc	
11_3379	 19.9	 37	 34	 0	 3	 ugcguggcacugugggcugggggaa	 cuuccagaguggacaggc	
11_5814	 19.1	 45	 43	 0	 2	 ucccaucccgcucuuggcucagg	 aggccuauggcuggguggcugggcuu	
3_28429	 19.1	 37	 35	 0	 2	 acagcuccucucucucucugaag	 ugcagagagaugcggggaggguuaa	
19_19217	 19	 38	 37	 0	 1	 uaaggaggaguaaugaguucuc	 aaacucauuaacccccccugaga	
8_42228	 18.7	 33	 32	 0	 1	 uucccaagucggaugcugcgcc	 gcagcauccgacuugggaac	
X_46390	 18.6	 47	 41	 0	 6	 aucucggccuuccagucucugc	 ugggcuuggacucggccggcaaga	
15_13683	 18.4	 34	 18	 0	 16	 agaaggaacaguggcgccaacag	 ugugggccagggugacuucagc	
19_20436	 18.2	 37	 24	 0	 13	 uugagacugaaguucacuucu	 uagugaaccaugaacucagca	
18_18115	 18.1	 34	 29	 0	 5	 aggagggccuagaauucauagag	 uguguauuccugguuguucug	
11_5986	 17.8	 33	 18	 0	 15	 caaggcucugggcaugggggacu	 ucuccaaagccaagggcacuguug	
13_9041	 17.7	 34	 31	 0	 3	 acgggauuuaaagauaacuca	 gacuuaucuuaaagccuguca	
8_41566	 17.6	 32	 24	 0	 8	 acugagcaccggccgcacgcgc	 ccgcgcgaccgggacucaga	
3_29609	 17.5	 42	 37	 0	 5	 aaggcuacuaagcaaugguug	 aaccauggcacugguguagccca	
1_23413	 17.2	 34	 33	 0	 1	 caggaaccguuuucucuaugacu	 ugaugggguaaagugguucuu	
3_29689	 16.9	 39	 36	 0	 3	 agggguguggcaucugccugagga	 ucgcagcauccacacccucac	
17_16966	 16.8	 38	 36	 0	 2	 uccccgcgagcgccgagcccu	 ggcccggaccuggcugggggccg	
12_6778	 16.8	 31	 27	 0	 4	 augcaugcgcacaguaggacc	 accacuguggugucuguaugua	
15_12217	 16.8	 33	 22	 0	 11	 ugggacagaauccaacuaugaa	 acaguuagacucugucccauggag	
7_39578	 16.5	 31	 24	 0	 7	 agagggccuccacuuugauggcc	 cacacaaaguggaagcacuuucu	
14_11007	 16.4	 30	 29	 0	 1	 agagucucuggagagagu	 ucucucugugucucugug	
16_14520	 16.2	 30	 13	 0	 17	 aagccaggcccagugucacuc	 uaugucacugggcauuggcuuuga	
15_13871	 15.9	 30	 20	 0	 10	 ugggagauacugcuaagaugc	 cucuguaccagcaucucccu	
17_16684	 15.9	 30	 29	 0	 1	 ggaaggugggugcuaagggcuga	 aguucauagcaaccccccuuaagccug	
12_8209	 15.7	 37	 30	 0	 7	 ugcagcggcucaccggccugc	 cagugccugcugagagcugccuc	
7_40811	 15.4	 37	 31	 0	 6	 uggggcuaaaggucugugccacu	 uggccaggauuuuaguccugau	
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14_10921	 15.2	 27	 24	 0	 3	 cucgcugcacaucugccacugcu	 cggcggcgacggcagcgagcc	
4_30830	 15.1	 28	 27	 0	 1	 uuugcucuggcuugacuggcc	 ccagaggacccagagccugcu	
4_31354	 15	 28	 25	 0	 3	 acuggcggcgguugcucucugc	 cagagacuaaucugucgccacc	
4_30911	 15	 28	 15	 0	 13	 uguaguuucaguuuuccuaacu	 aguuaggaaaacugaaacu	
2_25240	 14.9	 37	 27	 0	 10	 agggcuggucaacaaguaggaagg	 uuccuccuugguccugccccaga	
15_12848	 14.9	 27	 16	 0	 11	 aggagaaggguaggcugcuauu	 uaguggccaccuugaucugau	
7_39887	 14.8	 20	 18	 0	 2	 gagaacuucuagugucccugcu	 agagaccuggcugucucug	
16_14250	 14.7	 28	 25	 0	 3	 ccucucuccaguauagcuuuc	 aagcuacaacugaaggguagagcc	
19_20494	 14.7	 27	 14	 0	 13	 cugaggccuguggcaccacau	 gaggugcccuuggacucauga	
11_5771	 14.2	 27	 25	 0	 2	 aucucaccuagacucuucugcu	 caggugaaggucgagaugagacau	
7_38830	 14	 32	 16	 0	 16	 gcgggggugcgugccgcgagg	 cccgcggcggccgcccccguccu	
6_37184	 13.6	 24	 17	 2	 5	 aaggcaaaucaucucucuggcu	 cagagagaugacuugccuugua	
X_47332	 13.5	 25	 18	 0	 7	 acucgaaaaguuuuggauuuugg	 aggucuaaaacauuuugagucu	
10_1872	 13.5	 32	 31	 0	 1	 ugacccggccucuccccccagg	 cugggccuuggucccuggugagug	
11_2537	 13.4	 24	 13	 0	 11	 ccacucugcugggcagcccag	 uggcugccagcagagccugga	
3_28805	 13.4	 27	 20	 2	 5	 uaguaugauguccaauuuucugagc	 cagaagauccuggacaga	
8_43188	 13.2	 25	 19	 0	 6	 agacaccgugacuaagacaacc	 cugucuuaguuaggguuuuacugcu	
6_37711	 13.1	 32	 30	 0	 2	 ucuccugagugcugcagcuggca	 ccaguucugcacagcccu	
5_35460	 13	 24	 19	 0	 5	 cggguuacauagcaggcugacu	 ugugagucuguuaugugcccagg	
10_1837	 12.8	 37	 27	 0	 10	 ugagaggcacucugguuuuguga	 cuagccaggcugaugucucucuaacc	
12_6773	 12.8	 25	 24	 0	 1	 ugcugaauccagagguuacaucu	 ggugaucucggagauucaggugu	
17_15765	 12.8	 23	 19	 3	 1	 aguccugguguuggcugggagc	 acuuggcuagcaccagggacacgccu	
13_9210	 12.7	 24	 20	 0	 4	 uccggggauguuuuuguugcuc	 agccgcuaagaacuuccccaagc	
15_13271	 12.6	 23	 20	 0	 3	 uggccugagagguugugaugccu	 ccacacggccagucaggcag	
19_20193	 12.6	 17	 15	 0	 2	 aaggcucugugagauuugcaaug	 cugcaaaguagcagagcuguca	
19_19782	 12.1	 27	 14	 0	 13	 ucucuucaacuguucugguagg	 aaccaaacagcugugaaaagga	
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9_44761	 12	 14	 13	 0	 1	 aaugugacucagcuaccugaac	 ucagacugcugagucacauugca	
7_39386	 11.7	 23	 22	 0	 1	 ugugagacuuuguagcagcgu	 gaaguuacucugucucacuugu	
17_16932	 11.7	 29	 24	 0	 5	 acagcugcagacaguggccccgu	 uggccucucccugaagcucug	
11_3843	 11.6	 22	 20	 0	 2	 uacuggccacugcucaggggaca	 gccccgggcucugguugcaguucc	
1_23682	 11.5	 21	 18	 0	 3	 cacauggaguugcuguuacacc	 gaaguaacagcagcuccacugg	
8_41495	 11.2	 20	 10	 0	 10	 aaggcagugccuccagcgggc	 uggcuguaggcagugccu	
7_40714	 10.8	 31	 29	 0	 2	 ucuguugcuccccucugccaaca	 augggguggggaguaaggaugagaag	
3_27935	 10.5	 25	 22	 0	 3	 ugauugcuguauggcuuaauuc	 auaagccaccauagcaagcacug	
8_40985	 10.4	 21	 15	 0	 6	 ucacauccuugggauucugccu	 gaaggaucccaaaggcuugauug	
3_28881	 10.3	 20	 18	 0	 2	 agcaggcaggguaacuuuagagc	 ucuauuguugccugcuuggccaaa	
11_3101	 10.3	 19	 10	 0	 9	 cucccuggucuuaccauuacc	 uagugguacuagcucugggugcc	
	
	
	
